[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 178
1. Kobayashi H, Kajiwara H, Kanayama S, Yamada Y, Furukawa N, Noguchi T, Haruta S, Yoshida S, Sakata M, Sado T, Oi H: Molecular pathogenesis of endometriosis-associated clear cell carcinoma of the ovary (review). Oncol Rep; 2009 Aug;22(2):233-40
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Molecular pathogenesis of endometriosis-associated clear cell carcinoma of the ovary (review).
  • Epithelial ovarian cancer (EOC) is the leading cause of death in women with gynecological malignancies.
  • Among EOC, clear cell carcinoma (CCC) and endometrioid adenocarcinoma (EAC) differ from the other histological types with respect to their clinical characteristics and carcinogenesis.
  • The present article reviews the English language literature for biological, pathogenetic and pathophysiological studies on endometriosis-associated CCC of the ovary.
  • Retrograde menstruation or ovarian hemorrhage carries highly pro-oxidant factors, such as heme and iron, into the peritoneal cavity or ovarian endometrioma.
  • [MeSH-major] Adenocarcinoma, Clear Cell / etiology. Endometriosis / complications. Ovarian Neoplasms / etiology


2. Lewis MR, Deavers MT, Silva EG, Malpica A: Ovarian involvement by metastatic colorectal adenocarcinoma: still a diagnostic challenge. Am J Surg Pathol; 2006 Feb;30(2):177-84
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ovarian involvement by metastatic colorectal adenocarcinoma: still a diagnostic challenge.
  • Ovarian involvement by metastatic colorectal adenocarcinoma, although not an uncommon occurrence, remains a diagnostic challenge.
  • The gross and histologic features of such metastases overlap those of primary ovarian epithelial neoplasms such as endometrioid or mucinous adenocarcinoma.
  • The clinical and pathologic features of 86 cases of metastatic colorectal adenocarcinoma involving the ovary were reviewed.
  • In 23 cases, an ovarian mass was the first manifestation of the disease.
  • Ovarian involvement was bilateral in 49 cases and unilateral in 33 (including 20 cases in which the only involved ovary measured at least 10 cm in greatest dimension).
  • In general, the tumors had typical histologic features of metastatic colorectal adenocarcinoma, including a garland pattern and dirty necrosis.
  • In 23 cases, foci with a benign or low malignant potential appearance were seen.
  • In 9 of the cases, an ovarian primary was diagnosed or favored initially, and 5 of these cases were initially treated as ovarian primaries.
  • Metastatic colorectal adenocarcinoma should be considered in the differential diagnosis of an ovarian mass, even if the mass is large and unilateral or in a young patient, to secure proper treatment of these patients.
  • [MeSH-major] Adenocarcinoma / pathology. Colorectal Neoplasms / pathology. Ovarian Neoplasms / secondary
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / analysis. Carcinoma, Endometrioid / pathology. Diagnosis, Differential. Female. Humans. Immunohistochemistry. Middle Aged

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16434891.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


3. Steg A, Wang W, Blanquicett C, Grunda JM, Eltoum IA, Wang K, Buchsbaum DJ, Vickers SM, Russo S, Diasio RB, Frost AR, LoBuglio AF, Grizzle WE, Johnson MR: Multiple gene expression analyses in paraffin-embedded tissues by TaqMan low-density array: Application to hedgehog and Wnt pathway analysis in ovarian endometrioid adenocarcinoma. J Mol Diagn; 2006 Feb;8(1):76-83
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multiple gene expression analyses in paraffin-embedded tissues by TaqMan low-density array: Application to hedgehog and Wnt pathway analysis in ovarian endometrioid adenocarcinoma.
  • However, these pathways remain unexplored in ovarian endometrioid adenocarcinoma (OEA).
  • Expression values were normalized to uninvolved ovarian epithelium.
  • Amplification of RNA from FPE tissues was not successful.
  • The expression of Desert hedgehog (DHH), Indian hedgehog (IHH), Hedge-hog interacting protein (HHIP), Wnt10B, Wnt9B, and Wnt inhibitory factor (WIF1) were tumor-specific with no detectable expression in normal ovarian epithelium.

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • Biospecimen Research Database. Biospecimen Research Database .
  • Hazardous Substances Data Bank. FORMALDEHYDE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Oncogene. 1999 Dec 20;18(55):7844-51 [10630637.001]
  • [Cites] Cancer Res. 2004 Sep 1;64(17):6071-4 [15342389.001]
  • [Cites] CA Cancer J Clin. 2000 Jan-Feb;50(1):7-33 [10735013.001]
  • [Cites] Nature. 2000 Aug 31;406(6799):1005-9 [10984056.001]
  • [Cites] Nature. 2001 May 17;411(6835):349-54 [11357142.001]
  • [Cites] Cancer Res. 2001 Nov 15;61(22):8247-55 [11719457.001]
  • [Cites] Anal Biochem. 2002 Apr 15;303(2):209-14 [11950223.001]
  • [Cites] Endocrinology. 2002 Jul;143(7):2741-9 [12072409.001]
  • [Cites] Anticancer Res. 2002 Jul-Aug;22(4):2215-20 [12174906.001]
  • [Cites] Science. 2002 Aug 30;297(5586):1559-61 [12202832.001]
  • [Cites] J Cell Sci. 2002 Dec 1;115(Pt 23):4393-7 [12414986.001]
  • [Cites] Eur J Cancer. 2002 Dec;38(18):2435-45 [12460789.001]
  • [Cites] Nature. 2003 Mar 20;422(6929):313-7 [12629553.001]
  • [Cites] Cancer. 2003 May 15;97(10 Suppl):2648-59 [12733130.001]
  • [Cites] Br J Cancer. 2003 Oct 6;89(7):1298-304 [14520463.001]
  • [Cites] Development. 2003 Nov;130(22):5297-305 [14530294.001]
  • [Cites] Lancet. 1989 Jun 17;1(8651):1391 [2567404.001]
  • [Cites] J Clin Pathol. 1990 Jun;43(6):499-504 [1696290.001]
  • [Cites] Biotechniques. 1991 Sep;11(3):304, 306, 308 [1718327.001]
  • [Cites] Biotechniques. 1993 Mar;14(3):448-53 [7681300.001]
  • [Cites] Nat Genet. 1996 Sep;14(1):78-81 [8782823.001]
  • [Cites] Semin Oncol. 1996 Oct;23(5 Suppl 12):40-7 [8941409.001]
  • [Cites] Methods Mol Biol. 1998;86:23-6 [9664448.001]
  • [Cites] Development. 1998 Sep;125(18):3553-62 [9716521.001]
  • [Cites] Mol Carcinog. 1999 Jun;25(2):86-91 [10365909.001]
  • [Cites] Nature. 2003 Oct 23;425(6960):846-51 [14520411.001]
  • [Cites] Nature. 2003 Oct 23;425(6960):851-6 [14520413.001]
  • [Cites] Br J Cancer. 2004 Jan 12;90(1):224-9 [14710233.001]
  • [Cites] Nat Rev Cancer. 2003 Dec;3(12):903-11 [14737121.001]
  • [Cites] Gynecol Oncol. 2004 Feb;92(2):559-67 [14766248.001]
  • [Cites] Chin Med Sci J. 2004 Mar;19(1):25-30 [15104221.001]
  • [Cites] Oncology. 2004;66(4):310-5 [15218299.001]
  • [Cites] Cancer Res. 2004 Aug 15;64(16):5882-90 [15313933.001]
  • [Cites] Anal Biochem. 2000 Feb 15;278(2):175-84 [10660460.001]
  • (PMID = 16436637.001).
  • [ISSN] 1525-1578
  • [Journal-full-title] The Journal of molecular diagnostics : JMD
  • [ISO-abbreviation] J Mol Diagn
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA086359-06; United States / NCI NIH HHS / CA / P20 CA101955; United States / NCI NIH HHS / CA / CA101955-01; United States / NCI NIH HHS / CA / P50 CA101955; United States / NCI NIH HHS / CA / U24 CA086359
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Fixatives; 0 / Hedgehog Proteins; 0 / Trans-Activators; 0 / Wnt Proteins; 1HG84L3525 / Formaldehyde
  • [Other-IDs] NLM/ PMC1867577
  •  go-up   go-down


Advertisement
4. Levi F, Randimbison L, Blanc-Moya R, La Vecchia C: Second neoplasms after invasive and borderline ovarian cancer. Eur J Cancer Prev; 2009 Jun;18(3):216-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Second neoplasms after invasive and borderline ovarian cancer.
  • Excess risk of subsequent cancers has been documented in women diagnosed with ovarian cancer.
  • We updated to 2006 data on second cancers in women diagnosed with invasive and borderline ovarian cancer in the Swiss canton of Vaud.
  • Between 1974 and 2006, 304 borderline and 1530 invasive first ovarian tumours were abstracted from the Vaud Cancer Registry database and followed up till the end of 2006.
  • There was no change in the incidence of malignant cancers, but that of borderline tumours increased over more recent years.
  • Overall, 110 second neoplasms were observed versus 49.7 expected after invasive ovarian cancer (SIR 2.21; 95% CI: 1.82-2.67).
  • SIRs were above unity for ovary, colorectum and uterus.
  • After exclusion of synchronous neoplasms, SIR for all neoplasms declined to 1.09, and remained significant only for second ovarian cancers (SIR=4.93).
  • The present record linkage cohort study shows an excess risk for selected synchronous neoplasms in women diagnosed with both borderline and invasive ovarian cancer, likely because of shared genetic and perhaps environmental factors.
  • [MeSH-major] Neoplasms, Second Primary / etiology. Ovarian Neoplasms / pathology
  • [MeSH-minor] Adenocarcinoma, Clear Cell / pathology. Adenocarcinoma, Mucinous / pathology. Carcinoma, Endometrioid / pathology. Cohort Studies. Cystadenocarcinoma, Serous / pathology. Endometrial Neoplasms / pathology. Female. Humans. Incidence. Middle Aged. Neoplasm Invasiveness. Registries

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19491608.001).
  • [ISSN] 1473-5709
  • [Journal-full-title] European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation (ECP)
  • [ISO-abbreviation] Eur. J. Cancer Prev.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


5. Madore J, Ren F, Filali-Mouhim A, Sanchez L, Köbel M, Tonin PN, Huntsman D, Provencher DM, Mes-Masson AM: Characterization of the molecular differences between ovarian endometrioid carcinoma and ovarian serous carcinoma. J Pathol; 2010 Feb;220(3):392-400
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Characterization of the molecular differences between ovarian endometrioid carcinoma and ovarian serous carcinoma.
  • The histopathological diagnosis of high-grade endometrioid and serous carcinoma of the ovary is poorly reproducible under the current morphology based classification system, especially for anaplastic, high-grade tumours.
  • The transcription factor Wilms' tumour-1 (WT1) is differentially expressed among the gynaecological epithelia from which epithelial ovarian cancers (EOCs) are believed to originate.
  • In EOCs, WT1 protein is observed in the majority of serous carcinomas and in up to 30% of endometrioid carcinomas.
  • It is unclear whether the latter is a reflection of the actual incidence of WT1 protein expression in endometrioid carcinomas, or whether a significant number of high-grade serous carcinomas have been misclassified as endometrioid carcinoma.
  • The aim of this study was to better define the molecular characteristics of serous and endometrioid carcinomas in an attempt to address the problems with the current histopathological classification methods.
  • Gene expression profiles were analysed to identify reproducible gene expression phenotypes for endometrioid and serous carcinomas.
  • It was found that nuclear WT1 protein expression can identify misclassified high-grade endometrioid carcinomas and these tumours should be reassigned to serous histotype.
  • Although low-grade endometrioid carcinomas rarely progress to high-grade carcinomas, a combined WT1-negative, TP53-positive immunophenotype may identify an uncommon high-grade subtype of ovarian endometrioid carcinoma.
  • [MeSH-major] Carcinoma, Endometrioid / genetics. Cystadenocarcinoma, Serous / genetics. Ovarian Neoplasms / genetics

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.
  • [CommentIn] J Pathol. 2010 Sep;222(1):117; author reply 118 [20572050.001]
  • (PMID = 19967725.001).
  • [ISSN] 1096-9896
  • [Journal-full-title] The Journal of pathology
  • [ISO-abbreviation] J. Pathol.
  • [Language] eng
  • [Databank-accession-numbers] GEO/ GSE6008
  • [Grant] Canada / Canadian Institutes of Health Research / /
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CTNNB1 protein, human; 0 / Neoplasm Proteins; 0 / TP53 protein, human; 0 / Tumor Suppressor Protein p53; 0 / WT1 Proteins; 0 / beta Catenin; EC 3.1.3.48 / PTEN protein, human; EC 3.1.3.67 / PTEN Phosphohydrolase
  •  go-up   go-down


6. Brinton LA, Sakoda LC, Frederiksen K, Sherman ME, Kjaer SK, Graubard BI, Olsen JH, Mellemkjaer L: Relationships of uterine and ovarian tumors to pre-existing chronic conditions. Gynecol Oncol; 2007 Dec;107(3):487-94
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Relationships of uterine and ovarian tumors to pre-existing chronic conditions.
  • METHODS: Using record linkage techniques, we assessed the relationships between hospital and outpatient admissions for gallbladder disease, diabetes, hypertension, thyroid diseases and obesity and the subsequent development of uterine and ovarian cancers in Denmark between 1978 and 1998.
  • Based on a subsample of more than 99,000 women, including 1398 uterine and 2491 ovarian cancers, we derived relative risks (RRs) and 95% confidence intervals (CIs) associated with overall and histology-specific cancer risks after adjustment for age, calendar time and reproductive characteristics.
  • Although the "usual types" of endometrial cancer largely accounted for the observed associations, there was some evidence that uterine sarcomas (n=137) were related to prior diagnoses of thyroid diseases (2.78, 1.41-5.50).
  • In contrast, ovarian cancers were not strongly related to most documented chronic diseases.
  • An association of obesity and endometrioid ovarian cancer was not identified.
  • [MeSH-major] Chronic Disease / epidemiology. Ovarian Neoplasms / epidemiology. Uterine Neoplasms / epidemiology

  • MedlinePlus Health Information. consumer health - Coping with Chronic Illness.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Obstet Gynecol. 2002 Aug;100(2):288-96 [12151152.001]
  • [Cites] Int J Cancer. 2007 Jul 15;121(2):347-55 [17357139.001]
  • [Cites] Gynecol Oncol. 1985 Jun;21(2):228-34 [3988136.001]
  • [Cites] Nutr Cancer. 1995;23(2):141-9 [7644383.001]
  • [Cites] Arch Intern Med. 1995 Sep 25;155(17):1868-72 [7677553.001]
  • [Cites] Cancer. 1996 Feb 15;77(4):717-24 [8616764.001]
  • [Cites] Am J Epidemiol. 1996 Aug 15;144(4):363-72 [8712193.001]
  • [Cites] Cancer Causes Control. 1996 Nov;7(6):605-25 [8932921.001]
  • [Cites] Ann Epidemiol. 1997 Jan;7(1):46-53 [9034406.001]
  • [Cites] Int J Cancer. 1997 May 2;71(3):360-3 [9139868.001]
  • [Cites] J Natl Cancer Inst. 1997 Sep 17;89(18):1360-5 [9308706.001]
  • [Cites] Mod Pathol. 1997 Oct;10(10):963-8 [9346174.001]
  • [Cites] Cancer Res. 1997 Nov 15;57(22):5077-85 [9371506.001]
  • [Cites] Eur J Cancer. 1997 Sep;33(10):1634-7 [9389926.001]
  • [Cites] Gynecol Oncol. 1998 Jun;69(3):253-7 [9648597.001]
  • [Cites] Am J Epidemiol. 1998 Aug 1;148(3):234-40 [9690359.001]
  • [Cites] Int J Cancer. 1999 May 17;81(4):539-42 [10225441.001]
  • [Cites] Dan Med Bull. 1999 Jun;46(3):263-8 [10421985.001]
  • [Cites] Ann Epidemiol. 2000 Jan;10(1):14-23 [10658685.001]
  • [Cites] Cancer Causes Control. 2000 Feb;11(2):185-92 [10710204.001]
  • [Cites] J Natl Cancer Inst. 2000 Jul 19;92(14):1172-7 [10904091.001]
  • [Cites] Epidemiology. 2000 Mar;11(2):111-7 [11021606.001]
  • [Cites] Cancer Causes Control. 2000 Sep;11(8):707-11 [11065007.001]
  • [Cites] Am J Epidemiol. 2001 May 1;153(9):860-4 [11323316.001]
  • [Cites] Ann Epidemiol. 2001 Nov;11(8):568-74 [11709277.001]
  • [Cites] Obstet Gynecol Surv. 2002 Mar;57(3 Suppl):S1-7 [12074547.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2002 Sep;11(9):822-8 [12223425.001]
  • [Cites] Int J Cancer. 2003 May 10;104(6):669-76 [12640672.001]
  • [Cites] Oncology. 2003;64(4):341-5 [12759530.001]
  • [Cites] J Natl Cancer Inst. 2003 Aug 20;95(16):1244-8 [12928351.001]
  • [Cites] Am J Epidemiol. 2003 Oct 1;158(7):629-38 [14507598.001]
  • [Cites] Br J Cancer. 2003 Nov 3;89(9):1697-704 [14583772.001]
  • [Cites] Int J Cancer. 2004 Jan 10;108(2):262-8 [14639613.001]
  • [Cites] J Natl Cancer Inst. 2003 Dec 3;95(23):1797-800 [14652242.001]
  • [Cites] Cancer. 2004 Apr 1;100(7):1515-21 [15042687.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2004 Apr;13(4):607-12 [15066926.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2004 May;13(5):748-52 [15159305.001]
  • [Cites] Int J Gynecol Cancer. 2004 May-Jun;14(3):431-6 [15228415.001]
  • [Cites] Oncology. 2004;67(1):54-9 [15459496.001]
  • [Cites] N Engl J Med. 1976 Jun 3;294(23):1262-7 [177870.001]
  • [Cites] J Natl Cancer Inst. 1977 Oct;59(4):1055-60 [333120.001]
  • [Cites] Gynecol Oncol. 1978 Oct;6(5):451-8 [738623.001]
  • [Cites] Am J Obstet Gynecol. 1980 May 1;137(1):85-91 [7369293.001]
  • [Cites] Maturitas. 1980 Oct;2(3):185-90 [7442552.001]
  • [Cites] Gynecol Oncol. 1981 Feb;11(1):8-16 [6259021.001]
  • [Cites] Am J Obstet Gynecol. 1985 Apr 1;151(7):899-905 [3985056.001]
  • [Cites] Am J Obstet Gynecol. 1987 Jan;156(1):20-3 [3799753.001]
  • [Cites] Eur J Cancer Clin Oncol. 1988 Feb;24(2):189-94 [3356205.001]
  • [Cites] Jpn J Cancer Res. 1988 Sep;79(9):997-1004 [3142839.001]
  • [Cites] Eur J Cancer Clin Oncol. 1989 Oct;25(10):1451-6 [2591436.001]
  • [Cites] Am J Obstet Gynecol. 1990 Jan;162(1):148-54 [2301483.001]
  • [Cites] Int J Cancer. 1991 Sep 30;49(3):362-7 [1917134.001]
  • [Cites] Int J Cancer. 1992 Feb 20;50(4):567-71 [1537622.001]
  • [Cites] Am J Obstet Gynecol. 1992 Nov;167(5):1317-25 [1442985.001]
  • [Cites] J Clin Endocrinol Metab. 1993 Jul;77(1):199-204 [7686914.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1993 Jul-Aug;2(4):321-7 [8348055.001]
  • [Cites] Jpn J Cancer Res. 1994 Apr;85(4):346-50 [8200846.001]
  • [Cites] Ann Chir Gynaecol Suppl. 1994;208:20-4 [8092764.001]
  • [Cites] Br J Cancer. 1994 Nov;70(5):950-3 [7947103.001]
  • [Cites] Hypertension. 1999 Aug;34(2):320-5 [10454461.001]
  • [Cites] J Natl Cancer Inst. 1999 Sep 1;91(17):1459-67 [10469746.001]
  • [Cites] Gynecol Oncol. 2005 Feb;96(2):520-30 [15661246.001]
  • [Cites] Fam Pract. 2005 Oct;22(5):548-53 [15964871.001]
  • [Cites] Int J Epidemiol. 2005 Dec;34(6):1284-90 [16186164.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Dec;14(12):2929-35 [16365012.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2007 Feb;16(2):276-80 [17301260.001]
  • (PMID = 17825884.001).
  • [ISSN] 1095-6859
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Grant] United States / Intramural NIH HHS / / Z01 CP010126-11
  • [Publication-type] Journal Article; Research Support, N.I.H., Intramural
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS35834; NLM/ PMC2199881
  •  go-up   go-down


7. Jin KL, Pak JH, Park JY, Choi WH, Lee JY, Kim JH, Nam JH: Expression profile of histone deacetylases 1, 2 and 3 in ovarian cancer tissues. J Gynecol Oncol; 2008 Sep;19(3):185-90
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression profile of histone deacetylases 1, 2 and 3 in ovarian cancer tissues.
  • OBJECTIVE: To investigate the expression levels of histone deacetylase (HDAC) 1, 2, and 3 in ovarian cancer tissues and normal ovarian tissues.
  • METHODS: Randomly assigned each of six patients with serous, mucinous and endometrioid ovarian cancer were included.
  • Another six patients with normal ovarian tissue were included for comparison.
  • RT-PCR was performed to quantify the levels of HDACs1-3 mRNA in the cancer and normal tissues.
  • RESULTS: Increased mRNA expressions of HDCA1, HDAC 2 and HDAC 3 were detected in 83%, 67% and 83% of 18 cancer tissue samples, compared to normal tissue samples.
  • The relative densities of HDAC1 mRNA and HDAC3 mRNA in the serous, mucinous and endometrioid cancer tissues, and HDAC2 mRNA in serous cancer tissues were significantly higher than those of the normal tissues, respectively (p<0.05).
  • Overexpression of HDAC1, HDAC2 and HDAC3 proteins were detected in 94%, 72% and 83% of 18 cancer samples, respectively.
  • The relative densities of HDAC1 protein and HDAC3 protein in serous, mucinous and endometrioid cancer, and HDAC2 protein in serous and mucinous cancer tissues were significantly higher than those of normal tissues, respectively (p<0.05).
  • Most cancer tissues expressed moderate to strong staining of HDACs1, 2 and 3 in immunohistochemistry.
  • Staining of HDAC2 was weak in only one endometrioid cancer tissue.
  • CONCLUSION: HDACs1-3 are over expressed in ovarian cancer tissues and probably play a significant role in ovarian carcinogenesis.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Biol Chem. 2006 May 12;281(19):13548-58 [16533812.001]
  • [Cites] Genes Dev. 2000 Jan 15;14(2):121-41 [10652267.001]
  • [Cites] Biochem J. 2003 Mar 15;370(Pt 3):737-49 [12429021.001]
  • [Cites] Int J Cancer. 2001 Oct 15;94(2):257-67 [11668507.001]
  • [Cites] Nat Med. 2001 Apr;7(4):437-43 [11283670.001]
  • [Cites] Gastroenterology. 2001 Mar;120(4):889-99 [11231943.001]
  • [Cites] Cancer. 2004 Dec 15;101(12):2760-70 [15536623.001]
  • [Cites] Mol Cell Biol. 2005 Oct;25(19):8415-29 [16166625.001]
  • [Cites] J Biol Chem. 2000 May 26;275(21):16191-201 [10748092.001]
  • [Cites] Trends Cell Biol. 1999 May;9(5):193-8 [10322454.001]
  • [Cites] Cell. 1997 Aug 22;90(4):595-606 [9288740.001]
  • [Cites] Am J Physiol. 1997 Apr;272(4 Pt 1):G705-12 [9142899.001]
  • [Cites] Int J Cancer. 2004 Oct 20;112(1):26-32 [15305372.001]
  • [Cites] Curr Biol. 2004 Jul 27;14(14):R546-51 [15268870.001]
  • [Cites] Cancer Cell. 2004 May;5(5):455-63 [15144953.001]
  • [Cites] J Mol Biol. 2004 Apr 16;338(1):17-31 [15050820.001]
  • [Cites] Int J Cancer. 2003 Nov 10;107(3):353-8 [14506733.001]
  • [Cites] J Biol Chem. 2003 Sep 12;278(37):35775-80 [12837748.001]
  • [Cites] J Cell Physiol. 2000 Jun;183(3):347-54 [10797309.001]
  • [Cites] J Biol Chem. 2000 Apr 14;275(15):10887-92 [10753885.001]
  • [Cites] Ann N Y Acad Sci. 2003 Mar;983:84-100 [12724214.001]
  • (PMID = 19471575.001).
  • [ISSN] 2005-0380
  • [Journal-full-title] Journal of gynecologic oncology
  • [ISO-abbreviation] J Gynecol Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC2676472
  • [Keywords] NOTNLM ; HDAC1 / HDAC2 / HDAC3 / Ovarian cancer
  •  go-up   go-down


8. Grammatoglou X, Skafida E, Glava C, Katsamagkou E, Delliou E, Vasilakaki T: Synchronous endometrioid carcinoma of the uterine corpus and ovary. A case report and review of the literature. Eur J Gynaecol Oncol; 2009;30(4):437-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Synchronous endometrioid carcinoma of the uterine corpus and ovary. A case report and review of the literature.
  • Synchronous endometrioid carcinoma of the uterine corpus and ovary is an uncommon but well recognized event.
  • Diagnosis as either a separate independent primary or as a metastatic tumor requires careful consideration of a number of gross and histological features.
  • We report a case of a 52-year-old woman who came to our hospital with a cystic left ovarian mass (8 cm).
  • Histological examinations showed well differentiated endometrioid ovarian cancer and well differentiated endometrioid endometrial cancer.
  • The woman had not been previously treated with ovulation induction drugs.
  • Patients with synchronous endometrioid tumors of the endometrium and ovary are generally younger than reported for either endometrial adenocarcinomas or ovarian adenocarcinomas.
  • The prognosis of endometrioid type carcinomas is better than other histological types of carcinoma.
  • [MeSH-major] Carcinoma, Endometrioid / pathology. Endometrial Neoplasms / pathology. Neoplasms, Multiple Primary / pathology. Ovarian Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19761140.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Italy
  • [Number-of-references] 14
  •  go-up   go-down


9. Judson K, McCormick C, Vang R, Yemelyanova AV, Wu LS, Bristow RE, Ronnett BM: Women with undiagnosed colorectal adenocarcinomas presenting with ovarian metastases: clinicopathologic features and comparison with women having known colorectal adenocarcinomas and ovarian involvement. Int J Gynecol Pathol; 2008 Apr;27(2):182-90
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Women with undiagnosed colorectal adenocarcinomas presenting with ovarian metastases: clinicopathologic features and comparison with women having known colorectal adenocarcinomas and ovarian involvement.
  • Recognition of an ovarian tumor as a metastasis from an undiagnosed primary gastrointestinal tract carcinoma can be difficult when specific symptoms referable to the primary tumor are lacking and the tumor simulates a primary ovarian neoplasm grossly and microscopically.
  • Ovarian metastases of colorectal adenocarcinomas, in particular, continue to pose diagnostic challenges both clinically and pathologically.
  • Clinicopathologic features of 20 cases of ovarian metastases from undiagnosed colorectal adenocarcinomas (U-CRAs) were compared with those of 22 cases having metastases from known colorectal adenocarcinomas (K-CRAs).
  • Women with ovarian metastases from U-CRAs were significantly younger (mean age, 48 years; median, 47 years) than those with ovarian metastases from K-CRAs (mean, 61 years; median, 63 years) (P = 0.002), presented with clinical findings related to the ovarian metastases, often had elevated CA-125 levels, and lacked specific symptoms due to the colorectal carcinomas, which were diagnosed only at the time of intraoperative evaluation of the ovarian tumors.
  • Mean/median ovarian tumor sizes (12.8/13.0 cm for U-CRAs; 14.1/15.8 cm for K-CRAs) and frequencies of bilaterality (45% for U-CRAs and 36% for K-CRAs) were not significantly different for the 2 groups; frequencies of clinically unilateral tumors of more than 10 cm were similar in both groups (30% for U-CRAs and 45% for KCRAs).
  • Other features more commonly observed in ovarian metastases from U-CRAs included mucinous differentiation, extracellular mucin production, and some degree of cytokeratin 7 expression; endometrioid-like differentiation was more common in metastases from K-CRA, but a garland pattern of necrosis and the presence of a confluent glandular, rather than infiltrative, pattern of invasion were similarly common in both groups.
  • In cases having ovarian metastases from U-CRA, the younger age of the women, uniform presentation as pelvic masses without symptoms referable to the bowel, elevated CA-125 levels, occasional presentation as a large clinically unilateral tumor, frequent mucinous differentiation, and frequent coexpression of cytokeratin 7 are features that can contribute to misclassification of these metastases as primary ovarian neoplasms.
  • [MeSH-major] Adenocarcinoma / diagnosis. Adenocarcinoma / secondary. Colorectal Neoplasms / diagnosis. Colorectal Neoplasms / pathology. Ovarian Neoplasms / diagnosis. Ovarian Neoplasms / secondary
  • [MeSH-minor] Adult. Age Factors. Aged. Aged, 80 and over. Biomarkers, Tumor / metabolism. CA-125 Antigen / metabolism. Diagnosis, Differential. Female. Humans. Keratin-7 / metabolism. Middle Aged. Mucins / metabolism. Neoplasms, Unknown Primary / diagnosis. Neoplasms, Unknown Primary / metabolism. Neoplasms, Unknown Primary / pathology. Ovary / metabolism. Ovary / pathology. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18317225.001).
  • [ISSN] 1538-7151
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CA-125 Antigen; 0 / Keratin-7; 0 / Mucins
  •  go-up   go-down


10. Misir A, Sur M: Sertoliform endometrioid carcinoma of the ovary: a potential diagnostic pitfall. Arch Pathol Lab Med; 2007 Jun;131(6):979-81
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sertoliform endometrioid carcinoma of the ovary: a potential diagnostic pitfall.
  • Sertoliform endometrioid carcinoma of the ovary (SEC) is an uncommon variant that bears histologic similarity to Sertoli and Sertoli-Leydig cell tumors (SLTs).
  • A number of histologic features can be used to distinguish the 2 entities, the most important ones being (1) the presence of areas with the usual pattern of endometrioid carcinoma, and (2) the presence of mucin at the apical borders of the tumor cells.
  • Based on the clinicopathologic behavior of this entity, SEC should be considered a well-differentiated carcinoma with relatively good prognosis if limited to the ovary.
  • [MeSH-major] Carcinoma, Endometrioid / pathology. Diagnostic Errors / prevention & control. Ovarian Neoplasms / pathology. Sertoli Cell Tumor / pathology
  • [MeSH-minor] Adenocarcinoma, Mucinous / diagnosis. Adult. Aged. Carcinoid Tumor / diagnosis. Combined Modality Therapy. Diagnosis, Differential. Female. Humans. Krukenberg Tumor / diagnosis. Middle Aged

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17550331.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


11. Baize N, Mahamat A, Benizri E, Saint-Paul MC, Mounier N: Bone metastasis from endometrioid ovarian carcinoma: a case study and literature review. Eur J Gynaecol Oncol; 2009;30(3):326-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bone metastasis from endometrioid ovarian carcinoma: a case study and literature review.
  • INTRODUCTION: Bone metastases from epithelial ovarian carcinoma are rare, usually discovered postmortem.
  • Furthermore, only two cases of endometrioid ovarian carcinoma with metastasis to the skeletal structures have been described in the literature.
  • CASE REPORT: We present the case of a 58-year-old woman with a lytic metastasis in the left iliac ramus from endometrioid ovarian carcinoma that occurred seven years after the initial diagnosis.
  • DISCUSSION: A review of the literature since 1966 on bone metastasis of ovarian cancer is also presented.
  • [MeSH-major] Bone Neoplasms / secondary. Carcinoma, Endometrioid / secondary. Ovarian Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19697633.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Italy
  • [Number-of-references] 14
  •  go-up   go-down


12. Valenzuela P, Ramos P, Redondo S, Cabrera Y, Alvarez I, Ruiz A: Endometrioid adenocarcinoma of the ovary and endometriosis. Eur J Obstet Gynecol Reprod Biol; 2007 Sep;134(1):83-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endometrioid adenocarcinoma of the ovary and endometriosis.
  • OBJECTIVE: We present a retrospective analysis of 22 cases of endometrioid ovarian carcinoma, reviewed to identify endometriosis and its malignant transformation.
  • STUDY DESIGN: Twenty-two patients with endometrioid ovarian cancer were included in the review.
  • The origin of the tumours was considered endometriosis-related when the presence of malignant changes in endometriosis glands leading to endometrioid carcinoma were found.
  • One of them presented a clearly benign to malignant transformation area.
  • In the third, a pre-menopausal woman, ovarian endometriosis with only focal endometrioid carcinoma was observed.
  • The three of them had a clear-cell carcinoma component.
  • In the remaining of the patients, CA 125 value did not exceed 35 U/ml.
  • CONCLUSION: Although this association is not very frequent, patients with ovarian endometriosis and a high CA 125 serum level should be managed with special care, regardless of their pre-menopausal or post-menopausal status.
  • [MeSH-major] Adenocarcinoma, Clear Cell. Carcinoma, Endometrioid / etiology. Endometriosis / complications. Ovarian Neoplasms / etiology

  • Genetic Alliance. consumer health - Endometriosis.
  • MedlinePlus Health Information. consumer health - Endometriosis.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16844279.001).
  • [ISSN] 0301-2115
  • [Journal-full-title] European journal of obstetrics, gynecology, and reproductive biology
  • [ISO-abbreviation] Eur. J. Obstet. Gynecol. Reprod. Biol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / CA-125 Antigen
  •  go-up   go-down


13. Turbiner J, Moreno-Bueno G, Dahiya S, Sánchez-Estevez C, Hardisson D, Prat J, Oliva E, Palacios J: Clinicopathological and molecular analysis of endometrial carcinoma associated with tamoxifen. Mod Pathol; 2008 Aug;21(8):925-36
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinicopathological and molecular analysis of endometrial carcinoma associated with tamoxifen.
  • Use of tamoxifen for treatment and prevention of breast cancer is becoming increasingly common.
  • Tamoxifen has been associated with increased risk of endometrial carcinoma, although the exact mechanism of action is unknown.
  • The aim of our study was to seek a possible correlation between endometrial carcinoma, tamoxifen exposure and MSI, PTEN, beta-catenin and K-ras abnormalities.
  • A group of 18 patients with endometrial carcinoma following treatment with tamoxifen were selected.
  • A control group included 15 patients with endometrial carcinoma and associated ovarian hyperthecosis and one patient with endometrial carcinoma and adult granulosa cell tumor of the ovary, chosen because both conditions are associated with increased production of estrogen and increased risk of endometrial carcinoma development.
  • The second control group included 27 randomly selected consecutive patients with endometrial carcinoma without identifiable associated conditions.
  • There were 16 endometrioid endometrial carcinomas, one mixed carcinoma and one clear cell carcinoma among patients in the tamoxifen group.
  • All patients with ovarian hyperthecosis and adult granulosa cell tumor had endometrioid endometrial carcinoma.
  • In the random control group, there were 26 endometrioid endometrial carcinomas and one carcinosarcoma.
  • Immunohistochemical and mutational analysis for beta-catenin showed abnormalities in 4/11 (36%) and 3/10 (30%) informative cases in the tamoxifen group; 7/16 (44%) and 4/15 (27%) informative cases, respectively in the ovarian hyperthecosis group and 1/27 random control cases (4%) (P<0.05).
  • Patients with tamoxifen exposure had more K-ras mutations and fewer PTEN mutations and MSI as opposed to controls, but the results were not statistically significant.
  • In conclusion, there was a direct relationship between tamoxifen exposure and overexpression of beta-catenin oncoprotein, which is known to play a major role in the pathogenesis of estrogen-driven, type I endometrial adenocarcinoma.
  • [MeSH-minor] Aged. Aged, 80 and over. Biomarkers, Tumor / metabolism. Carcinoma, Endometrioid / chemically induced. Carcinoma, Endometrioid / genetics. Carcinoma, Endometrioid / pathology. Female. Gene Expression Regulation, Neoplastic / drug effects. Humans. Microsatellite Instability. Middle Aged. Neoplasm Proteins / genetics. Neoplasm Proteins / metabolism. Neoplasm Staging. PTEN Phosphohydrolase / genetics. PTEN Phosphohydrolase / metabolism. Proto-Oncogene Proteins p21(ras) / genetics. Proto-Oncogene Proteins p21(ras) / metabolism. Survival Rate. beta Catenin / genetics. beta Catenin / metabolism

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. TAMOXIFEN .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18500270.001).
  • [ISSN] 1530-0285
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 0 / Biomarkers, Tumor; 0 / CTNNB1 protein, human; 0 / Neoplasm Proteins; 0 / beta Catenin; 094ZI81Y45 / Tamoxifen; EC 3.1.3.48 / PTEN protein, human; EC 3.1.3.67 / PTEN Phosphohydrolase; EC 3.6.5.2 / Proto-Oncogene Proteins p21(ras)
  •  go-up   go-down


14. Nishimura N, Hachisuga T, Yokoyama M, Iwasaka T, Kawarabayashi T: Clinicopathologic analysis of the prognostic factors in women with coexistence of endometrioid adenocarcinoma in the endometrium and ovary. J Obstet Gynaecol Res; 2005 Apr;31(2):120-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinicopathologic analysis of the prognostic factors in women with coexistence of endometrioid adenocarcinoma in the endometrium and ovary.
  • AIM: To compare the survival and prognostic factors of patients with dual primary ovarian and endometrial cancers (primary group), and endometrial cancers metastatic to the ovaries (metastatic group).
  • METHODS: Thirty-six patients with gross tumors confined to the pelvis and of endometrioid adenocarcinoma subtype in both the endometrium and ovary were selected from our file of 546 Japanese women with endometrial carcinoma.
  • CONCLUSION: When encountering women with coexisting endometrioid carcinoma in the endometrium and ovary with gross tumor limited to the pelvis, more attention should be paid to LVSI of the tumor of the uterus as a poor prognostic indicator.
  • [MeSH-major] Carcinoma, Endometrioid / pathology. Endometrial Neoplasms / pathology. Ovarian Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15771637.001).
  • [ISSN] 1341-8076
  • [Journal-full-title] The journal of obstetrics and gynaecology research
  • [ISO-abbreviation] J. Obstet. Gynaecol. Res.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


15. Kulkarni JN, Gorasia TK, Choudhary JP, Mahajan PP: Endometrioid carcinoma of the upper urinary tract. J Cancer Res Ther; 2010 Oct-Dec;6(4):578-80
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endometrioid carcinoma of the upper urinary tract.
  • Herein, we report a second case of endometrioid carcinoma of the upper urinary tract presenting 17 years after hysterectomy for high grade adenocarcinoma of ovary.
  • The histology showed endometrioid carcinoma of upper urinary tract without any evidence of endometriosis.
  • [MeSH-major] Endometrial Neoplasms / diagnosis. Urologic Neoplasms / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21358108.001).
  • [ISSN] 1998-4138
  • [Journal-full-title] Journal of cancer research and therapeutics
  • [ISO-abbreviation] J Cancer Res Ther
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] India
  •  go-up   go-down


16. Pieretti-Vanmarcke R, Donahoe PK, Pearsall LA, Dinulescu DM, Connolly DC, Halpern EF, Seiden MV, MacLaughlin DT: Mullerian Inhibiting Substance enhances subclinical doses of chemotherapeutic agents to inhibit human and mouse ovarian cancer. Proc Natl Acad Sci U S A; 2006 Nov 14;103(46):17426-31
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mullerian Inhibiting Substance enhances subclinical doses of chemotherapeutic agents to inhibit human and mouse ovarian cancer.
  • Mullerian Inhibiting Substance (MIS), a biological modifier that causes regression of Mullerian ducts in male embryos, is effective as a single agent in vitro and in vivo against human and mouse ovarian cancer cell lines expressing MIS type II receptor; however, little is known about how recombinant human MIS (rhMIS), now being scaled for preclinical trials, could be used in combination with cytotoxic or targeted chemotherapeutic agents.
  • Mouse serous and endometrioid ovarian carcinoma cell lines were tested in vitro against rhMIS alone and with doxorubicin, paclitaxel, or cisplatin as agents in clinical use.
  • MIS increases p16 protein levels, and 5'-Aza-2'-deoxycytidine (AzadC) induces p16 mRNA; therefore, they were used in combination in vitro and in vivo with a human ovarian cancer cell line.
  • A paclitaxel-resistant human ovarian cancer cell line and its parental line both respond to rhMIS in vitro.
  • Additivity, synergy, or competition was observed with MIS and rapamycin, AzadC, doxorubicin, cisplatin, and paclitaxel, suggesting that MIS in combination with selective targeted therapies might achieve greater activity against ovarian cancer than the use of each individual agent alone.

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. MELPHALAN .
  • Hazardous Substances Data Bank. AZACITIDINE .
  • Hazardous Substances Data Bank. TAXOL .
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Biomed Sci. 1994 Jun;51(2):147-57 [8049612.001]
  • [Cites] Cancer Res. 1997 Mar 1;57(5):850-6 [9041185.001]
  • [Cites] Cancer Res. 1995 Oct 15;55(20):4525-30 [7553621.001]
  • [Cites] Am J Anat. 1977 Jul;149(3):353-75 [879051.001]
  • [Cites] J Surg Res. 1977 Aug;23(2):141-8 [886843.001]
  • [Cites] Science. 1979 Aug 31;205(4409):913-5 [472712.001]
  • [Cites] Am J Anat. 1979 Oct;156(2):265-84 [506954.001]
  • [Cites] Dev Biol. 1982 Jul;92(1):16-26 [7106377.001]
  • [Cites] Dev Biol. 1982 Jul;92(1):27-40 [7106385.001]
  • [Cites] Cancer Res. 1985 Oct;45(10):4970-9 [3861241.001]
  • [Cites] Cell. 1986 Jun 6;45(5):685-98 [3754790.001]
  • [Cites] Cancer Res. 1991 Apr 15;51(8):2101-6 [2009529.001]
  • [Cites] N Engl J Med. 1992 Feb 13;326(7):466-71 [1732773.001]
  • [Cites] Cancer Res. 1992 Mar 1;52(5):1182-6 [1531323.001]
  • [Cites] Protein Expr Purif. 1992 Jun;3(3):236-45 [1392620.001]
  • [Cites] Development. 1994 Jan;120(1):189-97 [8119126.001]
  • [Cites] Oncogene. 1995 Sep 21;11(6):1211-6 [7566983.001]
  • [Cites] Nat Med. 1995 Jul;1(7):686-92 [7585152.001]
  • [Cites] Endocrinology. 1996 Jan;137(1):160-5 [8536608.001]
  • [Cites] Cell. 1996 Aug 9;86(3):435-44 [8756725.001]
  • [Cites] N Engl J Med. 1997 May 22;336(21):1480-6 [9154766.001]
  • [Cites] Cancer Res. 1998 Jul 1;58(13):2825-31 [9661897.001]
  • [Cites] Gynecol Oncol. 1999 Apr;73(1):51-5 [10094880.001]
  • [Cites] Development. 1999 Jun;126(11):2551-61 [10226013.001]
  • [Cites] Endocrinology. 1999 Oct;140(10):4732-8 [10499532.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Jan 4;102(1):111-6 [15618407.001]
  • [Cites] Nat Med. 2005 Jan;11(1):63-70 [15619626.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Nov 23;96(24):13831-8 [10570158.001]
  • [Cites] Clin Cancer Res. 1999 Nov;5(11):3488-99 [10589763.001]
  • [Cites] J Biol Chem. 2000 Sep 8;275(36):27973-8 [10854429.001]
  • [Cites] J Biol Chem. 2000 Sep 15;275(37):28371-9 [10874041.001]
  • [Cites] J Biol Chem. 2000 Nov 24;275(47):37101-9 [10958795.001]
  • [Cites] N Engl J Med. 2001 Mar 15;344(11):783-92 [11248153.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Mar 13;98(6):3214-9 [11248058.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Mar 13;98(6):3393-7 [11248089.001]
  • [Cites] Mol Endocrinol. 2001 Jun;15(6):936-45 [11376112.001]
  • [Cites] Mol Endocrinol. 2001 Jun;15(6):946-59 [11376113.001]
  • [Cites] J Biol Chem. 2001 Jul 20;276(29):26799-806 [11356848.001]
  • [Cites] Nature. 2001 Nov 1;414(6859):105-11 [11689955.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Jan 8;99(1):239-44 [11773638.001]
  • [Cites] J Chromatogr B Analyt Technol Biomed Life Sci. 2002 Jan 5;766(1):89-98 [11820299.001]
  • [Cites] Clin Cancer Res. 2002 Aug;8(8):2640-6 [12171896.001]
  • [Cites] Nat Genet. 2002 Nov;32(3):408-10 [12368913.001]
  • [Cites] CA Cancer J Clin. 2003 Jan-Feb;53(1):5-26 [12568441.001]
  • [Cites] Cancer Res. 2003 Mar 15;63(6):1389-97 [12649204.001]
  • [Cites] Mol Cell Endocrinol. 2003 Dec 15;211(1-2):43-9 [14656475.001]
  • [Cites] J Biol Chem. 2003 Dec 19;278(51):51703-12 [14532292.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Dec 23;100(26):15601-6 [14671316.001]
  • [Cites] J Biol Chem. 2004 Jan 23;279(4):2737-46 [14576155.001]
  • [Cites] Front Biosci. 2004 Jan 1;9:619-31 [14766396.001]
  • [Cites] Int J Cancer. 2004 May 1;109(5):759-67 [14999786.001]
  • [Cites] N Engl J Med. 2004 Jun 3;350(23):2335-42 [15175435.001]
  • [Cites] Gynecol Oncol. 2004 Oct;95(1):1-8 [15385103.001]
  • [Cites] Clin Cancer Res. 2004 Oct 15;10(20):6779-88 [15501954.001]
  • [Cites] J Clin Oncol. 2005 Jun 10;23(17):3948-56 [15883410.001]
  • [Cites] J Clin Oncol. 2005 Nov 1;23(31):7889-96 [16204015.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Nov 8;102(45):16421-5 [16260730.001]
  • [Cites] Clin Cancer Res. 2006 Mar 1;12(5):1593-8 [16533786.001]
  • [Cites] Nature. 2006 Mar 30;440(7084):702-6 [16572177.001]
  • [Cites] Development. 2006 Jun;133(12):2359-69 [16687449.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Jul 25;103(30):11154-9 [16849428.001]
  • [Cites] Mol Endocrinol. 1994 Aug;8(8):1006-20 [7997230.001]
  • (PMID = 17088539.001).
  • [ISSN] 0027-8424
  • [Journal-full-title] Proceedings of the National Academy of Sciences of the United States of America
  • [ISO-abbreviation] Proc. Natl. Acad. Sci. U.S.A.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / K24 CA109416; United States / NCI NIH HHS / CA / U01 CA084242; United States / NCI NIH HHS / CA / R01 CA017393; United States / NCI NIH HHS / CA / CA 17393; United States / NCI NIH HHS / CA / 1K24 CA109416; United States / NCI NIH HHS / CA / P50 CA083638; United States / NICHD NIH HHS / HD / HD 32212
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Glycoproteins; 0 / Immunoglobulin G; 0 / Receptors, Peptide; 0 / Receptors, Transforming Growth Factor beta; 0 / Testicular Hormones; 0 / anti-Mullerian hormone receptor; 0 / antineoplastic agent K 18; 776B62CQ27 / decitabine; 80497-65-0 / Anti-Mullerian Hormone; M801H13NRU / Azacitidine; P88XT4IS4D / Paclitaxel; Q41OR9510P / Melphalan
  • [Other-IDs] NLM/ PMC1859945
  •  go-up   go-down


17. Mechery J, Adeyemi O: Testosterone secreting endometrioid adenocarcinoma of the ovary. J Obstet Gynaecol; 2005 Nov;25(8):822-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Testosterone secreting endometrioid adenocarcinoma of the ovary.
  • [MeSH-major] Carcinoma, Endometrioid / secretion. Ovarian Neoplasms / secretion. Testosterone / secretion

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. TESTOSTERONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16368600.001).
  • [ISSN] 0144-3615
  • [Journal-full-title] Journal of obstetrics and gynaecology : the journal of the Institute of Obstetrics and Gynaecology
  • [ISO-abbreviation] J Obstet Gynaecol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 3XMK78S47O / Testosterone
  •  go-up   go-down


18. Wang V, Li C, Lin M, Welch W, Bell D, Wong YF, Berkowitz R, Mok SC, Bandera CA: Ovarian cancer is a heterogeneous disease. Cancer Genet Cytogenet; 2005 Sep;161(2):170-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ovarian cancer is a heterogeneous disease.
  • The purpose of this study was to systematically evaluate the molecular profiles of different histologic types of epithelial ovarian cancer before the disease has metastasized beyond the ovary.
  • Stage 1 epithelial ovarian cancers were chosen for analysis of early genetic events associated with different cell types.
  • Hierarchal clustering analysis using dChip software revealed that the pattern of allele loss in eight regions on four chromosomes led to grouping of grade 3 tumors, endometrioid (grades 1 and 2) tumors, and clear cell tumors.
  • We conclude that ovarian cancer is a heterogeneous disease in which histologic phenotypes correlate with distinct genetic patterns.
  • [MeSH-major] Loss of Heterozygosity. Ovarian Neoplasms / genetics
  • [MeSH-minor] Adenocarcinoma, Clear Cell / genetics. Carcinoma, Endometrioid. Cystadenocarcinoma, Mucinous / genetics. Cystadenocarcinoma, Serous / genetics. Female. Humans

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16102589.001).
  • [ISSN] 0165-4608
  • [Journal-full-title] Cancer genetics and cytogenetics
  • [ISO-abbreviation] Cancer Genet. Cytogenet.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA86381; United States / NICHD NIH HHS / HD / K12-HD01265; United States / NCI NIH HHS / CA / P50CA165009; United States / NCI NIH HHS / CA / R33CA103595
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  •  go-up   go-down


19. Huang YD, Hung YC, Yeh LS, Chiang IP, Zeng GC, Chang WC: Synchronous ovarian endometrioid adenocarcinoma and endocervical mucinous adenocarcinoma. Taiwan J Obstet Gynecol; 2006 Sep;45(3):264-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Synchronous ovarian endometrioid adenocarcinoma and endocervical mucinous adenocarcinoma.
  • OBJECTIVE: We report a rare case of synchronous cancer consisting of ovarian endometrioid adenocarcinoma and endocervical mucinous adenocarcinoma.
  • Cytology of the pleural effusion showed no malignant cells.
  • Histology showed moderately to poorly differentiated endometrioid adenocarcinoma of the right ovary with extensive lymphovascular permeation, as well as paraaortic and bilateral pelvic lymph node metastases.
  • Extensive tumor thrombi were observed in the lymphovascular channels of the left ovary, bilateral tubes and uterus.
  • Endocervical adenocarcinoma, < 3 mm in depth, was also identified on the cervix.
  • The final surgical-pathologic stage of ovarian endometrioid adenocarcinoma was stage IIIc and of endocervical mucinous adenocarcinoma was stage IA1.
  • Adjuvant chemotherapy with carboplatin and paclitaxel was prescribed postoperatively, but the malignancy was not controlled due to lung, brain and vulva metastases.
  • CONCLUSION: The coexistence of primary neoplasms in the ovary and cervix is rare.
  • Diagnosis should be based on histologic examination and requires appropriate treatment for both tumors.
  • [MeSH-major] Adenocarcinoma, Mucinous / epidemiology. Carcinoma, Endometrioid / epidemiology. Neoplasms, Multiple Primary / pathology. Ovarian Neoplasms / epidemiology. Uterine Cervical Neoplasms / epidemiology


20. Cirpan T, Aygul S, Terek MC, Kazandi M, Dikmen Y, Zekioglu O, Sagol S: MMAC tumor supressor gene expression in ovarian endometriosis and ovarian adenocarcinoma. Eur J Gynaecol Oncol; 2007;28(4):278-81
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] MMAC tumor supressor gene expression in ovarian endometriosis and ovarian adenocarcinoma.
  • OBJECTIVE: The aim of this study was to investigate the role of MMAC1 protein in the relationship between ovarian endometriosis and clear cell and endometrioid-type ovarian adenocarcinomas.
  • METHODS: A total of 63 subjects who underwent surgery for a pelvic tumoral mass, 30 of whom were diagnosed with grade 1 to 3 ovarian adenocarcinoma and 33 of whom were diagnosed with grade 1 to 4 endometriosis during histopathological examination were included in this study.
  • The mean age for subjects with ovarian endometrioid type adenocarcinoma was 51.8 +/- 12.4, whereas the mean age for subjects with ovarian clear cell type adenocarcinoma was 59.5 +/- 13.7.
  • Ovarian carcinomas were graded in accordance with the FIGO 1989 grading system.
  • RESULTS: Of the 63 subjects included in the immunohistochemical study, ovarian endometrioid adenocarcinoma was identified in 18 subjects, while 12 subjects were diagnosed with ovarian clear cell adenocarcinoma and 33 subjects with ovarian endometriosis.
  • No significant relationships were observed between age and MMAC immune staining in the ovarian endometrioid adenocarcinoma (r = -0.41, p = 0.08) and ovarian endometriosis (r = 0.12, p = 0.50) groups, whereas a significant relationship was observed in the ovarian clear cell adenocarcinoma group (r = 0.631, p = 0.02).
  • No significant relationships were observed between CA125 levels and MMAC immune staining in the ovarian endometrioide adenocarcinoma (r = 0.056, p = 0.82), ovarian endometriosis (r = 0.21, p = 0.36) and ovarian clear cell adenocarcinoma (r = 0.363, p = 0.24) groups.
  • No correlations were detected between MMAC immune staining and ovarian endometrioide adenocarcinoma or ovarian clear cell adenocarcinoma stage (r = -0.22, p = 0.37; r = 0.44, p = 0.14, respectively).
  • No significant relationships with respect to MMAC immune staining were detected between the endometriosis and ovarian clear cell adenocarcinoma groups (p = 0.05) and between the ovarian clear cell adenocarcinoma and ovarian endometrioid adenocarcinoma groups (p = 0.27).
  • A significant relationship with respect to MMAC immune staining was observed between ovarian endometrioide adenocarcinoma and endometriosis groups (p = 0.001).
  • CONCLUSION: Immunohistochemical determination of MMAC defective protein expressions could be considered for utilization as a new, simple and useful technique in determination of endometriosis patients with increased risk of malignant transformation, patients where early surgical treatment would be necessary and patients that should be subjected to follow-up controls with a higher frequency.
  • [MeSH-major] Adenocarcinoma, Clear Cell / genetics. Endometriosis / genetics. Ovarian Neoplasms / genetics. PTEN Phosphohydrolase / metabolism
  • [MeSH-minor] Adult. Cell Transformation, Neoplastic. Female. Genes, Tumor Suppressor / physiology. Humans. Immunohistochemistry. Middle Aged. Ovarian Diseases / diagnosis. Ovarian Diseases / genetics


21. Tringler B, Liu W, Corral L, Torkko KC, Enomoto T, Davidson S, Lucia MS, Heinz DE, Papkoff J, Shroyer KR: B7-H4 overexpression in ovarian tumors. Gynecol Oncol; 2006 Jan;100(1):44-52
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] B7-H4 overexpression in ovarian tumors.
  • OBJECTIVES: Despite great advances in therapeutic management, the mortality rate for ovarian cancer has remained relatively stable over the past 50 years.
  • This study was designed to evaluate the expression of B7-H4 protein, recently identified as a potential molecular marker of breast and ovarian cancer by quantitative PCR analysis, in benign tumors, tumors of low malignant potential and malignant tumors of the ovary.
  • METHODS: Archival formalin-fixed tissue blocks from serous, mucinous, endometrioid and clear cell ovarian tumors were evaluated by immunohistochemistry for the distribution of B7-H4 expression, and staining intensity was measured by automated image analysis.
  • RESULTS: B7-H4 cytoplasmic and membranous expression was detected in all primary serous (n = 32), endometrioid (n = 12), and clear cell carcinomas (n = 15), and in all metastatic serous (n = 23) and endometrioid (n = 7) ovarian carcinomas.
  • The proportion of positive cells and median staining intensity was greater in serous carcinomas than in serous cystadenomas or serous tumors of low malignant potential, and the differences were statistically significant (P < 0.0001 and P = 0.034, respectively).
  • The median staining intensity was also significantly greater in endometrioid carcinomas than in endometriosis (P = 0.005).
  • CONCLUSIONS: The consistent overexpression of B7-H4 in serous, endometrioid and clear cell ovarian carcinomas and the relative absence of expression in most normal somatic tissues indicates that B7-H4 should be further investigated as a potential diagnostic marker or therapeutic target for ovarian cancer.
  • [MeSH-major] Antigens, CD80 / biosynthesis. Biomarkers, Tumor / biosynthesis. Ovarian Neoplasms / metabolism
  • [MeSH-minor] Adenocarcinoma, Clear Cell / immunology. Adenocarcinoma, Clear Cell / metabolism. Adenocarcinoma, Clear Cell / pathology. Adenocarcinoma, Mucinous / immunology. Adenocarcinoma, Mucinous / metabolism. Adenocarcinoma, Mucinous / pathology. Adult. Aged. Aged, 80 and over. Blotting, Western. Carcinoma, Endometrioid / immunology. Carcinoma, Endometrioid / metabolism. Carcinoma, Endometrioid / pathology. Cystadenocarcinoma, Serous / immunology. Cystadenocarcinoma, Serous / metabolism. Cystadenocarcinoma, Serous / pathology. Female. Humans. Immunohistochemistry. Middle Aged. Neoplasm Metastasis. Neoplasm Staging. V-Set Domain-Containing T-Cell Activation Inhibitor 1

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16256178.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD80; 0 / Biomarkers, Tumor; 0 / V-Set Domain-Containing T-Cell Activation Inhibitor 1; 0 / VTCN1 protein, human
  •  go-up   go-down


22. Dai L, Li C, Shedden KA, Misek DE, Lubman DM: Comparative proteomic study of two closely related ovarian endometrioid adenocarcinoma cell lines using cIEF fractionation and pathway analysis. Electrophoresis; 2009 Apr;30(7):1119-31
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparative proteomic study of two closely related ovarian endometrioid adenocarcinoma cell lines using cIEF fractionation and pathway analysis.
  • The proteomic profiles from two distinct ovarian endometrioid tumor-derived cell lines, (MDAH-2774 and TOV-112D) each with different morphological characteristics and genetic mutations, have been studied.
  • Characterization of the differential global protein expression between these two cell lines has important implications for the understanding of the pathogenesis of ovarian endometrioid carcinoma.
  • Canonical pathway analysis using IPA demonstrates that important signaling pathways are highly associated with one of these two cell lines versus the other, such as the PI3K/AKT pathway, which is found to be significantly predominant in MDAH-2774 but not in TOV-112D.

  • COS Scholar Universe. author profiles.
  • Cellosaurus - a cell line knowledge resource. culture/stock collections - Cellosaurus - a cell line knowledge resource .
  • Cellosaurus - a cell line knowledge resource. culture/stock collections - Cellosaurus - a cell line knowledge resource .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Cancer. 2000 Jan;82(1):142-50 [10638981.001]
  • [Cites] J Immunol. 2008 Apr 15;180(8):5575-81 [18390742.001]
  • [Cites] Nat Biotechnol. 2001 Mar;19(3):242-7 [11231557.001]
  • [Cites] Cancer. 2001 Apr 15;91(8):1494-9 [11301397.001]
  • [Cites] Oncogene. 2001 Oct 4;20(45):6617-26 [11641787.001]
  • [Cites] Cancer Res. 2001 Nov 15;61(22):8247-55 [11719457.001]
  • [Cites] Cancer. 2001 Dec 15;92(12):3068-75 [11753986.001]
  • [Cites] Proteomics. 2002 Jan;2(1):76-84 [11788994.001]
  • [Cites] Anal Chem. 2002 Oct 15;74(20):5383-92 [12403597.001]
  • [Cites] Hematol Oncol Clin North Am. 2003 Aug;17(4):927-43 [12959183.001]
  • [Cites] Anal Chem. 2004 Jul 15;76(14):4193-201 [15253663.001]
  • [Cites] Proteomics. 2004 Aug;4(8):2476-95 [15274142.001]
  • [Cites] Cancer. 1978 Nov;42(5):2352-9 [719612.001]
  • [Cites] Br J Cancer. 1996 Sep;74(5):717-21 [8795573.001]
  • [Cites] Curr Opin Oncol. 1997 Sep;9(5):465-70 [9327225.001]
  • [Cites] Int J Cancer. 1997 Nov 27;73(5):678-83 [9398045.001]
  • [Cites] Cytometry. 1999 Oct 15;38(5):201-13 [10516606.001]
  • [Cites] Cancer Res. 2004 Nov 1;64(21):7678-81 [15520168.001]
  • [Cites] J Proteome Res. 2005 Jan-Feb;4(1):36-42 [15707355.001]
  • [Cites] Electrophoresis. 2005 Apr;26(7-8):1383-8 [15759303.001]
  • [Cites] Mol Cell Biochem. 2005 Jul;275(1-2):25-55 [16335783.001]
  • [Cites] J Proteome Res. 2007 Jun;6(6):2186-94 [17441747.001]
  • [Cites] Brief Bioinform. 2008 Mar;9(2):156-65 [17905794.001]
  • [Cites] In Vitro Cell Dev Biol Anim. 2000 Jun;36(6):357-61 [10949993.001]
  • (PMID = 19288585.001).
  • [ISSN] 1522-2683
  • [Journal-full-title] Electrophoresis
  • [ISO-abbreviation] Electrophoresis
  • [Language] ENG
  • [Grant] United States / NIGMS NIH HHS / GM / R01 GM049500-12; United States / NCI NIH HHS / CA / R01 CA100104; United States / NIGMS NIH HHS / GM / R01GM49500; United States / NIGMS NIH HHS / GM / GM049500-12; United States / NIGMS NIH HHS / GM / R01 GM049500; United States / NCI NIH HHS / CA / R01CA100104; United States / NCI NIH HHS / CA / R01 CA100104-05; United States / NCI NIH HHS / CA / CA100104-05
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Validation Studies
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Proteome
  • [Other-IDs] NLM/ NIHMS80058; NLM/ PMC2674123
  •  go-up   go-down


23. Deodhar KK: Multinucleate (histiocytic) giant cells in endometrioid adenocarcinoma of the ovary: a rare finding. Indian J Pathol Microbiol; 2010 Oct-Dec;53(4):883-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multinucleate (histiocytic) giant cells in endometrioid adenocarcinoma of the ovary: a rare finding.
  • [MeSH-major] Carcinoma, Endometrioid / pathology. Cell Nucleus / pathology. Giant Cells / cytology. Ovarian Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21045467.001).
  • [ISSN] 0974-5130
  • [Journal-full-title] Indian journal of pathology & microbiology
  • [ISO-abbreviation] Indian J Pathol Microbiol
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] India
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, Differentiation, Myelomonocytic; 0 / CD68 antigen, human
  •  go-up   go-down


24. Silva EG, Deavers MT, Bodurka DC, Malpica A: Association of low-grade endometrioid carcinoma of the uterus and ovary with undifferentiated carcinoma: a new type of dedifferentiated carcinoma? Int J Gynecol Pathol; 2006 Jan;25(1):52-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Association of low-grade endometrioid carcinoma of the uterus and ovary with undifferentiated carcinoma: a new type of dedifferentiated carcinoma?
  • Low-grade endometrioid carcinomas, either of the endometrium or the ovaries, usually have an excellent prognosis.
  • The association of this type of tumor with undifferentiated carcinoma is rare.
  • The endometrioid carcinoma involved the endometrium in 14 cases, the endometrium and 1 or both ovaries in 9 cases, and the ovaries in 2 cases.
  • Undifferentiated carcinoma associated with low-grade endometrioid carcinoma was found at presentation in 19 grade 1 or 2 endometrioid carcinomas: 15 in the endometrium and 5 in the ovary.
  • In one of these cases, undifferentiated carcinoma was found in the endometrium and the ovary.
  • Undifferentiated carcinoma was found after resection of low-grade endometrioid carcinoma in six cases, involving the retroperitoneum, pelvis, vagina, or liver.
  • The undifferentiated carcinoma was composed exclusively of diffuse sheets and solid nests of epithelial cells in l0 cases.
  • In four cases, the diagnosis was made recently, with short follow-ups of 3 and 4 months.
  • Foci of undifferentiated carcinoma may be confused with solid endometrioid adenocarcinoma erroneously leading to the diagnosis of a grade 3 or a significantly less aggressive grade 2 endometrioid carcinoma.
  • The recognition of undifferentiated carcinoma in an otherwise low-grade endometrioid adenocarcinoma is extremely important because it indicates aggressive behavior.
  • [MeSH-major] Carcinoma, Endometrioid / pathology. Cell Transformation, Neoplastic. Endometrial Neoplasms / pathology. Ovarian Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Int J Gynecol Pathol. 2006 Jul;25(3):304
  • (PMID = 16306785.001).
  • [ISSN] 0277-1691
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


25. Kurman RJ, McConnell TG: Precursors of endometrial and ovarian carcinoma. Virchows Arch; 2010 Jan;456(1):1-12
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Precursors of endometrial and ovarian carcinoma.
  • This review discusses precursor lesions of endometrial and ovarian carcinoma with an emphasis on the unique molecular alterations that have led to the development of binary classification schemes for tumors of both the endometrium and ovary.
  • While such a system is well established for endometrial carcinoma, only recently has a binary classification scheme been proposed for ovarian carcinoma.
  • Furthermore, similarities and differences of the precursor lesions of specific tumors of these two genital tract organs are also addressed with a brief discussion of the clinical implications of their diagnosis.
  • [MeSH-major] Endometrial Neoplasms / pathology. Ovarian Neoplasms / pathology. Precancerous Conditions / pathology
  • [MeSH-minor] Adenocarcinoma, Mucinous / pathology. Carcinoma, Endometrioid / pathology. Endometrial Hyperplasia / pathology. Female. Humans. Tumor Suppressor Protein p53 / metabolism

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gynecol Oncol. 1995 Oct;59(1):81-6 [7557621.001]
  • [Cites] Cancer Res. 1991 Oct 1;51(19):5308-14 [1913654.001]
  • [Cites] Br J Cancer. 2001 Jan;84(2):209-17 [11161379.001]
  • [Cites] Jpn J Cancer Res. 1999 Jan;90(1):55-9 [10076565.001]
  • [Cites] Cancer Res. 1998 Aug 1;58(15):3254-8 [9699651.001]
  • [Cites] Proc Natl Acad Sci U S A. 1993 Jun 1;90(11):4961-5 [8506342.001]
  • [Cites] Clin Cancer Res. 2008 Apr 15;14(8):2263-9 [18369088.001]
  • [Cites] Gynecol Oncol. 1992 Jul;46(1):51-4 [1634141.001]
  • [Cites] Int J Gynecol Pathol. 2000 Oct;19(4):314-21 [11109159.001]
  • [Cites] Cancer Biol Ther. 2006 Jul;5(7):779-85 [16721043.001]
  • [Cites] Eur J Cancer. 2003 Sep;39(13):1818-27 [12932658.001]
  • [Cites] Int J Gynecol Pathol. 2008 Jan;27(1):1-9 [18156967.001]
  • [Cites] Cancer Res. 1998 May 15;58(10 ):2095-7 [9605750.001]
  • [Cites] Gynecol Oncol. 1994 Sep;54(3):264-8 [8088602.001]
  • [Cites] Int J Gynecol Pathol. 2008 Apr;27(2):151-60 [18317228.001]
  • [Cites] Int J Surg Pathol. 2004 Jul;12(3):207-23 [15306933.001]
  • [Cites] Gynecol Oncol. 1996 Feb;60(2):238-44 [8631545.001]
  • [Cites] Am J Surg Pathol. 1996 Nov;20(11):1331-45 [8898837.001]
  • [Cites] J Natl Cancer Inst. 2000 Jun 7;92 (11):924-30 [10841828.001]
  • [Cites] Cancer. 1985 Jul 15;56(2):403-12 [4005805.001]
  • [Cites] Gynecol Oncol. 2000 Apr;77(1):55-65 [10739691.001]
  • [Cites] Am J Pathol. 2004 May;164(5):1511-8 [15111296.001]
  • [Cites] Histopathology. 1995 Oct;27(4):367-71 [8847068.001]
  • [Cites] N Engl J Med. 1993 Oct 28;329(18):1318-27 [8413413.001]
  • [Cites] Am J Pathol. 1991 Oct;139(4):777-85 [1656759.001]
  • [Cites] Gynecol Oncol. 2008 May;109(2):168-73 [18342932.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Nov 10;95(23 ):13513-8 [9811831.001]
  • [Cites] Curr Opin Obstet Gynecol. 2007 Feb;19(1):3-9 [17218844.001]
  • [Cites] Am J Surg Pathol. 2006 May;30(5):614-24 [16699316.001]
  • [Cites] Hum Pathol. 2000 May;31(5):539-57 [10836293.001]
  • [Cites] Arch Pathol Lab Med. 1981 Nov;105(11):615-8 [6895302.001]
  • [Cites] Int J Gynecol Pathol. 2007 Apr;26(2):103-14 [17413975.001]
  • [Cites] Gynecol Oncol. 2006 Dec;103(3):883-7 [16806438.001]
  • [Cites] Am J Pathol. 1995 Jan;146(1):182-8 [7856726.001]
  • [Cites] Gynecol Oncol. 2003 Aug;90(2):378-81 [12893203.001]
  • [Cites] Am J Surg Pathol. 1992 Jun;16(6):600-10 [1599038.001]
  • [Cites] J Natl Cancer Inst. 1994 Aug 17;86(16):1216-21 [8040889.001]
  • [Cites] Am J Surg Pathol. 2009 Jun;33(6):844-53 [19342944.001]
  • [Cites] Int J Gynecol Pathol. 2008 Jul;27(3):318-25 [18580308.001]
  • [Cites] Anal Quant Cytol Histol. 1986 Mar;8(1):46-8 [3954843.001]
  • [Cites] Eur J Gynaecol Oncol. 2006;27(4):389-92 [17009632.001]
  • [Cites] Am J Surg Pathol. 1996 Nov;20(11):1319-30 [8898836.001]
  • [Cites] Am J Pathol. 1997 Jan;150(1):177-85 [9006334.001]
  • [Cites] Am J Pathol. 2001 Jun;158(6):1895-8 [11395362.001]
  • [Cites] Int J Gynecol Pathol. 2003 Jan;22(1):37-41 [12496696.001]
  • [Cites] J Natl Cancer Inst. 2000 Jul 5;92(13):1088-91 [10880552.001]
  • [Cites] Cancer Res. 2004 Oct 1;64(19):6915-8 [15466181.001]
  • [Cites] Int J Surg Pathol. 2004 Oct;12(4):319-31 [15494858.001]
  • [Cites] Cancer. 1998 Mar 15;82(6):1088-95 [9506354.001]
  • [Cites] J Pathol. 2004 Mar;202(3):336-40 [14991899.001]
  • [Cites] Am J Surg Pathol. 2005 Feb;29(2):218-24 [15644779.001]
  • [Cites] Cancer Res. 2000 Dec 15;60(24):7052-6 [11156411.001]
  • [Cites] Am J Obstet Gynecol. 1993 Jul;169(1):181-2 [8392791.001]
  • [Cites] J Pathol. 2006 Apr;208(5):708-13 [16429393.001]
  • [Cites] Int J Gynecol Cancer. 2008 May-Jun;18(3):487-91 [17692090.001]
  • [Cites] Histopathology. 1997 Mar;30(3):249-55 [9088954.001]
  • [Cites] Cancer Res. 2000 Mar 15;60(6):1750-2 [10749149.001]
  • [Cites] J Natl Cancer Inst. 1993 Sep 15;85(18):1513-9 [8360934.001]
  • [Cites] Gynecol Oncol. 2000 Mar;76(3):287-90 [10684697.001]
  • [Cites] Am J Surg Pathol. 2006 Feb;30(2):230-6 [16434898.001]
  • [Cites] Gynecol Oncol. 1983 Feb;15(1):10-7 [6822361.001]
  • [Cites] Cancer. 1994 Apr 1;73(7):1859-64 [8137211.001]
  • [Cites] Pathology. 1979 Jan;11(1):5-26 [431978.001]
  • [Cites] Gynecol Oncol. 1999 Sep;74(3):385-94 [10479498.001]
  • [Cites] Am J Surg Pathol. 1998 Aug;22(8):1012-9 [9706982.001]
  • [Cites] Cancer. 2000 Feb 15;88(4):814-24 [10679651.001]
  • [Cites] Am J Surg Pathol. 2005 Jun;29(6):707-23 [15897738.001]
  • [Cites] CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96 [18287387.001]
  • [Cites] Hum Pathol. 1995 Nov;26(11):1260-7 [7590702.001]
  • [Cites] Am J Pathol. 2009 May;174(5):1597-601 [19349352.001]
  • [Cites] J Pathol. 2001 Nov;195(4):451-6 [11745677.001]
  • [Cites] Am J Pathol. 2002 Apr;160(4):1223-8 [11943707.001]
  • [Cites] Histopathology. 1981 Jan;5(1):61-8 [7216177.001]
  • [Cites] Am J Surg Pathol. 1999 Sep;23(9):1102-8 [10478671.001]
  • [Cites] Oncogene. 1994 Apr;9(4):1163-6 [8134118.001]
  • [Cites] Jpn J Cancer Res. 1998 Oct;89(10 ):985-90 [9849574.001]
  • [Cites] N Engl J Med. 1988 Sep 1;319(9):525-32 [2841597.001]
  • [Cites] Virchows Arch. 2004 Mar;444(3):213-23 [14747944.001]
  • [Cites] Am J Surg Pathol. 1982 Mar;6(2):93-108 [7102898.001]
  • [Cites] Gynecol Obstet Invest. 2000;50 Suppl 1:44-50 [11093061.001]
  • [Cites] Hum Pathol. 1995 Nov;26(11):1268-74 [7590703.001]
  • [Cites] Gynecol Oncol. 1992 Dec;47(3):298-305 [1473741.001]
  • [Cites] Cancer Res. 1994 Mar 15;54(6):1604-7 [8137266.001]
  • [Cites] Cancer Res. 1998 Jun 15;58(12 ):2500-3 [9635567.001]
  • [Cites] J Natl Cancer Inst. 2003 Mar 19;95(6):484-6 [12644542.001]
  • [Cites] Cancer. 2008 Oct 15;113(8):2073-81 [18720479.001]
  • [Cites] Am J Surg Pathol. 2006 Dec;30(12):1519-30 [17122507.001]
  • (PMID = 19859732.001).
  • [ISSN] 1432-2307
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Tumor Suppressor Protein p53
  • [Number-of-references] 88
  •  go-up   go-down


26. Tafe LJ, Garg K, Chew I, Tornos C, Soslow RA: Endometrial and ovarian carcinomas with undifferentiated components: clinically aggressive and frequently underrecognized neoplasms. Mod Pathol; 2010 Jun;23(6):781-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endometrial and ovarian carcinomas with undifferentiated components: clinically aggressive and frequently underrecognized neoplasms.
  • Carcinomas of the endometrium and ovary with undifferentiated components are uncommon neoplasms that are likely underdiagnosed.
  • We identified 32 carcinomas with undifferentiated components as defined by Silva and co-workers, 26 endometrial and 6 of ovarian origin.
  • Most patients (58% of endometrial and 83% of ovarian carcinomas with undifferentiated components) presented at advanced stages (FIGO III-IV).
  • Twenty tumors, entirely undifferentiated, consisted of sheets of dyshesive, ovoid cells with uniform, large vesicular nuclei, whereas 12 tumors contained combinations of differentiated endometrioid adenocarcinoma with undifferentiated components.
  • The tumors were frequently misdiagnosed; they received a wide range of diagnoses, including FIGO grade 2 or 3 endometrioid carcinoma, carcinosarcoma, high-grade sarcoma including endometrial stromal sarcoma, neuroendocrine carcinoma, lymphoma, granulosa cell tumor and epithelioid sarcoma.
  • Endometrial and ovarian carcinomas with undifferentiated components have a broad histologic differential diagnosis, but they show specific histologic features that should enable accurate diagnosis.
  • [MeSH-major] Carcinoma / pathology. Cell Differentiation. Endometrial Neoplasms / pathology. Ovarian Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Biomarkers, Tumor / analysis. Biomarkers, Tumor / genetics. Carcinoma, Endometrioid / pathology. DNA Mismatch Repair. Diagnosis, Differential. Female. Gene Expression Regulation, Neoplastic. Humans. Immunohistochemistry. Lymphatic Metastasis. Microsatellite Instability. Middle Aged. Neoplasm Invasiveness. Neoplasm Staging. Predictive Value of Tests. Time Factors. Treatment Outcome. Young Adult

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20305618.001).
  • [ISSN] 1530-0285
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


27. Bignone PA, Lee KY, Liu Y, Emilion G, Finch J, Soosay AE, Charnock FM, Beck S, Dunham I, Mungall AJ, Ganesan TS: RPS6KA2, a putative tumour suppressor gene at 6q27 in sporadic epithelial ovarian cancer. Oncogene; 2007 Feb 1;26(5):683-700
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] RPS6KA2, a putative tumour suppressor gene at 6q27 in sporadic epithelial ovarian cancer.
  • It is expressed in normal ovarian epithelium, whereas reduced or absent in tumours or cell lines.
  • We show that RPS6KA2 is monoallelically expressed in the ovary suggesting that loss of a single expressed allele is sufficient to cause complete loss of expression in cancer cells.
  • Re-expression of RPS6KA2 in ovarian cancer cell lines suppressed colony formation.
  • [MeSH-major] Chromosomes, Human, Pair 6 / genetics. Genes, Tumor Suppressor / physiology. Neoplasms, Glandular and Epithelial / genetics. Ovarian Neoplasms / genetics. Ribosomal Protein S6 Kinases, 90-kDa / metabolism
  • [MeSH-minor] Adenocarcinoma, Clear Cell / genetics. Adenocarcinoma, Clear Cell / metabolism. Adenocarcinoma, Clear Cell / pathology. Adenocarcinoma, Mucinous / genetics. Adenocarcinoma, Mucinous / metabolism. Adenocarcinoma, Mucinous / pathology. Amino Acid Sequence. Apoptosis. Carcinoma, Endometrioid / genetics. Carcinoma, Endometrioid / metabolism. Carcinoma, Endometrioid / pathology. Cell Cycle. Cell Proliferation. Chromosome Deletion. Chromosome Mapping. Cystadenocarcinoma, Serous / genetics. Cystadenocarcinoma, Serous / metabolism. Cystadenocarcinoma, Serous / pathology. DNA Methylation. DNA, Neoplasm / genetics. DNA, Neoplasm / metabolism. Female. Gene Expression Regulation, Neoplastic. Humans. Immunoprecipitation. Loss of Heterozygosity. MAP Kinase Signaling System / genetics. Mitogen-Activated Protein Kinases. Molecular Sequence Data. Polymerase Chain Reaction. Polymorphism, Single-Stranded Conformational. RNA Interference. Sequence Homology, Amino Acid. Transfection. Tumor Cells, Cultured


28. Güzin K, Tekcan C, Naki MM, Kayataş S, Zemheri E, Kanadikirik F, Berkman S: Synchronous primary cancers of the endometrium and ovary: a case report. Eur J Gynaecol Oncol; 2006;27(4):425-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Synchronous primary cancers of the endometrium and ovary: a case report.
  • Synchronous primary cancers of the endometrium and ovary are found in 5% of women with endometrial cancer and 10% of women with ovarian cancer.
  • She did not define abnormal uterine bleeding.
  • Screening ultrasound revealed a papillary containing structure, irregular, cystic 16 x 15 x 10 cm right ovarian mass.
  • Preoperative endometrial biopsy revealed endometrioid adenocarcinoma.
  • Intraoperative and histological examinations showed Stage IIIC papillary serous carcinoma and stage IC endometrioid adenocarcinoma.
  • [MeSH-major] Carcinoma, Endometrioid / diagnosis. Endometrial Neoplasms / diagnosis. Neoplasms, Multiple Primary / etiology. Ovarian Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17009644.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


29. Dinulescu DM, Ince TA, Quade BJ, Shafer SA, Crowley D, Jacks T: Role of K-ras and Pten in the development of mouse models of endometriosis and endometrioid ovarian cancer. Nat Med; 2005 Jan;11(1):63-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Role of K-ras and Pten in the development of mouse models of endometriosis and endometrioid ovarian cancer.
  • Epithelial ovarian tumors present a complex clinical, diagnostic and therapeutic challenge because of the difficulty of early detection, lack of known precursor lesions and high mortality rates.
  • Endometrioid ovarian carcinomas are frequently associated with endometriosis, but the mechanism for this association remains unknown.
  • Here we present the first genetic models of peritoneal endometriosis and endometrioid ovarian adenocarcinoma in mice, both based on the activation of an oncogenic K-ras allele.
  • In addition, we find that expression of oncogenic K-ras or conditional Pten deletion within the ovarian surface epithelium gives rise to preneoplastic ovarian lesions with an endometrioid glandular morphology.
  • Furthermore, the combination of the two mutations in the ovary leads to the induction of invasive and widely metastatic endometrioid ovarian adenocarcinomas with complete penetrance and a disease latency of only 7 weeks.
  • The ovarian cancer model described in this study recapitulates the specific tumor histomorphology and metastatic potential of the human disease.
  • [MeSH-major] Disease Models, Animal. Endometriosis / genetics. Ovarian Neoplasms / genetics. Protein Tyrosine Phosphatases / genetics. Tumor Suppressor Proteins / genetics. ras Proteins / genetics


30. Bolat F, Gumurdulu D, Erkanli S, Kayaselcuk F, Zeren H, Ali Vardar M, Kuscu E: Maspin overexpression correlates with increased expression of vascular endothelial growth factors A, C, and D in human ovarian carcinoma. Pathol Res Pract; 2008;204(6):379-87
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Maspin overexpression correlates with increased expression of vascular endothelial growth factors A, C, and D in human ovarian carcinoma.
  • Few studies have compared maspin with VEGF in ovarian carcinoma.
  • Therefore, we investigated the expression and correlation of maspin, VEGFA, VEGFC, and VEGFD with the tumorigenesis of the ovary and clinicopathologic variables.
  • Using immunohistochemistry, we examined maspin, VEGFA, VEGFC, and VEGFD expression in 60 ovarian carcinoma tissues (35 serous papillary carcinomas, 18 endometrioid carcinomas, and 7 primary ovarian mucinous carcinomas).
  • The VEGFA score was positively correlated with high tumor grade (P=.04), lymphovascular space invasion (LVSI) (P<.001), International Federation of Gynecology and Obstetrics (FIGO) stage (P=.009), maspin, VEGFC (P=.003), and VEGFD (P=.003), but it was not correlated with the presence of ascites and metastatic lymph nodes.
  • Maspin, VEGFC, and VEGFD are expressed in ovarian tumors with a poor prognostic parameters, and seem to play a role in ovarian cancer angiogenesis, progression, and lymph node metastases.
  • Our results indicate that in contrast to most other carcinomas, maspin expression is directly associated with the biological aggressiveness of ovarian carcinoma.
  • These results may offer new insights regarding the role of maspin in ovarian cancer and might also affect the diagnosis and treatment strategies.
  • [MeSH-major] Adenocarcinoma / metabolism. Ovarian Neoplasms / metabolism. Serpins / metabolism. Vascular Endothelial Growth Factor A / metabolism. Vascular Endothelial Growth Factor C / metabolism. Vascular Endothelial Growth Factor D / metabolism
  • [MeSH-minor] Adolescent. Adult. Aged. Biomarkers, Tumor / metabolism. Female. Humans. Lymph Nodes / metabolism. Lymph Nodes / pathology. Lymphatic Metastasis. Middle Aged. Neoplasm Staging. Ovary / metabolism. Ovary / pathology. Prognosis. Survival Rate

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18343598.001).
  • [ISSN] 0344-0338
  • [Journal-full-title] Pathology, research and practice
  • [ISO-abbreviation] Pathol. Res. Pract.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / SERPIN-B5; 0 / Serpins; 0 / VEGFA protein, human; 0 / VEGFC protein, human; 0 / Vascular Endothelial Growth Factor A; 0 / Vascular Endothelial Growth Factor C; 0 / Vascular Endothelial Growth Factor D
  •  go-up   go-down


31. Terada T: Adenosquamous carcinoma of the ovary arising from endometriosis: two case reports. Cases J; 2009;2:6661
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenosquamous carcinoma of the ovary arising from endometriosis: two case reports.
  • The author reports two cases of adenosquamous carcinoma arising from endometriosis of ovaries.
  • Both patients underwent hysterectomy and bilateral salpingo-oophorectomy for ovarian carcinomas.
  • Grossly, both ovarian tumors were located in the left ovaries, and were cystic tumors with mural tumors.
  • Both mural tumors were composed of grade I endometroid adenocarcinoma and squamous cell carcinoma.
  • A differentiation of endometrioid adenocarcinoma from the endometriosis were present in a few areas.
  • Likewise, a differentiation of squamous cell carcinoma from the endometriosis were recognized in several areas.
  • The pathologic diagnosis was adenosquamous carcinoma arising from endometriosis of the ovary in both cases, rather than endometrioid adenocarcinoma with malignant squamous differentiation.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 1978 Jul;42(1):326-9 [208753.001]
  • [Cites] Gynecol Obstet Invest. 2000;50 Suppl 1:11-7 [11093056.001]
  • [Cites] Clin Obstet Gynecol. 1966 Jun;9(2):384-411 [5330412.001]
  • [Cites] Gynecol Oncol. 1988 May;30(1):143-8 [3366390.001]
  • (PMID = 20184682.001).
  • [ISSN] 1757-1626
  • [Journal-full-title] Cases journal
  • [ISO-abbreviation] Cases J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2827079
  •  go-up   go-down


32. Işin Doğan Ekici A, Küçükali T, Coşkun Salman M, Ayhan A: Triple simultaneous primary gynecological malignancies in a 56-year-old patient. Int J Gynecol Cancer; 2006 Sep-Oct;16(5):1947-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In this report, the clinical and pathologic findings of a 56-year-old female patient with synchronous triple primary gynecological cancers including well-differentiated ovarian mucinous cystadenocarcinoma, well-differentiated endometrial endometrioid adenocarcinoma, and uterine leiomyosarcoma were presented.
  • Synchronous primary, well-differentiated endometrial endometrioid adenocarcinoma and leiomyosarcoma of uterus without any ovarian neoplasm has only been once described in the English literature.
  • To our knowledge, the presented patient is the first case in aspect of accompanying ovarian mucinous adenocarcinoma to endometrial endometrioid adenocarcinoma and leiomyosarcoma of uterus.
  • [MeSH-major] Carcinoma, Endometrioid / pathology. Cystadenocarcinoma, Mucinous / pathology. Leiomyosarcoma / pathology. Neoplasms, Multiple Primary / pathology. Ovarian Neoplasms / pathology. Uterine Neoplasms / pathology
  • [MeSH-minor] Endometrium / pathology. Female. Humans. Middle Aged. Myometrium / pathology. Ovary / pathology

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17009998.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


33. McCluggage WG: Immunohistochemistry as a diagnostic aid in cervical pathology. Pathology; 2007 Feb;39(1):97-111
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • As with biopsies from other sites in the female genital tract, immunohistochemistry is now being increasingly used in cervical pathology as an aid to diagnosis.
  • In the broad field of cervical glandular lesions, topics covered include: the value of markers such as MIB1, p16 and bcl-2 in distinguishing adenocarcinoma in situ and glandular dysplasia from benign mimics; markers of mesonephric lesions, including CD10; markers of value in the diagnosis of minimal deviation adenocarcinoma, such as HIK1083; markers of value in distinguishing metastatic cervical adenocarcinoma in the ovary from primary ovarian endometrioid or mucinous adenocarcinoma.
  • A panel of markers, comprising oestrogen receptor, vimentin, monoclonal carcinoembryonic antigen and p16, is of value in distinguishing between a cervical adenocarcinoma and an endometrial adenocarcinoma of endometrioid type.
  • Markers of use in the diagnosis of cervical neuroendocrine neoplasms, including small cell and large cell neuroendocrine carcinoma, are discussed.
  • It is stressed that small cell neuroendocrine carcinomas may be negative with most of the commonly used neuroendocrine markers and this does not preclude the diagnosis. p63, a useful marker of squamous neoplasms within the cervix, is of value in distinguishing small cell neuroendocrine carcinoma (p63 negative) from small cell squamous carcinoma (p63 positive) and in confirming that a poorly differentiated carcinoma is squamous in type.
  • [MeSH-major] Biomarkers, Tumor / analysis. Uterine Cervical Neoplasms / diagnosis
  • [MeSH-minor] Diagnosis, Differential. Female. Humans. Immunohistochemistry

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • International Agency for Research on Cancer - Screening Group. diagnostics - A practical manual on visual screening for cervical neoplasia .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17365826.001).
  • [ISSN] 0031-3025
  • [Journal-full-title] Pathology
  • [ISO-abbreviation] Pathology
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Number-of-references] 104
  •  go-up   go-down


34. Castiblanco G A, Pires N Y, Wistuba O I, Riquelme S E, Andrade M L, Corvalán R A: [Pathogenic role of PTEN tumor suppressor gene in ovarian cancer associated to endometriosis]. Rev Med Chil; 2006 Mar;134(3):271-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Pathogenic role of PTEN tumor suppressor gene in ovarian cancer associated to endometriosis].
  • [Transliterated title] Rol patogénico del gen supresor de tumores PTEN en cáncer ovárico asociado a endometriosis.
  • BACKGROUND: Endometrioid carcinoma and clear cell carcinoma of the ovary are associated to endometriosis.
  • Somatic mutations of PTEN (10q23.3) are present in endometrial endometrioid carcinoma.
  • Therefore, these mutations could be also present in ovarian tumors.
  • AIM: To determine the cellular proliferation index using Ki 67, the immunohistochemical expression of PTEN and LOH in patients with ovarian endometriosis without atypia (EN), ovarian endometriosis with atypia (EA) and endometriosis with adjacent ovarian carcinoma (ET).
  • MATERIAL AND METHODS: Paraffin embedded samples of 37 endometrioid and clear cell carcinomas of the ovary (CC/CE), 15 solitary ovarian EN and 15 ovarian EA, were studied.
  • [MeSH-major] Adenocarcinoma, Clear Cell / genetics. Carcinoma, Endometrioid / genetics. Endometriosis / genetics. Ovarian Neoplasms / genetics. PTEN Phosphohydrolase / genetics


35. Määttä M, Bützow R, Luostarinen J, Petäjäniemi N, Pihlajaniemi T, Salo S, Miyazaki K, Autio-Harmainen H, Virtanen I: Differential expression of laminin isoforms in ovarian epithelial carcinomas suggesting different origin and providing tools for differential diagnosis. J Histochem Cytochem; 2005 Oct;53(10):1293-300
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differential expression of laminin isoforms in ovarian epithelial carcinomas suggesting different origin and providing tools for differential diagnosis.
  • Immunohistochemistry was used to study the distribution of laminin (Ln) chains, collagen types IV (alpha 1/2), VII, and XVIII and Lutheran antigen (Lu) in 36 frozen ovarian carcinoma samples.
  • Surface epithelial basement membrane (BM) of the normal ovary showed immunoreactivity for Ln alpha1, alpha3-alpha5, beta1-3, gamma1, and gamma2 chains and type IV and XVIII collagens.
  • Contrary to serous tumors, BMs of mucinous carcinomas showed Ln alpha4 chain, but not Ln alpha1 and beta2 chains.
  • Ln alpha1 chain was found in most endometrioid carcinomas, whereas chains of Ln-5 were only moderately detectable in comparison with serous and mucinous carcinomas.
  • In the normal ovary, Lu immunoreactivity was confined to basal aspect in the ovarian epithelial cells, but in tumor specimens Lu immunostainings showed variable polarized and nonpolarized patterns.
  • The results suggest that the three types of ovarian carcinoma have distinct differences in their Ln distribution and can be grouped based on their expression pattern.
  • [MeSH-major] Adenocarcinoma / metabolism. Laminin / biosynthesis. Ovarian Neoplasms / metabolism
  • [MeSH-minor] Basement Membrane / metabolism. Carcinoma, Endometrioid / diagnosis. Carcinoma, Endometrioid / metabolism. Carcinoma, Endometrioid / ultrastructure. Cystadenocarcinoma, Mucinous / diagnosis. Cystadenocarcinoma, Mucinous / metabolism. Cystadenocarcinoma, Mucinous / ultrastructure. Cystadenocarcinoma, Serous / diagnosis. Cystadenocarcinoma, Serous / metabolism. Cystadenocarcinoma, Serous / ultrastructure. Diagnosis, Differential. Epithelium / metabolism. Epithelium / ultrastructure. Female. Humans. Immunohistochemistry. Ovary / metabolism. Ovary / ultrastructure. Protein Isoforms / biosynthesis

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15923364.001).
  • [ISSN] 0022-1554
  • [Journal-full-title] The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society
  • [ISO-abbreviation] J. Histochem. Cytochem.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Laminin; 0 / Protein Isoforms
  •  go-up   go-down


36. Storey DJ, Rush R, Stewart M, Rye T, Al-Nafussi A, Williams AR, Smyth JF, Gabra H: Endometrioid epithelial ovarian cancer : 20 years of prospectively collected data from a single center. Cancer; 2008 May 15;112(10):2211-20
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endometrioid epithelial ovarian cancer : 20 years of prospectively collected data from a single center.
  • BACKGROUND: Clinicopathological features and outcome of women with endometrioid and serous ovarian adenocarcinoma were compared.
  • METHODS: Between 1984 and 2004, baseline and follow-up data were prospectively recorded on 1545 patients with ovarian cancer.
  • Of these, 270 had pure endometrioid tumors; 659 had pure serous adenocarcinoma of the ovary.
  • RESULTS: Median age of diagnosis for patients with endometrioid tumors was younger than those with serous adenocarcinoma of the ovary (60 years vs 62 years; P = .013).
  • More endometrioid tumors were optimally debulked overall (71% vs 45%; P < .001), but there was no difference according to stage.
  • Objective and CA125 PBC response rates were not significantly different, but median PFS was better for patients with endometrioid tumors (24 months vs 13 months; P < .0001) as was overall median survival (48 months vs 22 months; P < .0001).
  • Patients with concurrent endometrioid ovarian and endometrial malignancies had a survival advantage compared with those with ovarian malignancies alone.
  • CONCLUSIONS: Despite similar PBC response rates, endometrioid histology is associated with better survival compared with serous adenocarcinoma of the ovary, even with stage III or poorly differentiated tumors.
  • [MeSH-major] Cystadenocarcinoma, Serous / pathology. Endometrial Neoplasms / pathology. Ovarian Neoplasms / pathology


37. Gungor T, Kanat-Pektas M, Ustunyurt E, Mollamahmutoglu L: Synchronous primary tumors of the female genital tract: a single center experience. Arch Gynecol Obstet; 2009 May;279(5):667-72
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: The majority of the study population (52.4%) was diagnosed with independent primary endometrial and ovarian tumors.
  • Tobacco use was significantly more frequent in women with synchronous cervical-ovarian tumors.
  • Diabetes mellitus and hypertension were significantly more frequent in women with endometrial-ovarian tumors.
  • Although the women with synchronous cervical-ovarian tumors were significantly younger and leaner, they had shorter survival periods.
  • Synchronous primary tumors of endometrium and ovary are supposed to have better prognosis as they are diagnosed at early stage and low grade.
  • [MeSH-major] Adenocarcinoma / epidemiology. Endometrial Neoplasms / epidemiology. Granulosa Cell Tumor / epidemiology. Neoplasms, Multiple Primary / epidemiology. Ovarian Neoplasms / epidemiology
  • [MeSH-minor] Adult. Age Factors. Aged. Aged, 80 and over. Carcinoma, Endometrioid. Cohort Studies. Female. Hospitals, Teaching. Humans. Middle Aged. Overweight. Retrospective Studies. Risk Factors. Survival Analysis. Turkey / epidemiology

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18802716.001).
  • [ISSN] 1432-0711
  • [Journal-full-title] Archives of gynecology and obstetrics
  • [ISO-abbreviation] Arch. Gynecol. Obstet.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


38. Rosen DG, Zhang Z, Chang B, Wang X, Lin E, Liu J: Low membranous expression of beta-catenin and high mitotic count predict poor prognosis in endometrioid carcinoma of the ovary. Mod Pathol; 2010 Jan;23(1):113-22
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Low membranous expression of beta-catenin and high mitotic count predict poor prognosis in endometrioid carcinoma of the ovary.
  • Mutations in the beta-catenin gene are common in ovarian endometrioid carcinoma.
  • The purpose of this study was to retrospectively assess the expression of beta-catenin in ovarian endometrioid carcinoma and correlate its expression with the Gynecologic Oncology Group's (GOG) grading system, clinicopathological characteristics, and patient survival.
  • A total of 49 patients with primary ovarian endometrioid carcinoma were included in this study.
  • We found that a low membranous expression of beta-catenin and a high mitotic count (>15 per 10 high-power fields) were significantly associated with poor prognosis and early recurrence of ovarian endometrioid carcinoma.
  • Young age at the time of diagnosis, advanced disease stage, and suboptimal debulking were among the clinical factors predicting poor survival and early disease recurrence.
  • The presence of squamous differentiation, a papillary pattern or nuclear pleomorphism did not show any correlation with overall survival or disease-free survival.
  • Low membranous expression of beta-catenin and high mitotic count are poor prognostic indicators in patients with ovarian endometrioid carcinoma, whereas the GOG grading system showed no prognostic value.
  • Our data suggest that there is a need to define a better grading system for ovarian endometrioid carcinoma.

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19820688.001).
  • [ISSN] 1530-0285
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA131183; United States / NCI NIH HHS / CA / CA016672; United States / NCI NIH HHS / CA / IP50CA83638
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / beta Catenin
  •  go-up   go-down


39. Pearce CL, Wu AH, Gayther SA, Bale AE, Australian Cancer Study (Ovarian Cancer) and Australian Cancer Study Group, Beck PA, Beesley J, Chanock S, Cramer DW, DiCioccio R, Edwards R, Fredericksen ZS, Garcia-Closas M, Goode EL, Green AC, Hartmann LC, Hogdall E, Kjaer SK, Lissowska J, McGuire V, Modugno F, Moysich K, Ness RB, Ramus SJ, Risch HA, Sellers TA, Song H, Stram DO, Terry KL, Webb PM, Whiteman DC, Whittemore AS, Zheng W, Pharoah PD, Chenevix-Trench G, Pike MC, Schildkraut J, Berchuck A, Ovarian Cancer Association Consortium: Progesterone receptor variation and risk of ovarian cancer is limited to the invasive endometrioid subtype: results from the Ovarian Cancer Association Consortium pooled analysis. Br J Cancer; 2008 Jan 29;98(2):282-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Progesterone receptor variation and risk of ovarian cancer is limited to the invasive endometrioid subtype: results from the Ovarian Cancer Association Consortium pooled analysis.
  • There is evidence that progesterone plays a role in the aetiology of invasive epithelial ovarian cancer.
  • Previous studies have suggested that genetic variants in the progesterone receptor gene (PGR) may be associated with ovarian cancer risk, although results have been inconsistent.
  • We have established an international consortium to pool resources and data from many ovarian cancer case-control studies in an effort to identify variants that influence risk.
  • In this study, three PGR single nucleotide polymorphisms (SNPs), for which previous data have suggested they affect ovarian cancer risk, were examined.
  • A total of 4788 ovarian cancer cases and 7614 controls from 12 case-control studies were included in this analysis.
  • Unconditional logistic regression was used to model the association between each SNP and ovarian cancer risk and two-sided P-values are reported.
  • Overall, risk of ovarian cancer was not associated with any of the three variants studied.
  • However, in histopathological subtype analyses, we found a statistically significant association between risk of endometrioid ovarian cancer and the PROGINS allele (n=651, OR=1.17, 95% CI=1.01-1.36, P=0.036).
  • We also observed borderline evidence of an association between risk of endometrioid ovarian cancer and the +331C/T variant (n=725 cases; OR=0.80, 95% CI 0.62-1.04, P=0.100).
  • These data suggest that while these three variants in the PGR are not associated with ovarian cancer overall, the PROGINS variant may play a modest role in risk of endometrioid ovarian cancer.

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • Coriell Cell Repositories. culture/stock collections - Coriell Cell Repositories .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Carcinogenesis. 2001 May;22(5):717-21 [11323389.001]
  • [Cites] Br J Cancer. 2001 Mar 2;84(5):714-21 [11237375.001]
  • [Cites] Int J Cancer. 2001 Nov 20;95(6):394-7 [11668524.001]
  • [Cites] J Natl Cancer Inst. 2002 Jan 2;94(1):32-8 [11773280.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Sep 17;99(19):12263-8 [12218173.001]
  • [Cites] Cancer Biol Ther. 2002 May-Jun;1(3):300-6 [12432283.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2003 Jan;12(1):42-6 [12540502.001]
  • [Cites] Nat Genet. 2003 Feb;33(2):177-82 [12524541.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2003 Mar;12(3):226-7 [12646513.001]
  • [Cites] Gynecol Oncol. 2003 Aug;90(2):378-81 [12893203.001]
  • [Cites] J Natl Cancer Inst. 2004 Mar 17;96(6):434-42 [15026468.001]
  • [Cites] Fertil Steril. 2004 Jul;82(1):186-95 [15237010.001]
  • [Cites] N Engl J Med. 1987 Mar 12;316(11):650-5 [3821795.001]
  • [Cites] Am J Obstet Gynecol. 1989 Jul;161(1):10-6 [2750791.001]
  • [Cites] EMBO J. 1990 May;9(5):1603-14 [2328727.001]
  • [Cites] Eur J Cancer. 1992;28A(11):1872-6 [1389530.001]
  • [Cites] Mol Endocrinol. 1993 Oct;7(10):1244-55 [8264658.001]
  • [Cites] Am J Epidemiol. 1994 Apr 1;139(7):654-61 [8166126.001]
  • [Cites] Br J Cancer. 1995 Mar;71(3):451-5 [7880723.001]
  • [Cites] Cancer Res. 1995 Jul 1;55(13):2743-5 [7796397.001]
  • [Cites] Br J Cancer. 1997;75(9):1398-9 [9155067.001]
  • [Cites] Cancer Res. 1998 May 15;58(10):2095-7 [9605750.001]
  • [Cites] Br J Cancer. 1998 Jul;78(2):277 [9683307.001]
  • [Cites] J Soc Gynecol Investig. 1998 Sep-Oct;5(5):271-6 [9773403.001]
  • [Cites] J Natl Cancer Inst. 1998 Dec 2;90(23):1774-86 [9839517.001]
  • [Cites] Cancer Causes Control. 1999 Oct;10(5):397-402 [10530609.001]
  • [Cites] J Clin Endocrinol Metab. 2004 Dec;89(12):6340-7 [15579801.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2004 Dec;13(12):2141-7 [15598772.001]
  • [Cites] J Natl Cancer Inst. 2005 Jan 5;97(1):51-9 [15632380.001]
  • [Cites] Am J Epidemiol. 2005 Mar 1;161(5):442-51 [15718480.001]
  • [Cites] Int J Cancer. 2005 Nov 20;117(4):611-8 [15924337.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Nov;14(11 Pt 1):2536-43 [16284375.001]
  • [Cites] Cancer. 2005 Dec 15;104(12):2807-16 [16284991.001]
  • [Cites] Gynecol Oncol. 2006 May;101(2):287-95 [16360811.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2006 Sep;15(9):1738-41 [16985038.001]
  • [Cites] Carcinogenesis. 2006 Nov;27(11):2235-42 [16774946.001]
  • [Cites] J Mol Endocrinol. 2007 Feb;38(1-2):331-50 [17293450.001]
  • [Cites] Cancer Res. 2007 Apr 1;67(7):3027-35 [17409409.001]
  • [Cites] BMC Cancer. 2007;7:60 [17411440.001]
  • [Cites] Int J Cancer. 2008 Jan 1;122(1):170-6 [17721999.001]
  • [Cites] Am J Epidemiol. 2000 Aug 1;152(3):233-41 [10933270.001]
  • [Cites] Br J Cancer. 2000 Dec;83(11):1488-94 [11076658.001]
  • [Cites] Int J Cancer. 2001 Nov 20;95(6):370-4 [11668519.001]
  • (PMID = 18219286.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / PC / N01-PC-6710; United States / NCI NIH HHS / PC / N01 PC067010; United States / NCI NIH HHS / CA / P30 CA016056; United States / NCI NIH HHS / CA / CA16056; United States / NCI NIH HHS / CA / CA14089; United States / NCI NIH HHS / CA / 5R01-CA074850; United States / NCI NIH HHS / CA / R03-CA113148; United States / NCI NIH HHS / CA / R03 CA113148; United States / NCI NIH HHS / CA / R01 CA080742; United States / NCI NIH HHS / CA / R01 CA074850; United States / NCI NIH HHS / CA / CA71966; United States / NCI NIH HHS / CA / 5R01-CA080742; United States / NCI NIH HHS / CA / CA63464; United States / Intramural NIH HHS / / ; United States / NCI NIH HHS / CA / P30 CA014089; United States / NCI NIH HHS / CA / CA17054; United States / NCI NIH HHS / CA / R01 CA063464; United States / NCI NIH HHS / CA / U01 CA063464; United States / NCI NIH HHS / CA / CA61132; United States / NCI NIH HHS / CA / R01 CA 61107; United States / NCI NIH HHS / CA / P01 CA017054
  • [Publication-type] Journal Article; Meta-Analysis; Research Support, N.I.H., Extramural; Research Support, N.I.H., Intramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Receptors, Progesterone
  • [Other-IDs] NLM/ PMC2361465
  •  go-up   go-down


40. Rabban JT, Gupta D, Zaloudek CJ, Chen LM: Synchronous ovarian granulosa cell tumor and uterine serous carcinoma: a rare association of a high-risk endometrial cancer with anestrogenic ovarian tumor. Gynecol Oncol; 2006 Dec;103(3):1164-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Synchronous ovarian granulosa cell tumor and uterine serous carcinoma: a rare association of a high-risk endometrial cancer with anestrogenic ovarian tumor.
  • BACKGROUND: Ovarian granulosa cell tumors are often associated with endometrial hyperplasia or carcinoma.
  • The endometrial carcinoma is thought to occur under the influence of the estrogen receptor pathway and is typically a low-grade, low-stage endometrioid adenocarcinoma.
  • CASE: We present a case of a woman with a granulosa cell tumor of the ovary and a synchronous serous carcinoma of the endometrium.
  • CONCLUSIONS: Not all uterine tumors associated with ovarian granulosa cell tumors have low-risk histology.
  • [MeSH-major] Cystadenocarcinoma, Serous / diagnosis. Granulosa Cell Tumor / diagnosis. Neoplasms, Multiple Primary / diagnosis. Ovarian Neoplasms / diagnosis. Uterine Neoplasms / diagnosis
  • [MeSH-minor] Aged, 80 and over. Diagnosis, Differential. Female. Humans


41. Messalli EM, Scaffa C, Mainini G, Rotondi M, Pecori E, Cobellis L: Third stage ovarian carcinoma--case report: the necessity of a multidisciplinary approach to treatment. Eur J Gynaecol Oncol; 2006;27(3):291-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Third stage ovarian carcinoma--case report: the necessity of a multidisciplinary approach to treatment.
  • Ovarian carcinoma, part of a heterogeneous group of tumours, is the main cause of death by gynaecological neoplasms.
  • The diagnosis, in general, is delayed.
  • In fact the case, here reported, refers to a patient who came under our observation for a bilateral ovarian mass discovered casually during an abdominal ultrasound exam carried out for renal colic.
  • The histological report was G3, angioinvasive bilateral ovarian endometrioid adenocarcinoma.
  • It is concluded that the complexity of similar cases always requires a multidisciplinary approach as in our case, involving an oncologist, hematologist, surgeon, gynaecologist, radiologist, anaesthesiologist, and nursing staff in the management of third stage ovarian cancer patients to obtain the best treatment thus guaranteeing a higher survival rate and better quality of life.
  • [MeSH-major] Carcinoma, Endometrioid / surgery. Ovarian Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16800262.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


42. Santillan A, Bristow RE: Paraneoplastic cerebellar degeneration in a woman with ovarian cancer. Nat Clin Pract Oncol; 2006 Feb;3(2):108-12; quiz 1 p following 112
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Paraneoplastic cerebellar degeneration in a woman with ovarian cancer.
  • During her initial admission, the patient improved to some degree and was discharged with a possible diagnosis of viral meningitis.
  • A general and gynecological examination was otherwise unremarkable.
  • DIAGNOSIS: Stage IIIC endometrioid adenocarcinoma of the ovary with paraneoplastic cerebellar degeneration.
  • [MeSH-major] Carcinoma, Endometrioid / diagnosis. Ovarian Neoplasms / diagnosis. Paraneoplastic Cerebellar Degeneration / diagnosis


43. Li WH, Zhang JM: [Endometrioid carcinoma of ovary with prominent spindle cell component and resembling sex-cord tumor: report of a case]. Zhonghua Bing Li Xue Za Zhi; 2007 Aug;36(8):567-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Endometrioid carcinoma of ovary with prominent spindle cell component and resembling sex-cord tumor: report of a case].
  • [MeSH-major] Carcinoma, Endometrioid / pathology. Ovarian Neoplasms / pathology. Sex Cord-Gonadal Stromal Tumors / pathology

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17980110.001).
  • [ISSN] 0529-5807
  • [Journal-full-title] Zhonghua bing li xue za zhi = Chinese journal of pathology
  • [ISO-abbreviation] Zhonghua Bing Li Xue Za Zhi
  • [Language] chi
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] China
  •  go-up   go-down


44. MacLaughlan SD, Palomino WA, Mo B, Lewis TD, Lininger RA, Lessey BA: Endometrial expression of Cyr61: a marker of estrogenic activity in normal and abnormal endometrium. Obstet Gynecol; 2007 Jul;110(1):146-54
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To compare the expression of Cyr61 in normal cycling endometrium with endometrium from women with polycystic ovarian syndrome (PCOS) and endometrial hyperplasia and adenocarcinoma.
  • Endometrial biopsies were obtained from normal fertile controls throughout the menstrual cycle and compared with endometrium from ovulatory and anovulatory women with PCOS and complex endometrial hyperplasia and endometrioid adenocarcinoma.
  • Regulation of Cyr61 protein was studied in a steroid-responsive endometrial carcinoma cell line, ECC1.
  • In contrast, elevated levels of Cyr61, ER-alpha, Ki67, and cFos were all found in the midsecretory endometrium of ovulatory PCOS patients, endometrial cancer patients, and hyperplasia patients.
  • As a unique marker of estrogen action, Cyr61 may be an early biomarker for the development of hyperplasia or adenocarcinoma in this group of women.
  • [MeSH-major] Adenocarcinoma / metabolism. Endometrial Hyperplasia / metabolism. Endometrial Neoplasms / metabolism. Endometrium / metabolism. Immediate-Early Proteins / metabolism. Intercellular Signaling Peptides and Proteins / metabolism. Polycystic Ovary Syndrome / metabolism

  • MedlinePlus Health Information. consumer health - Polycystic Ovary Syndrome.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17601910.001).
  • [ISSN] 0029-7844
  • [Journal-full-title] Obstetrics and gynecology
  • [ISO-abbreviation] Obstet Gynecol
  • [Language] eng
  • [Grant] United States / NICHD NIH HHS / HD / U54 HD35041
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers; 0 / CYR61 protein, human; 0 / Cysteine-Rich Protein 61; 0 / Estrogens; 0 / Immediate-Early Proteins; 0 / Intercellular Signaling Peptides and Proteins; 0 / RNA, Messenger
  •  go-up   go-down


45. Xue LY, Zou SM, Zheng S, Xie YQ, Wen P, Liu XY, Lin DM, Lü N: [Expression of fascin and CK14 in different histological types of cancer and its differential diagnostic significance]. Zhonghua Zhong Liu Za Zhi; 2010 Nov;32(11):838-44
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Expression of fascin and CK14 in different histological types of cancer and its differential diagnostic significance].
  • OBJECTIVE: To investigate and analyze the expression of fascin and CK14 in multiple histological types of cancer and to explore the potential value of the two proteins as markers in diagnosis and differential diagnosis of various cancer types.
  • METHODS: Tissue microarray containing esophageal squamous cell carcinoma (SCC), lung SCC, larynx SCC, uterine cervical SCC, SCC of external genital organs, lung adenocarcinoma, gastric adenocarcinoma, colorectal adenocarcinoma, heptocellular carcinoma, pancreatic ductal adenocarcinoma, breast infiltrating ductal carcinoma, thyroid papillary carcinoma, uterine endometrioid adenocarcinoma, ovarian serous adenocarcinoma and renal clear cell carcinoma, 30 cases each, as well as corresponding normal controls was constructed.
  • The expression of fascin and CK14 among different types of carcinoma and corresponding normal controls was detected by immunohistochemistry.
  • In lung adenocarcinoma, gastric adenocarcinoma, colorectal adenocarcinoma, hepatocellular carcinoma, pancreatic ductal adenocarcinoma, breast infiltrating dutal adenocarcinoma, thyroid papillary carcinoma, uterine endometrioid adenocarcinoma, ovarian serous adenocarcinoma and renal clear cell carcinoma, the positive rates were 38.0%, 23.3%, 14.3%, 10.3%, 73.3%, 13.3%, 6.7%, 60.0%, 66.7% and 10.0%, respectively.
  • It was weak and focal in lung adenocarcinoma, gastric adenocarcinoma, colorectal adenocarcinoma, hepatocellular carcinoma, pancreatic ductal adenocarcinoma, breast infiltrating dutal adenocarcinoma, thyroid papillary carcinoma, uterine endometrioid adenocarcinoma, ovarian serous adenocarcinoma, and renal clear cell carcinoma, with a positive rate of 13.3%, 13.3%, 20.7%, 41.4%, 46.7%, 6.7%, 40.0%, 13.3%, 20.0% and 6.7%, respectively.
  • CONCLUSION: Fascin and CK14 are highly expressed in SCC, compared with other histological types of carcinoma.
  • Combination of fascin and CK14 should be a valuable marker in diagnosis and differential diagnosis of carcinoma.
  • [MeSH-major] Adenocarcinoma / metabolism. Carcinoma, Squamous Cell / metabolism. Carrier Proteins / metabolism. Keratin-14 / metabolism. Laryngeal Neoplasms / metabolism. Microfilament Proteins / metabolism
  • [MeSH-minor] Breast Neoplasms / metabolism. Breast Neoplasms / pathology. Carcinoma, Hepatocellular / metabolism. Carcinoma, Hepatocellular / pathology. Colorectal Neoplasms / metabolism. Colorectal Neoplasms / pathology. Cystadenocarcinoma, Serous / metabolism. Cystadenocarcinoma, Serous / pathology. Diagnosis, Differential. Esophageal Neoplasms / metabolism. Esophageal Neoplasms / pathology. Female. Humans. Liver Neoplasms / metabolism. Liver Neoplasms / pathology. Lung Neoplasms / metabolism. Lung Neoplasms / pathology. Male. Ovarian Neoplasms / metabolism. Ovarian Neoplasms / pathology. Stomach Neoplasms / metabolism. Stomach Neoplasms / pathology. Uterine Cervical Neoplasms / metabolism. Uterine Cervical Neoplasms / pathology

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21223690.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Carrier Proteins; 0 / Keratin-14; 0 / Microfilament Proteins; 146808-54-0 / fascin
  •  go-up   go-down


46. O'Neill CJ, McCluggage WG: p16 expression in the female genital tract and its value in diagnosis. Adv Anat Pathol; 2006 Jan;13(1):8-15
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] p16 expression in the female genital tract and its value in diagnosis.
  • In cervical squamous lesions, p16 is positive in most high-grade cervical intraepithelial neoplasia (CIN) and in some cases of low-grade CIN, usually those associated with high-risk HPV. p16 may be useful to identify small focal high-grade CIN lesions, to distinguish some cases of CIN involving immature metaplastic squamous epithelium from immature metaplastic squamous epithelium not involved by CIN and to distinguish high-grade CIN from benign mimics.
  • In cervical glandular lesions, p16 is useful, as part of a panel, in the distinction between adenocarcinoma in situ (diffusely positive) and benign mimics, including tuboendometrial metaplasia and endometriosis, which are usually p16-negative or focally positive. p16 may be used, in combination with other markers, to distinguish between a cervical adenocarcinoma (diffuse positivity) and an endometrioid-type endometrial adenocarcinoma (negative or focally positive).
  • In the vulva, p16 is positive in HPV-associated vulval intraepithelial neoplasia (VIN) but negative in VIN not associated with HPV.
  • In the uterus, p16 positivity is more common and widespread in leiomyosarcomas than leiomyomas, and this may be a useful aid to diagnosis, although problematic uterine smooth muscle neoplasms have not been extensively studied.
  • Metastatic cervical adenocarcinomas in the ovary are usually diffusely p16-positive, and because these may closely mimic a primary ovarian endometrioid or mucinous adenocarcinoma, this may be a valuable diagnostic aid, although p16 expression in primary ovarian adenocarcinomas of these morphologic subtypes has not been widely investigated.
  • Some ovarian serous carcinomas, similar to their uterine counterparts, are p16-positive.
  • [MeSH-major] Cyclin-Dependent Kinase Inhibitor p16 / analysis. Genital Neoplasms, Female / diagnosis
  • [MeSH-minor] Adenocarcinoma / chemistry. Adenocarcinoma / diagnosis. Adenocarcinoma / genetics. Biomarkers, Tumor / analysis. Biomarkers, Tumor / genetics. Carcinoma, Small Cell / chemistry. Carcinoma, Small Cell / diagnosis. Carcinoma, Small Cell / genetics. Cystadenocarcinoma, Serous / chemistry. Cystadenocarcinoma, Serous / diagnosis. Cystadenocarcinoma, Serous / genetics. Diagnosis, Differential. Endometrial Neoplasms / chemistry. Endometrial Neoplasms / diagnosis. Endometrial Neoplasms / genetics. Female. Genes, p16. Genitalia, Female / chemistry. Genitalia, Female / physiopathology. Humans. Immunohistochemistry. Ovarian Neoplasms / chemistry. Ovarian Neoplasms / diagnosis. Ovarian Neoplasms / genetics. Tumor Suppressor Proteins / analysis. Tumor Suppressor Proteins / genetics. Uterine Cervical Neoplasms / chemistry. Uterine Cervical Neoplasms / diagnosis. Uterine Cervical Neoplasms / genetics. Uterine Neoplasms / chemistry. Uterine Neoplasms / diagnosis. Uterine Neoplasms / genetics. Vulvar Neoplasms / chemistry. Vulvar Neoplasms / classification. Vulvar Neoplasms / diagnosis. Vulvar Neoplasms / genetics

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16462152.001).
  • [ISSN] 1072-4109
  • [Journal-full-title] Advances in anatomic pathology
  • [ISO-abbreviation] Adv Anat Pathol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cyclin-Dependent Kinase Inhibitor p16; 0 / Tumor Suppressor Proteins
  • [Number-of-references] 65
  •  go-up   go-down


47. Keita M, Bessette P, Pelmus M, Ainmelk Y, Aris A: Expression of interleukin-1 (IL-1) ligands system in the most common endometriosis-associated ovarian cancer subtypes. J Ovarian Res; 2010;3:3
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of interleukin-1 (IL-1) ligands system in the most common endometriosis-associated ovarian cancer subtypes.
  • OBJECTIVES: Endometrioid carcinoma of the ovary is one of the most types of epithelial ovarian cancer associated to endometrioisis.
  • Endometrioid tumors as well as endometriotic implants are characterized by the presence of epithelial cells, stromal cells, or a combination of booth, that resemble the endometrial cells, suggesting a possible endometrial origin of these tumors.
  • Pro-inflammatory cytokines, including interleukin-1 (IL-1) have been reported to be involved in both endometriosis and ovarian carcinogenesis.
  • The major objective of this study was to determine the level expression of IL-1 ligands system (IL-1alpha, IL-1beta and IL-1RA) in the most common subtypes of ovarian cancer cells compared to endometrial cells.
  • METHODS: We used primary endometrial cells, endometrial cell line RL-952 and different subtypes of epithelial ovarian cancer cell lines including TOV-112D (endometrioid), TOV-21G (clear cell) and OV-90 (serous).
  • RESULTS: We demonstrated that IL-1 ligands were expressed by all endometriosis-associated ovarian cancer subtypes and endometrial cells.
  • In contrast to other cancer ovarian cells, endometrioid cells exhibit a specific decrease of cell-associated IL-1RA expression and its soluble secretion.
  • CONCLUSION: Endometrioid ovarian cancer exhibits an alteration in the expression of IL-1RA, a key protector against tumorogenic effects of IL-1.
  • This suggests a possible link between the endometrium, the tissue ectopic endometriosis and endometrioid ovarian cancer.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cytokine. 1996 Jul;8(7):578-85 [8891439.001]
  • [Cites] Hum Reprod. 1995 Sep;10(9):2472-7 [8530693.001]
  • [Cites] Mol Cell Endocrinol. 1994 May;101(1-2):307-14 [9397965.001]
  • [Cites] Annu Rev Immunol. 1998;16:27-55 [9597123.001]
  • [Cites] Cancer. 1998 Aug 15;83(4):788-96 [9708947.001]
  • [Cites] J Reprod Immunol. 1998 Aug;39(1-2):117-31 [9786457.001]
  • [Cites] Cancer Lett. 1999 Aug 3;142(2):179-84 [10463774.001]
  • [Cites] Int J Oncol. 1999 Dec;15(6):1251-4 [10568836.001]
  • [Cites] Fertil Steril. 2000 Jan;73(1):166-70 [10632434.001]
  • [Cites] Mol Hum Reprod. 2000 Mar;6(3):269-75 [10694276.001]
  • [Cites] Adv Exp Med Biol. 2000;479:277-88 [10897428.001]
  • [Cites] Horm Res. 2000;53(6):300-4 [11146371.001]
  • [Cites] Fertil Steril. 2001 Mar;75(3):489-95 [11239529.001]
  • [Cites] Am J Reprod Immunol. 2001 Apr;45(4):193-9 [11327545.001]
  • [Cites] Cancer. 2001 Dec 15;92(12):3068-75 [11753986.001]
  • [Cites] Biol Reprod. 2002 Feb;66(2):401-6 [11804955.001]
  • [Cites] Ann N Y Acad Sci. 2002 Mar;955:89-100; discussion 118, 396-406 [11949968.001]
  • [Cites] Obstet Gynecol. 2002 Oct;100(4):788-95 [12383550.001]
  • [Cites] Nature. 2002 Dec 19-26;420(6917):860-7 [12490959.001]
  • [Cites] Hum Reprod. 2003 Mar;18(3):593-7 [12615831.001]
  • [Cites] Nat Rev Cancer. 2003 Jul;3(7):502-16 [12835670.001]
  • [Cites] Nat Rev Cancer. 2004 Jan;4(1):71-8 [14708027.001]
  • [Cites] Eur Cytokine Netw. 2003 Oct-Dec;14(4):246-55 [14715418.001]
  • [Cites] J Endocrinol. 2004 Feb;180(2):203-12 [14765973.001]
  • [Cites] Gynecol Obstet Invest. 2004;57(1):53-4 [14974460.001]
  • [Cites] Nat Rev Immunol. 2004 Aug;4(8):641-8 [15286730.001]
  • [Cites] J Clin Endocrinol Metab. 2004 Oct;89(10):5094-100 [15472211.001]
  • [Cites] Cancer Cell. 2005 Mar;7(3):211-7 [15766659.001]
  • [Cites] Gynecol Oncol. 2006 May;101(2):331-41 [16473398.001]
  • [Cites] Clin Cancer Res. 2006 Feb 15;12(4):1088-96 [16489061.001]
  • [Cites] Cancer Metastasis Rev. 2006 Sep;25(3):387-408 [17043764.001]
  • [Cites] Reproduction. 2007 Jan;133(1):265-74 [17244752.001]
  • [Cites] Fertil Steril. 2007 Sep;88(3):594-9 [17292896.001]
  • [Cites] Hum Reprod. 2007 May;22(5):1464-73 [17324958.001]
  • [Cites] J Reprod Immunol. 2008 Jan;77(1):75-84 [17517439.001]
  • [Cites] Reproduction. 2007 Sep;134(3):525-34 [17709570.001]
  • [Cites] PLoS Med. 2008 Dec 2;5(12):e232 [19053170.001]
  • [Cites] Fertil Steril. 1992 Mar;57(3):535-42 [1371258.001]
  • [Cites] Fertil Steril. 1992 May;57(5):990-7 [1374045.001]
  • [Cites] Cancer Res. 1992 Apr 15;52(8):2248-52 [1559228.001]
  • [Cites] Fertil Steril. 1991 May;55(5):952-7 [1827077.001]
  • [Cites] J Biol Chem. 1991 Jun 5;266(16):10331-6 [1828071.001]
  • [Cites] Prog Growth Factor Res. 1990;2(4):193-205 [2151936.001]
  • [Cites] J Clin Invest. 1994 Oct;94(4):1463-9 [7523451.001]
  • [Cites] Fertil Steril. 1993 Aug;60(2):276-9 [7687965.001]
  • [Cites] Biol Reprod. 1994 Sep;51(3):480-5 [7803619.001]
  • [Cites] Immunol Lett. 1993 Dec;39(1):45-52 [8144190.001]
  • [Cites] J Clin Invest. 1993 May;91(5):2194-206 [8387543.001]
  • [Cites] Endocrinology. 1993 Nov;133(5):2391-4 [8404691.001]
  • [Cites] Br J Cancer. 1997;75(6):855-9 [9062407.001]
  • (PMID = 20181040.001).
  • [ISSN] 1757-2215
  • [Journal-full-title] Journal of ovarian research
  • [ISO-abbreviation] J Ovarian Res
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2832771
  •  go-up   go-down


48. Mukonoweshuro P, Oriowolo A: Stromal osseous metaplasia in a low-grade ovarian adenocarcinoma. Gynecol Oncol; 2005 Oct;99(1):222-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Stromal osseous metaplasia in a low-grade ovarian adenocarcinoma.
  • BACKGROUND: Stromal osseous metaplasia is a rare and curious finding in tumors of the ovary.
  • CASE REPORT: The patient, a 66-year-old P3 G3 white female, had a past history of stage 1c left ovarian, well-differentiated endometrioid adenocarcinoma removed in 1981.
  • The tumor recurred 21 years later with prominent stromal osseous metaplasia that had not been present in the primary.
  • DISCUSSION: The pathogenesis of osseous metaplasia in epithelial tumors of the ovary is unclear; however, it is probable that a metaplastic process involving multipotential stromal stem cells results in bone formation.
  • CONCLUSION: Benign osseous metaplasia in ovarian tumors is rare and its histogenesis remains unclear.
  • As far as we know, this process does not appear to have any prognostic or pathological significance.
  • [MeSH-major] Carcinoma, Endometrioid / pathology. Neoplasm Recurrence, Local / pathology. Ovarian Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16023183.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


49. Feng W, Marquez RT, Lu Z, Liu J, Lu KH, Issa JP, Fishman DM, Yu Y, Bast RC Jr: Imprinted tumor suppressor genes ARHI and PEG3 are the most frequently down-regulated in human ovarian cancers by loss of heterozygosity and promoter methylation. Cancer; 2008 Apr 1;112(7):1489-502
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Imprinted tumor suppressor genes ARHI and PEG3 are the most frequently down-regulated in human ovarian cancers by loss of heterozygosity and promoter methylation.
  • BACKGROUND: Imprinted tumor suppressor genes may be particularly important in the pathogenesis of ovarian cancer.
  • Two imprinted genes, paternally expressed 3 (PEG3) and aplasia Ras homologue member I (ARHI), are the most frequently down-regulated in ovarian cancers on gene expression arrays.
  • RESULTS: PEG3 was down-regulated in 75% and ARHI was down-regulated in 88% of 40 ovarian cancers.
  • ARHI CpG islands I and II were hypermethylated in 13 of 42 ovarian cancers (31%) and in 5 of 42 ovarian cancers (12%), respectively, and hypermethylation was associated with reduced ARHI expression in all 18 samples of ovarian cancer with CpG island hypermethylation.
  • PEG3 was hypermethylated in 11 of 42 ovarian cancers (26%), and PEG3 expression was down-regulated in 10 of those 11 cancers.
  • PEG3 and ARHI expression was highly correlated in human ovarian cancers (correlation coefficient [R]=0.69; P< .0001).
  • PEG3 and ARHI also were methylated concordantly in ovarian cancers (R=0.36; P= .019).
  • Re-expression of PEG3, similar to that of ARHI, markedly inhibited ovarian cancer growth.
  • CONCLUSIONS: Loss of expression of the growth-inhibitory imprinted genes ARHI and PEG3 through promoter methylation, LOH, and other mechanisms may stimulate clonogenic growth and contribute to the pathogenesis of a majority of ovarian cancers.
  • [MeSH-major] DNA Methylation. Genomic Imprinting. Kruppel-Like Transcription Factors / genetics. Ovarian Neoplasms / genetics. Promoter Regions, Genetic / genetics. rho GTP-Binding Proteins / genetics
  • [MeSH-minor] Adenocarcinoma, Clear Cell / genetics. Adenocarcinoma, Clear Cell / secondary. Adenocarcinoma, Mucinous / genetics. Adenocarcinoma, Mucinous / secondary. Carcinoma, Endometrioid / genetics. Carcinoma, Endometrioid / secondary. Case-Control Studies. CpG Islands. Cystadenocarcinoma, Serous / genetics. Cystadenocarcinoma, Serous / secondary. DNA Primers / chemistry. Down-Regulation. Female. Gene Expression Profiling. Gene Expression Regulation, Neoplastic. Genes, Tumor Suppressor / physiology. Humans. Loss of Heterozygosity. Oligonucleotide Array Sequence Analysis. Ovary / metabolism. Ovary / pathology. RNA, Messenger / genetics. RNA, Messenger / metabolism. Reverse Transcriptase Polymerase Chain Reaction. Tumor Cells, Cultured

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18286529.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA64602; United States / NCI NIH HHS / CA / CA80957
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DIRAS3 protein, human; 0 / DNA Primers; 0 / Kruppel-Like Transcription Factors; 0 / PEG3 protein, human; 0 / RNA, Messenger; EC 3.6.5.2 / rho GTP-Binding Proteins
  •  go-up   go-down


50. Zang X, Sullivan PS, Soslow RA, Waitz R, Reuter VE, Wilton A, Thaler HT, Arul M, Slovin SF, Wei J, Spriggs DR, Dupont J, Allison JP: Tumor associated endothelial expression of B7-H3 predicts survival in ovarian carcinomas. Mod Pathol; 2010 Aug;23(8):1104-12
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tumor associated endothelial expression of B7-H3 predicts survival in ovarian carcinomas.
  • Previous studies have correlated their overexpression with poor prognosis and decreased tumor-infiltrating lymphocytes in various carcinomas including uterine endometrioid carcinomas, and mounting evidence supports an immuno-inhibitory role in ovarian cancer prognosis.
  • We sought to examine the expression of B7-H3 and B7x in 103 ovarian borderline tumors and carcinomas and study associations with clinical outcome.
  • Using immunohistochemical tissue microarray analysis on tumor specimens, we found that 93 and 100% of these ovarian tumors express B7-H3 and B7x, respectively, with expression found predominantly on cell membranes and in cytoplasm.
  • In contrast, only scattered B7-H3- and B7x-positive cells were detected in non-neoplastic ovarian tissues.
  • These results show that ovarian borderline tumors and carcinomas aberrantly express B7-H3 and B7x, and that B7-H3-positive tumor vasculature is associated with high-grade serous histological subtype, increased recurrence and reduced survival.
  • B7-H3 expression in tumor vasculature may be a reflection of tumor aggressiveness and has diagnostic and immunotherapeutic implications in ovarian carcinomas.

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gynecol Oncol. 2007 Jul;106(1):119-27 [17509674.001]
  • [Cites] Science. 2006 Sep 29;313(5795):1960-4 [17008531.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Dec 4;104(49):19458-63 [18042703.001]
  • [Cites] Int J Gynecol Pathol. 2008 Apr;27(2):161-74 [18317227.001]
  • [Cites] Hum Pathol. 2008 Aug;39(8):1239-51 [18602670.001]
  • [Cites] Clin Cancer Res. 2008 Aug 15;14(16):5150-7 [18694993.001]
  • [Cites] Mod Pathol. 2009 Mar;22(3):393-402 [19060844.001]
  • [Cites] Cancer. 2009 Jul 1;115(13):2891-902 [19472394.001]
  • [Cites] CA Cancer J Clin. 2009 Jul-Aug;59(4):225-49 [19474385.001]
  • [Cites] Cancer Res. 2009 Aug 1;69(15):6275-81 [19584290.001]
  • [Cites] Annu Rev Immunol. 2000;18:813-27 [10837076.001]
  • [Cites] Nat Immunol. 2001 Mar;2(3):269-74 [11224528.001]
  • [Cites] Nature. 2001 May 17;411(6835):380-4 [11357146.001]
  • [Cites] Nat Rev Cancer. 2002 Oct;2(10):795-803 [12360282.001]
  • [Cites] N Engl J Med. 2003 Jan 16;348(3):203-13 [12529460.001]
  • [Cites] Nat Rev Cancer. 2002 Feb;2(2):83-90 [12635171.001]
  • [Cites] Immunity. 2003 Jun;18(6):849-61 [12818165.001]
  • [Cites] Immunity. 2003 Jun;18(6):863-73 [12818166.001]
  • [Cites] Genomics. 2003 Sep;82(3):365-77 [12906861.001]
  • [Cites] Nat Immunol. 2003 Sep;4(9):899-906 [12925852.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Sep 2;100(18):10388-92 [12920180.001]
  • [Cites] J Immunol. 2004 Aug 15;173(4):2500-6 [15294965.001]
  • [Cites] Nat Med. 2004 Sep;10(9):942-9 [15322536.001]
  • [Cites] N Engl J Med. 2004 Dec 9;351(24):2519-29 [15590954.001]
  • [Cites] Clin Cancer Res. 2005 Mar 1;11(5):1842-8 [15756008.001]
  • [Cites] Int J Cancer. 2005 Jul 20;115(6):849-60 [15729716.001]
  • [Cites] Am J Pathol. 2005 Aug;167(2):465-73 [16049332.001]
  • [Cites] Gynecol Oncol. 2006 Jan;100(1):44-52 [16256178.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Dec 20;102(51):18538-43 [16344461.001]
  • [Cites] Nature. 2006 Feb 9;439(7077):682-7 [16382236.001]
  • [Cites] Trends Immunol. 2006 Apr;27(4):195-201 [16500147.001]
  • [Cites] Semin Oncol. 2006 Apr;33(2 Suppl 6):S3-11 [16716797.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Jul 5;103(27):10391-6 [16798883.001]
  • [Cites] Clin Cancer Res. 2007 Sep 15;13(18 Pt 1):5271-9 [17875755.001]
  • (PMID = 20495537.001).
  • [ISSN] 1530-0285
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] ENG
  • [Grant] United States / NIDDK NIH HHS / DK / DK083076-01; United States / NIDDK NIH HHS / DK / DP2 DK083076; United States / NIDDK NIH HHS / DK / DP2 DK083076-01
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, CD80; 0 / B7 Antigens; 0 / Biomarkers, Tumor; 0 / CD276 protein, human; 0 / Receptors, Immunologic
  • [Other-IDs] NLM/ NIHMS249186; NLM/ PMC2976590
  •  go-up   go-down


51. Kato N, Toukairin M, Asanuma I, Motoyama T: Immunocytochemistry for hepatocyte nuclear factor-1beta (HNF-1beta): a marker for ovarian clear cell carcinoma. Diagn Cytopathol; 2007 Apr;35(4):193-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunocytochemistry for hepatocyte nuclear factor-1beta (HNF-1beta): a marker for ovarian clear cell carcinoma.
  • Recent microarray studies have shown that the expression of hepatocyte nuclear factor-1beta (HNF-1beta) was significantly up-regulated in clear cell carcinoma (CCC) of the ovary.
  • In contrast, two serous adenocarcinoma cell lines never showed immunoreactivity.
  • Based on these results, 21 archival Papanicolaou-stained slides of peritoneal fluid (5 CCCs, 12 serous, 2 mucinous, and 2 endometrioid adenocarcinomas) were decolorized and immunostained under heating pretreatment.
  • Five of 5 CCCs were distinctively positive for HNF-1beta, whereas all non-CCC ovarian cancers were negative for this protein.
  • HNF-1beta is likely to be helpful for the diagnosis of CCC in the peritoneal fluid.
  • [MeSH-major] Adenocarcinoma, Clear Cell / diagnosis. Biomarkers, Tumor / analysis. Hepatocyte Nuclear Factor 1-beta / metabolism. Immunohistochemistry / methods. Ovarian Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2007 Wiley-Liss, Inc.
  • (PMID = 17351940.001).
  • [ISSN] 8755-1039
  • [Journal-full-title] Diagnostic cytopathology
  • [ISO-abbreviation] Diagn. Cytopathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Alcohols; 0 / Biomarkers, Tumor; 0 / Fixatives; 138674-15-4 / Hepatocyte Nuclear Factor 1-beta
  •  go-up   go-down


52. Saglam A, Bozdag G, Kuzey GM, Kuçukali T, Ayhan A: Four synchronous female genital malignancies: the ovary, cervix, endometrium and fallopian tube. Arch Gynecol Obstet; 2008 Jun;277(6):557-62
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Four synchronous female genital malignancies: the ovary, cervix, endometrium and fallopian tube.
  • OBJECTIVE: To present a unique case of a 63 year-old woman with coexistent adenocarcinoma of the ovary, endometrium, cervix and fallopian tube.
  • The frozen section of the mass on the right adnex revealed malign mucinous carcinoma of the ovary.
  • As usual, optimal debulking was performed as initial surgical staging procedure of ovarian cancer.
  • The microscopic examination of the right ovary revealed a typical mucinous cystadenocarcinoma.
  • Furthermore, the focal endometrial irregularity at the left uterine cornus turned out to be a well differentiated endometrial carcinoma of the endometrioid type with <1/3 myometrial invasion.
  • The pale infiltrative lesion in the cervix also turned out to be an adenocarcinoma of the endocervical type with deep stromal invasion and areas of diffuse glandular dysplasia and in-situ glandular neoplasia at the periphery.
  • Besides, several sections from the left fallopian tube uncovered diffuse dysplasia in the lining epithelium and a focus of adenocarcinoma with papillary and cribriform pattern.
  • In such cases, the validity of immunohistochemical and cloning studies are not clear.
  • [MeSH-major] Adenocarcinoma / pathology. Endometrial Neoplasms / pathology. Fallopian Tube Neoplasms / pathology. Neoplasms, Multiple Primary / pathology. Ovarian Neoplasms / pathology. Uterine Cervical Neoplasms / pathology


53. Grisaru-Granovsky S, Salah Z, Maoz M, Pruss D, Beller U, Bar-Shavit R: Differential expression of protease activated receptor 1 (Par1) and pY397FAK in benign and malignant human ovarian tissue samples. Int J Cancer; 2005 Jan 20;113(3):372-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differential expression of protease activated receptor 1 (Par1) and pY397FAK in benign and malignant human ovarian tissue samples.
  • In our present study we investigated the expression pattern of protease activated receptor 1 hPar1 in ovarian carcinoma tissue samples.
  • Abundant hPar1 mRNA and protein were detected in "low malignant potential" and in invasive carcinomas, regardless of the histological subtype.
  • In contrast, no hPar1 expression was detected on the cell surface of normal ovarian epithelium.
  • In early stages of ovarian carcinoma (Ia), the contra lateral normal ovary showed strong PAR1 expression as opposed to the lack of expression in the ovarian epithelium obtained from normal individuals.
  • Although abundant expression of alphavbeta5 integrin was observed in all tissues specimens examined, regardless of either normal or malignant, the level of activated FAK was differentially expressed.
  • Phosphorylated FAK was seen in invasive ovarian carcinoma, but not in the normal ovarian epithelium.
  • The abundant hPar1 levels in pathological malignant ovarian carcinoma is likely to transmit signals leading to the phosphorylation of FAK and thereby alterations in the integrin functional state.
  • Altogether our data suggest that hPar1 and FAK cooperate to promote ovarian cancer malignancy.
  • [MeSH-major] Ovarian Neoplasms / metabolism. Receptor, PAR-1 / metabolism
  • [MeSH-minor] Adenocarcinoma, Clear Cell / genetics. Adenocarcinoma, Clear Cell / metabolism. Adenocarcinoma, Clear Cell / pathology. Adenocarcinoma, Mucinous / genetics. Adenocarcinoma, Mucinous / metabolism. Adenocarcinoma, Mucinous / pathology. Carcinoma, Endometrioid / genetics. Carcinoma, Endometrioid / metabolism. Carcinoma, Endometrioid / pathology. Cystadenocarcinoma, Serous / genetics. Cystadenocarcinoma, Serous / metabolism. Cystadenocarcinoma, Serous / pathology. Epithelium / metabolism. Epithelium / pathology. Female. Focal Adhesion Kinase 1. Focal Adhesion Protein-Tyrosine Kinases. Gene Expression Regulation, Neoplastic. Humans. Immunoenzyme Techniques. In Situ Hybridization. Integrins / genetics. Integrins / metabolism. Neoplasm Invasiveness / pathology. Ovary / metabolism. Ovary / pathology. Phosphorylation. Protein-Tyrosine Kinases / genetics. Protein-Tyrosine Kinases / metabolism. RNA, Messenger / genetics. RNA, Messenger / metabolism. Receptors, Vitronectin / genetics. Receptors, Vitronectin / metabolism. Reverse Transcriptase Polymerase Chain Reaction

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15455382.001).
  • [ISSN] 0020-7136
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Integrins; 0 / RNA, Messenger; 0 / Receptor, PAR-1; 0 / Receptors, Vitronectin; 0 / integrin alphaVbeta5; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.2 / Focal Adhesion Kinase 1; EC 2.7.10.2 / Focal Adhesion Protein-Tyrosine Kinases; EC 2.7.10.2 / PTK2 protein, human
  •  go-up   go-down


54. Logani S, Oliva E, Arnell PM, Amin MB, Young RH: Use of novel immunohistochemical markers expressed in colonic adenocarcinoma to distinguish primary ovarian tumors from metastatic colorectal carcinoma. Mod Pathol; 2005 Jan;18(1):19-25
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Use of novel immunohistochemical markers expressed in colonic adenocarcinoma to distinguish primary ovarian tumors from metastatic colorectal carcinoma.
  • Distinguishing primary ovarian carcinoma, particularly endometrioid and mucinous subtypes, from metastatic colorectal carcinoma to the ovary is often difficult on histologic examination alone.
  • We evaluated a panel consisting of antibodies to CDX2, beta-catenin and P504S in 23 primary ovarian adenocarcinomas (13 mucinous and 10 endometrioid) and compared the findings to 22 metastatic colorectal adenocarcinomas (seven mucinous and 15 nonmucinous tumors with endometrioid-like morphology hereafter referred to as pseudo-endometrioid) to the ovary stained with the same panel.
  • In contrast, only three (13%) primary ovarian tumors expressed at least two markers and none expressed all three.
  • Strong (2+, 3+) and diffuse (>40%) expression for CDX2 was noted in 21 (95%) metastatic tumors and five (22%) primary ovarian tumors (three mucinous, two endometrioid).
  • P504S was similarly expressed in seven (32%) metastatic and none of the primary ovarian carcinomas.
  • Immunohistochemical expression of gene products and enzymes of colorectal carcinogenesis in some primary ovarian carcinomas suggest that the morphologic similarities between colorectal and mucinous/endometrioid carcinoma of the ovary extends to the genetic level, although differences in the level of expression exist between these tumors.
  • Diffuse expression of all three markers (CDX2, beta-catenin and P504S) in a tumor in the ovary was found to be virtually diagnostic of metastasis from a colorectal primary in this study.
  • [MeSH-major] Adenocarcinoma / pathology. Biomarkers / analysis. Colonic Neoplasms / pathology. Colorectal Neoplasms / secondary. Ovarian Neoplasms / pathology
  • [MeSH-minor] Cytoskeletal Proteins / analysis. Diagnosis, Differential. Female. Homeodomain Proteins / analysis. Humans. Immunohistochemistry. Racemases and Epimerases / analysis. Trans-Activators / analysis. beta Catenin

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15389251.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers; 0 / CDX2 protein, human; 0 / CTNNB1 protein, human; 0 / Cytoskeletal Proteins; 0 / Homeodomain Proteins; 0 / Trans-Activators; 0 / beta Catenin; EC 5.1.- / Racemases and Epimerases; EC 5.1.99.4 / alpha-methylacyl-CoA racemase
  •  go-up   go-down


55. Terada T, Kawaguchi M: Primary clear cell adenocarcinoma of the peritoneum. Tohoku J Exp Med; 2005 Jul;206(3):271-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary clear cell adenocarcinoma of the peritoneum.
  • A 49-year-old Japanese woman underwent hysterectomy and bilateral salpingo-oophorectomy for endometrial endometrioid adenocarcinoma grade III, which was composed of undifferentiated carcinoma cells (98%) and tubular carcinoma cells (2%).
  • No clear cell adenocarcinoma elements were noted in this tumor.
  • Two peritoneal cystic tumors were detected by imaging modalities around the stomach and spleen, 15 months and 21 months after the follow-up period of the endometrial carcinoma, respectively.
  • They showed proliferation of carcinoma cells arranged in solid nest, tubular, and papillary patterns.
  • The morphologies fulfilled the criteria of clear cell adenocarcinoma.
  • The morphologies and immunohistochemical findings of the two peritoneal clear cell adenocarcinomas were different from those of endometrial carcinoma.
  • We believe that the two clear cell adenocarcinomas are not metastatic lesions from the endometrial carcinoma of the uterus, and that they are primary clear cell adenocarcinomas of the peritoneum.
  • Our case was characterized by cyst formations and encapsulation in addition to the common histological features of clear cell adenocarcinoma of the uterus and ovary.
  • [MeSH-major] Adenocarcinoma, Clear Cell / diagnosis. Peritoneal Neoplasms / diagnosis
  • [MeSH-minor] Cell Proliferation. Cytoplasm / metabolism. Endometrial Neoplasms / metabolism. Female. Humans. Hysterectomy. Immunohistochemistry. Middle Aged. Ovary / pathology. Periodic Acid-Schiff Reaction. Spleen / metabolism. Stomach / metabolism. Uterine Neoplasms. Uterus / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15942157.001).
  • [ISSN] 0040-8727
  • [Journal-full-title] The Tohoku journal of experimental medicine
  • [ISO-abbreviation] Tohoku J. Exp. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


56. O'Gorman T, Olaitan A: Primary malignant melanoma arising in an ovarian cystic teratoma. Eur J Gynaecol Oncol; 2009;30(1):88-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary malignant melanoma arising in an ovarian cystic teratoma.
  • Cystic ovarian teratomas are common tumours.
  • Malignant melanoma developing in a teratoma, however, is an extremely rare diagnosis.
  • She underwent laparotomy and bilateral salpingo-oophorectomy for a large right ovarian tumour.
  • Histopathology revealed a malignant melanoma and carcinoid tumour in the right ovarian teratoma and an endometrioid adenocarcinoma in the left ovary.
  • An extraovarian primary maelanoma could not be found.
  • [MeSH-major] Carcinoma, Endometrioid / pathology. Dermoid Cyst / pathology. Melanoma / pathology. Neoplasms, Second Primary. Ovarian Neoplasms / pathology

  • Genetic Alliance. consumer health - Teratoma.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19317266.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


57. Torng PL, Lee YC, Huang CY, Ye JH, Lin YS, Chu YW, Huang SC, Cohen P, Wu CW, Lin CT: Insulin-like growth factor binding protein-3 (IGFBP-3) acts as an invasion-metastasis suppressor in ovarian endometrioid carcinoma. Oncogene; 2008 Apr 3;27(15):2137-47
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Insulin-like growth factor binding protein-3 (IGFBP-3) acts as an invasion-metastasis suppressor in ovarian endometrioid carcinoma.
  • Metastasis and invasion occur in the majority of epithelial ovarian carcinoma at diagnosis.
  • To delineate the molecular signature in ovarian cancer invasion, we established and characterized a human ovarian endometrioid carcinoma (EC) cell line OVTW59-P0 and its invasion-related sublines (P1-P4, in the order of increasing invasive activity).
  • By microarray analysis of different gene expression among P0-P4 sublines, one group of gene was found negatively correlated with cancer invasion.
  • Re-expression of IGFBP-3 in P4 effectively inhibited cell migration, invasion and metastasis, but did not affect cell proliferation.
  • Our results provide evidence and indicate that IGFBP-3 plays an important role as an invasion-metastasis suppressor in ovarian EC.
  • [MeSH-major] Carcinoma, Endometrioid / genetics. Genes, Tumor Suppressor. Insulin-Like Growth Factor Binding Protein 3 / physiology. Ovarian Neoplasms / genetics

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17952116.001).
  • [ISSN] 1476-5594
  • [Journal-full-title] Oncogene
  • [ISO-abbreviation] Oncogene
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Validation Studies
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Insulin-Like Growth Factor Binding Protein 3
  •  go-up   go-down


58. Köbel M: [Ovarian carcinoma. Do the subtypes reflect different diseases?]. Pathologe; 2008 Nov;29 Suppl 2:160-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Ovarian carcinoma. Do the subtypes reflect different diseases?].
  • Lack of therapeutic options and poor reproducibility of histopathological subtypes have been the reasons that ovarian carcinomas are currently treated as monolithic entity.
  • With slight modifications of the WHO based subtype classification we have shown that subtypes (i.e. serous, endometrioid, clear cell, mucinous) can be reproducibly used to stratify patients according to disease-specific survival.
  • [MeSH-major] Ovarian Neoplasms / classification. Ovarian Neoplasms / pathology
  • [MeSH-minor] Adenocarcinoma, Clear Cell / classification. Adenocarcinoma, Clear Cell / genetics. Adenocarcinoma, Clear Cell / pathology. Adenocarcinoma, Mucinous / classification. Adenocarcinoma, Mucinous / genetics. Adenocarcinoma, Mucinous / pathology. Carcinoma, Endometrioid / classification. Carcinoma, Endometrioid / genetics. Carcinoma, Endometrioid / pathology. Cystadenocarcinoma, Serous / classification. Cystadenocarcinoma, Serous / genetics. Cystadenocarcinoma, Serous / pathology. DNA Mutational Analysis. Diagnosis, Differential. Female. Genetic Markers / genetics. Humans. Observer Variation. Ovary / pathology. Practice Guidelines as Topic. Prognosis. Tumor Suppressor Protein p53 / genetics

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gynecol Oncol. 1998 Jul;70(1):2-12 [9698465.001]
  • [Cites] Int J Gynecol Pathol. 2002 Oct;21(4):407-11 [12352190.001]
  • [Cites] Clin Cancer Res. 2008 Jan 1;14 (1):89-96 [18172257.001]
  • [Cites] Gynecol Oncol. 2001 Feb;80(2):189-93 [11161858.001]
  • [Cites] Onkologie. 2002 Jun;25(3):240-7 [12119458.001]
  • [Cites] Br J Cancer. 2006 May 22;94(10):1369-74 [16641903.001]
  • [Cites] APMIS. 1991 Apr;99(4):353-8 [2036219.001]
  • [Cites] Gynecol Oncol. 2004 Oct;95(1):89-94 [15385115.001]
  • [Cites] BMC Cancer. 2008 Jan 22;8:17 [18208621.001]
  • [Cites] Am J Pathol. 2004 May;164(5):1511-8 [15111296.001]
  • [Cites] Hum Pathol. 2008 Aug;39(8):1239-51 [18602670.001]
  • [Cites] Cancer Res. 2002 Aug 15;62(16):4722-9 [12183431.001]
  • [Cites] Lancet. 2003 Sep 13;362(9387):869-75 [13678974.001]
  • [Cites] Gynecol Oncol. 2008 Apr;109(1):129-39 [18234305.001]
  • [Cites] Am J Surg Pathol. 2007 Aug;31(8):1168-74 [17667538.001]
  • [Cites] Breast Cancer Res Treat. 2008 Dec;112(3):453-9 [18193353.001]
  • [Cites] Am J Surg Pathol. 2009 Jan;33(1):14-21 [18830127.001]
  • [Cites] J Clin Oncol. 2003 Jan 15;21(2):283-90 [12525520.001]
  • [Cites] Am J Surg Pathol. 2005 Feb;29(2):218-24 [15644779.001]
  • [Cites] Am J Pathol. 1977 Jun;87(3):686-720 [194486.001]
  • [Cites] Int J Gynecol Pathol. 2000 Apr;19(2):158-63 [10782413.001]
  • [Cites] Mod Pathol. 2006 Apr;19(4):581-7 [16554733.001]
  • [Cites] Am J Surg Pathol. 2004 Apr;28(4):453-63 [15087664.001]
  • [Cites] Neoplasia. 2008 Sep;10(9):1021-7 [18714364.001]
  • [Cites] PLoS One. 2007 Nov 07;2(11):e1138 [17987122.001]
  • [Cites] Histopathology. 2006 Jan;48(2):149-56 [16405663.001]
  • [Cites] Nature. 2005 Apr 14;434(7035):917-21 [15829967.001]
  • [Cites] Arch Pathol Lab Med. 1991 Apr;115(4):377-81 [1672813.001]
  • (PMID = 18709371.001).
  • [ISSN] 1432-1963
  • [Journal-full-title] Der Pathologe
  • [ISO-abbreviation] Pathologe
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Genetic Markers; 0 / TP53 protein, human; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


59. Stewart CJ, Brennan BA, Chan T, Netreba J: WT1 expression in endometrioid ovarian carcinoma with and without associated endometriosis. Pathology; 2008 Oct;40(6):592-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] WT1 expression in endometrioid ovarian carcinoma with and without associated endometriosis.
  • AIMS: To determine how frequently endometrioid ovarian carcinomas (EOC) express WT1 protein, and to correlate the results with the presence of endometriosis and p53 immunoreactivity.
  • CONCLUSIONS: Nuclear WT1 expression is present in a minority of EOC and this should be considered if immunohistochemistry is used as an adjunct in sub-typing ovarian carcinomas.
  • The negative correlation of WT1 staining with endometriosis supports the possibility that some EOC, including unusual histological variants, arise from the ovarian surface epithelium.
  • [MeSH-major] Carcinoma, Endometrioid / metabolism. Endometriosis / metabolism. Ovarian Neoplasms / metabolism. WT1 Proteins / biosynthesis


60. Lalich D, Tawfik O, Chapman J, Fraga G: Cutaneous metastasis of ovarian carcinoma with shadow cells mimicking a primary pilomatrical neoplasm. Am J Dermatopathol; 2010 Jul;32(5):500-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cutaneous metastasis of ovarian carcinoma with shadow cells mimicking a primary pilomatrical neoplasm.
  • Shadow cells are characteristic of pilomatricoma, although they have been described in other cutaneous and visceral neoplasms, particularly endometrioid adenocarcinomas of the female genital tract.
  • We describe a metastasis of an ovarian endometrioid adenocarcinoma with shadow cells to the skin that was initially misinterpreted as a pilomatricoma.
  • We compare the histology of the ovarian neoplasm to 21 pilomatricomas.
  • [MeSH-major] Carcinoma, Endometrioid / secondary. Ovarian Neoplasms / pathology. Pilomatrixoma / pathology. Skin Neoplasms / secondary
  • [MeSH-minor] Adult. Arm. Biopsy. Cell Differentiation. Diagnosis, Differential. Female. Humans. Ovariectomy. Ovary / pathology. Skin / pathology

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20526175.001).
  • [ISSN] 1533-0311
  • [Journal-full-title] The American Journal of dermatopathology
  • [ISO-abbreviation] Am J Dermatopathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


61. Matsuura Y, Kitajima M, Hachisuga T, Tanimoto A, Okura N, Kihara I: Malignant mixed müllerian tumor with malignant neuroectodermal components (teratoid carcinosarcoma) of the ovary: Report of a case with clinicopathologic findings. J Obstet Gynaecol Res; 2010 Aug;36(4):907-11
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant mixed müllerian tumor with malignant neuroectodermal components (teratoid carcinosarcoma) of the ovary: Report of a case with clinicopathologic findings.
  • Malignant mixed müllerian tumor (MMMT) or carcinosarcoma of the female genital tract is a rare neoplasm.
  • Malignant ovarian tumor composed of müllerian epithelial tumor and malignant germ cell tumor is also rare, with most cases composed of endometrioid adenocarcinoma and yolk sac tumor.
  • Ovarian MMMT with malignant neuroectodermal components resembling immature teratoma is extremely rare.
  • We report a case of teratoid carcinosarcoma of the ovary occurring in a 40-year-old female.
  • Microscopic examination showed a heterogenous mixed tumor composed of malignant epithelial, malignant mesodermal and malignant neuroectodermal components.
  • This quite rare ovarian tumor closely resembled nasopharyngeal tumors described as 'teratoid carcinosarcoma' is biologically aggressive.
  • We report the fourth case of ovarian teratoid carcinosarcoma.
  • Further cases need to be accumulated to make diagnosis and to determine a successful treatment modality.
  • [MeSH-major] Carcinosarcoma / pathology. Mixed Tumor, Mullerian / pathology. Ovarian Neoplasms / pathology. Teratoma / pathology
  • [MeSH-minor] Adult. Fatal Outcome. Female. Humans. Ovary / pathology. Ovary / surgery

  • Genetic Alliance. consumer health - Malignant mixed Mullerian tumor.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20666968.001).
  • [ISSN] 1447-0756
  • [Journal-full-title] The journal of obstetrics and gynaecology research
  • [ISO-abbreviation] J. Obstet. Gynaecol. Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


62. Kitajima K, Kaji Y, Kuwata Y, Imanaka K, Sugihara R, Sugimura K: Magnetic resonance imaging findings of endometrioid adenocarcinoma of the ovary. Radiat Med; 2007 Aug 01;25(7):346-54
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Magnetic resonance imaging findings of endometrioid adenocarcinoma of the ovary.
  • PURPOSE: We assessed magnetic resonance imaging (MRI) features and clinical characteristics of ovarian endometrioid adenocarcinoma.
  • MATERIALS AND METHODS: A total of 31 patients with 39 surgically proven ovarian endometrioid adenocarcinomas were analyzed retrospectively.
  • Histologically, 13 lesions in 12 patients arose from proven endometriomas (group A), and 26 lesions in 19 patients did not coexist with endometrioma (group B).
  • CONCLUSION: MRI of ovarian endometrioid adenocarcinomas revealed two types: a solid type and a cystic type.
  • [MeSH-major] Adenocarcinoma / pathology. Endometrial Neoplasms / pathology. Magnetic Resonance Imaging / methods. Ovarian Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - MRI Scans.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. GADOPENTETATE DIMEGLUMINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Magn Reson Imaging. 1997 Jul-Aug;7(4):689-95 [9243390.001]
  • [Cites] Cancer. 1970 Nov;26(5):1141-52 [5476794.001]
  • [Cites] Radiology. 1991 Jul;180(1):73-8 [2052726.001]
  • [Cites] Gynecol Oncol. 1999 Mar;72(3):342-6 [10053105.001]
  • [Cites] Radiographics. 2006 Mar-Apr;26(2):407-17 [16549606.001]
  • [Cites] Eur Radiol. 2001;11(6):946-51 [11419167.001]
  • [Cites] Radiology. 2000 Jan;214(1):39-46 [10644099.001]
  • [Cites] Radiology. 1991 Nov;181(2):481-8 [1924792.001]
  • [Cites] Int J Gynaecol Obstet. 1997 Dec;59(3):245-50 [9486515.001]
  • [Cites] AJR Am J Roentgenol. 2000 Nov;175(5):1423-30 [11044056.001]
  • [Cites] Gynecol Oncol. 1990 Dec;39(3):337-46 [2258081.001]
  • (PMID = 17705005.001).
  • [ISSN] 0288-2043
  • [Journal-full-title] Radiation medicine
  • [ISO-abbreviation] Radiat Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Contrast Media; K2I13DR72L / Gadolinium DTPA
  •  go-up   go-down


63. Wang-Johanning F, Liu J, Rycaj K, Huang M, Tsai K, Rosen DG, Chen DT, Lu DW, Barnhart KF, Johanning GL: Expression of multiple human endogenous retrovirus surface envelope proteins in ovarian cancer. Int J Cancer; 2007 Jan 1;120(1):81-90
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of multiple human endogenous retrovirus surface envelope proteins in ovarian cancer.
  • Individual classes of human endogenous retrovirus (HERV) genes and proteins are expressed in cancer, but expression of more than one type of HERV is rare.
  • We report here the expression of multiple HERV genes and proteins in ovarian cell lines and tissues.
  • Expression of HERV-K env mRNA was greater in ovarian epithelial tumors than in normal ovarian tissues (N = 254).
  • The expression of this protein on the surface and in the cytoplasm of ovarian cancer cells was confirmed using anti-HERV-K specific antibody by flow cytometric analysis.
  • A significantly increased expression of HERV-K was observed in tumors with low malignant potential and low grade, relative to expression in normal ovarian tissues.
  • The increase in expression of HERV-K env protein took place in a stepwise fashion in serous papillary adenocarcinoma.
  • Interestingly, we found that other classes of HERV env mRNAs, including ERV3 and HERV-E, are expressed in the same ovarian cancer tissues that expressed HERV-K.
  • Furthermore, anti-HERV antibodies including anti-ERV3 (30%), anti-HERV-E (40%) and anti-HERV-K (55%) were detected in patients with ovarian cancer, but not in normal female controls.
  • HERV env proteins are frequently transcribed and translated in ovarian epithelial tumors, and multiple HERV families are detectable in ovarian cancer.
  • HERV env proteins, and especially those expressed on the cell surface, may serve as novel tumor targets for detection, diagnosis and immunotherapy of ovarian cancer.
  • [MeSH-major] Endogenous Retroviruses / metabolism. Gene Products, env / physiology. Membrane Proteins / metabolism. Ovarian Neoplasms / metabolism
  • [MeSH-minor] Adenocarcinoma, Clear Cell / metabolism. Adenocarcinoma, Clear Cell / virology. Adenocarcinoma, Mucinous / metabolism. Adenocarcinoma, Mucinous / virology. Adult. Aged. Aged, 80 and over. Amino Acid Sequence. Base Sequence. Carcinoma, Endometrioid / metabolism. Carcinoma, Endometrioid / virology. Case-Control Studies. Cystadenocarcinoma, Serous / metabolism. Cystadenocarcinoma, Serous / virology. Enzyme-Linked Immunosorbent Assay. Female. Flow Cytometry. Fluorescent Antibody Technique. Humans. Immunoenzyme Techniques. Middle Aged. Molecular Sequence Data. Ovary / metabolism. RNA, Messenger / genetics. RNA, Messenger / metabolism. Reverse Transcriptase Polymerase Chain Reaction. Tissue Array Analysis. Tumor Cells, Cultured

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17013901.001).
  • [ISSN] 0020-7136
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Gene Products, env; 0 / Membrane Proteins; 0 / Np9 protein, HERV-K, human; 0 / RNA, Messenger
  •  go-up   go-down


64. Chiang YC, Chen CA, Huang CY, Hsieh CY, Cheng WF: Synchronous primary cancers of the endometrium and ovary. Int J Gynecol Cancer; 2008 Jan-Feb;18(1):159-64
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Synchronous primary cancers of the endometrium and ovary.
  • Simultaneous detection of malignancy in the endometrium and ovary represents an uncommon event.
  • The histologic determination was followed by the World Health Organization Committee classification, and cancer stage was based on the staging system of the FIGO.
  • The incidence of synchronous primary endometrial and ovarian cancers was 3.3% in patients with endometrial cancer and 2.7% in patients with ovarian cancer.
  • However, the impact of adjuvant therapy on survival did not reach statistic significance (P= 0.15 for chemotherapy; P= 0.69 for radiotherapy).
  • We conclude that the majority of the patients belonged to concordant endometrioid histology in endometrium and ovary, and it tends to be early stage and low grade with favorable prognosis.
  • [MeSH-major] Endometrial Neoplasms / pathology. Neoplasms, Multiple Primary / pathology. Ovarian Neoplasms / pathology
  • [MeSH-minor] Adenocarcinoma / secondary. Adenocarcinoma, Clear Cell / secondary. Adult. Carcinoma, Endometrioid / secondary. Cystadenocarcinoma, Serous / secondary. Female. Humans. Middle Aged. Prognosis. Retrospective Studies. Risk Factors

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17506847.001).
  • [ISSN] 1525-1438
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


65. Hong FZ, Wang B, Li HM, Liew CT: [Hypermethylation of fragile histidine triad gene and 3p14 allelic deletion in ovarian carcinomas]. Zhonghua Bing Li Xue Za Zhi; 2005 May;34(5):257-61
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Hypermethylation of fragile histidine triad gene and 3p14 allelic deletion in ovarian carcinomas].
  • In this study, the methylation status of FHIT and LOH of 3p14 in 61 cases of human sporadic ovary carcinomas were investigated.
  • METHODS: Sixty-one primary ovary carcinomas and 10 borderline ovarian tumors were analyzed with methylation specific PCR (MSP) to detect the CpG island methylation status in the FHIT promoter region.
  • In addition, 45 cases of ovary carcinomas and their corresponding non-tumor ovary tissues were investigated with D3S1287 microsatellite polymorphic marker for LOH.
  • RESULTS: Hypermethylation of FHIT gene was observed in 39.3% (24/61) of ovarian carcinomas.
  • The frequencies of hypermethylation in serous ovarian carcinoma, mucinous ovarian carcinoma, endometrioid ovarian carcinoma and ovary borderline tumor were 45.2% (19/42), 14.3% (1/7), 33.3% (4/12) and 60.0% (6/10), respectively.
  • The status of FHIT methylation was not associated with clinical stage and differentiation grade, there was no significant difference between the malignant and borderline tumors.
  • CONCLUSION: Hypermethylation and allelic deletion of FHIT are frequent events in ovarian carcinomas and are important mechanisms for the loss of expression of this gene.
  • [MeSH-major] Acid Anhydride Hydrolases / genetics. Chromosomes, Human, Pair 3. Cystadenocarcinoma, Serous / genetics. Loss of Heterozygosity. Neoplasm Proteins / genetics. Ovarian Neoplasms / genetics

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16181544.001).
  • [ISSN] 0529-5807
  • [Journal-full-title] Zhonghua bing li xue za zhi = Chinese journal of pathology
  • [ISO-abbreviation] Zhonghua Bing Li Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / DNA, Neoplasm; 0 / Neoplasm Proteins; 0 / fragile histidine triad protein; EC 3.6.- / Acid Anhydride Hydrolases
  •  go-up   go-down


66. Testa AC, Timmerman D, Exacoustos C, Fruscella E, Van Holsbeke C, Bokor D, Arduini D, Scambia G, Ferrandina G: The role of CnTI-SonoVue in the diagnosis of ovarian masses with papillary projections: a preliminary study. Ultrasound Obstet Gynecol; 2007 May;29(5):512-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The role of CnTI-SonoVue in the diagnosis of ovarian masses with papillary projections: a preliminary study.
  • OBJECTIVES: To describe sonographically the distribution patterns of a second-generation contrast agent in the microcirculation of unilocular and multilocular ovarian masses with papillary projections, and to investigate whether qualitative evaluation of the passage of the contrast agent can improve the performance of sonography in distinguishing between benign and malignant masses with papillary projections.
  • METHODS: Thirty-three patients with unilocular or multilocular ovarian masses with papillary projections were enrolled into the study in three clinical centers.
  • RESULTS: Twenty-four (73%) lesions were benign, eight (24%) were borderline ovarian tumors, and one patient presented with an endometrioid ovarian adenocarcinoma.
  • CONCLUSION: Qualitative evaluation of blood circulation in papillary projections using CnTI-SonoVue examination does not improve the discrimination of benign from borderline/malignant ovarian masses with papillary projections.
  • [MeSH-major] Contrast Media. Ovarian Neoplasms / ultrasonography. Phospholipids. Sulfur Hexafluoride
  • [MeSH-minor] Adnexa Uteri / pathology. Adnexa Uteri / ultrasonography. Adult. Aged. Aged, 80 and over. Female. Humans. Image Enhancement / methods. Microbubbles. Microcirculation / ultrasonography. Middle Aged. Ovarian Cysts / pathology. Ovarian Cysts / ultrasonography. Ovary / pathology. Ovary / ultrasonography. Sensitivity and Specificity. Ultrasonography, Doppler, Color / methods

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. SULFUR HEXAFLUORIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2007 ISUOG.
  • (PMID = 17444549.001).
  • [ISSN] 0960-7692
  • [Journal-full-title] Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology
  • [ISO-abbreviation] Ultrasound Obstet Gynecol
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Contrast Media; 0 / Phospholipids; 0 / contrast agent BR1; WS7LR3I1D6 / Sulfur Hexafluoride
  •  go-up   go-down


67. Shimada M, Kigawa J, Ohishi Y, Yasuda M, Suzuki M, Hiura M, Nishimura R, Tabata T, Sugiyama T, Kaku T: Clinicopathological characteristics of mucinous adenocarcinoma of the ovary. Gynecol Oncol; 2009 Jun;113(3):331-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinicopathological characteristics of mucinous adenocarcinoma of the ovary.
  • OBJECTIVE: We conducted the present study to clarify the clinicopathological characteristics of mucinous adenocarcinoma.
  • METHODS: Two hundred twenty-five patients were diagnosed with mucinous adenocarcinoma at individual institutes and underwent primary treatment between 1998 and 2003.
  • Of 189 patients undergoing central pathological review, 64 patients (33.9%) were diagnosed with mucinous invasive adenocarcinoma, 45 mucinous intraepithelial carcinoma, and 42 mucinous tumor of borderline malignancy.
  • Twenty-five patients were diagnosed with other histological subtypes, including 8 endometrioid adenocarcinoma, 5 clear cell carcinoma, 3 serous adenocarcinoma, and 4 mixed type.
  • There were 13 cases of metastatic mucinous adenocarcinoma, including 7 pseudomyxoma peritonei.
  • Four hundred thirty-three patients with serous adenocarcinoma were used as controls.
  • RESULTS: Forty-five patients with mucinous invasive carcinoma were in FIGO I-II stages and 19 in III-IV stages.
  • There was no difference in the outcome between mucinous invasive adenocarcinoma and serous adenocarcinoma in I-II stage patients and III-IV stage patients with optimal operation.
  • In contrast, patients with mucinous invasive adenocarcinoma receiving suboptimal operation showed a significantly worse prognosis (survival rate: 27.8% vs. 61.5%).
  • The response rate to chemotherapy for mucinous invasive adenocarcinoma was significantly lower than for serous adenocarcinoma (12.5% vs. 67.7%).
  • CONCLUSIONS: The diagnosis of mucinous invasive adenocarcinoma was difficult.
  • Since patients with mucinous invasive adenocarcinoma had a lower response to chemotherapy, aggressive cytoreductive surgery was an effective treatment to improve the prognosis for advanced stage patients.
  • A new chemotherapeutic regimen should be established for mucinous adenocarcinoma of the ovary.
  • [MeSH-major] Adenocarcinoma, Mucinous / pathology. Ovarian Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19275957.001).
  • [ISSN] 1095-6859
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


68. Körner M, Burckhardt E, Mazzucchelli L: Higher frequency of chromosomal aberrations in ovarian endometriosis compared to extragonadal endometriosis: A possible link to endometrioid adenocarcinoma. Mod Pathol; 2006 Dec;19(12):1615-23
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Higher frequency of chromosomal aberrations in ovarian endometriosis compared to extragonadal endometriosis: A possible link to endometrioid adenocarcinoma.
  • Endometriosis may progress to invasive endometrioid adenocarcinoma, particularly in the ovary.
  • Up to now, little is known of the molecular mechanisms possibly involved in the malignant transformation of endometriosis.
  • Therefore, in this study, extragonadal endometriosis (n = 10), ovarian endometriosis without malignancy (n = 10), ovarian endometriosis with direct transition into endometrioid adenocarcinoma (n = 8), and normal endometrium (n = 12) were investigated for numerical chromosomal aberrations by fluorescence in situ hybridization using centromere enumeration probes.
  • Trisomies 1 and 7, and monosomies 9 and 17 were found in endometriosis, ovarian endometrioid adenocarcinoma, and normal endometrium.
  • The proportions of aneusomic cells were significantly higher in ovarian endometrioid carcinoma compared with ovarian endometriosis (P < 0.001), and in ovarian endometriosis compared with extragonadal endometriosis and normal endometrium (P < 0.001).
  • The data provide new evidence of a common lineage of endometriosis and ovarian endometrioid carcinoma.
  • The higher frequency of chromosomal aberrations in endometrioid carcinoma than in endometriosis may reflect an expansion of aberrant cell clones already present in endometriosis during the progression to cancer.
  • The higher frequency of chromosomal aberrations in ovarian endometriosis than in extragonadal endometriosis suggests a role of the ovarian stromal milieu in the induction of genetic changes, which may eventually lead to invasive cancer.
  • [MeSH-major] Aneuploidy. Carcinoma, Endometrioid / genetics. Endometriosis / genetics. Ovarian Neoplasms / genetics. Precancerous Conditions / genetics

  • Genetic Alliance. consumer health - Endometriosis.
  • MedlinePlus Health Information. consumer health - Endometriosis.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16980942.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Neoplasm
  •  go-up   go-down


69. Stolnicu S, Preda O, Dohan M, Puscasiu L, García-Galvis OF, Nogales FF: Pseudoglandular hepatoid differentiation in endometrioid carcinoma of the ovary simulates oxyphilic cell change. Int J Gynecol Pathol; 2008 Oct;27(4):521-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pseudoglandular hepatoid differentiation in endometrioid carcinoma of the ovary simulates oxyphilic cell change.
  • A 42-year-old patient had a stage III ovarian endometrioid adenocarcinoma with areas of hepatoid carcinoma (HC) of clear cell and eosinophilic pseudoglandular type that was difficult to differentiate from endometrioid carcinoma of oxyphilic type and sex cord-stromal tumor.
  • Immunohistochemically, endometrioid adenocarcinoma was positive for CA125, estrogen and progesterone receptors, CAM5.2, cytokeratin (CK) 7 and 19, and vimentin.
  • HC areas were positive for hep par1, polyclonal carcinoembryonic antigens, CD10, alpha-fetoprotein, epithelial membrane antigens, and antimitochondrial antibodies and shared with endometrioid carcinoma focal CK7, and constant positive CK19, CAM5.2, and progesterone receptors.
  • In the differential diagnosis, a hepatic immunophenotype of oxyphilic, mitochondriae-rich areas (demonstrated by antimitochondrial antibodies) was identified by HC specific (hep par1) and characteristic markers: canalicular, cytoplasmic and membranous polyclonal carcinoembryonic antigens, CD10 patterns, and alpha-fetoprotein).
  • Trabecular and clear vacuolated areas of HC resembled luteinized cells of sex cord-stromal ovarian tumors, but the membranous positivity to CAM5.2 supported epithelial (hepatoid) identity.
  • The partial preservation of an endometrioid immunophenotype in HC (positive CK7 and 19 and progesterone receptors) would support an origin from endometrioid carcinoma.
  • [MeSH-major] Carcinoma, Endometrioid / pathology. Ovarian Neoplasms / pathology
  • [MeSH-minor] Adult. Carcinoma, Hepatocellular / pathology. Cell Differentiation / physiology. Female. Humans. Immunohistochemistry. Oxyphil Cells / pathology

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18753970.001).
  • [ISSN] 1538-7151
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


70. Buttarelli M, Houvenaeghel G, Lelièvre L, Jacquemier J, Guiramand J, Delpero JR: [Pelvic posterior exenteration with immediate colo-rectal anastomosis: is it justified and feasible in advanced stage ovarian carcinoma?]. Ann Chir; 2006 Oct;131(8):431-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Pelvic posterior exenteration with immediate colo-rectal anastomosis: is it justified and feasible in advanced stage ovarian carcinoma?].
  • [Transliterated title] Une exentération pelvienne postérieure avec anastomose est-elle faisable et justifiée dans le traitement des cancers de l'ovaire à un stade évolué?
  • PURPOSE: The aim of this study is to show that the removal of the rectum is not an obstacle to implement an optimal surgery in advanced epithelial cancer of the ovary.
  • MATERIAL AND METHODS: Retrospective study on a population of 44 women with advanced epithelial cancer of the ovary.
  • CONCLUSION: The posterior exenteration, when it's necessary, for advanced epithelial cancer of the ovary must not be an obstacle to obtain an optimal surgery.
  • [MeSH-major] Adenocarcinoma / surgery. Carcinoma, Endometrioid / surgery. Carcinosarcoma / surgery. Colon / surgery. Ovarian Neoplasms / surgery. Pelvic Exenteration. Rectum / surgery
  • [MeSH-minor] Adenocarcinoma, Clear Cell / pathology. Adenocarcinoma, Clear Cell / surgery. Adenocarcinoma, Mucinous / pathology. Adenocarcinoma, Mucinous / surgery. Adult. Aged. Aged, 80 and over. Anastomosis, Surgical. Colostomy. Cystadenocarcinoma, Serous / pathology. Cystadenocarcinoma, Serous / surgery. Cystectomy. Feasibility Studies. Female. Humans. Hysterectomy. Ileostomy. Middle Aged. Neoplasm Recurrence, Local. Neoplasm Staging. Ovary / pathology. Preoperative Care. Quality of Life. Retrospective Studies. Time Factors. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16707093.001).
  • [ISSN] 0003-3944
  • [Journal-full-title] Annales de chirurgie
  • [ISO-abbreviation] Ann Chir
  • [Language] fre
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


71. Sciallis AP, Aubry MC, Bell DA: Ciliated adenocarcinoma of the ovary with evidence of serous differentiation: report of a case. Int J Gynecol Pathol; 2009 Sep;28(5):447-52
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ciliated adenocarcinoma of the ovary with evidence of serous differentiation: report of a case.
  • A patient with bilateral ovarian adenocarcinomas composed predominantly of ciliated cells incidentally found at autopsy is reported.
  • Although obviously malignant, a majority of the cells expressed well-differentiated cilia with terminal bar formation.
  • Although morphologically resembling an endometrioid-type neoplasm, immunohistochemical and molecular studies were more consistent with a serous phenotype, especially in light of its apparent origination from a serous adenofibroma.
  • [MeSH-major] Adenocarcinoma / pathology. Cilia / pathology. Ovarian Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19696614.001).
  • [ISSN] 1538-7151
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


72. Hayasaka T, Nakahara K, Kojimahara T, Saito-Sekiguchi M, Motoyama T, Kurachi H: Endometrioid adenocarcinoma with a functioning stroma. J Obstet Gynaecol Res; 2007 Jun;33(3):381-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endometrioid adenocarcinoma with a functioning stroma.
  • A case of a 70-year-old woman with endometrioid adenocarcinoma of the ovary with functioning stroma is presented.
  • The surgical specimens consisted of a multilocular cystic ovarian tumor of 95 mm in diameter and an enlarged uterus.
  • Histologically, the tumor was composed of proliferating, atypical, columnar cancer cells resembling early secretory endometrial cells, and condensation of plumed stromal cells resembling theca lutein cells.
  • The diagnosis of endometrial adenocarcinoma of the ovary with functioning stroma was made.
  • Almost all types of ovarian tumor have been reported to be associated with endocrine abnormalities.
  • Mucinous epithelial ovarian tumors most commonly present with estrogenic stroma, although the frequency of endometrioid adenocarcinoma with functioning stroma is very low.
  • [MeSH-major] Carcinoma, Endometrioid / pathology. Estradiol / blood. Follicle Stimulating Hormone / blood. Ovarian Neoplasms / pathology. Ovary / pathology

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. ESTRADIOL .
  • Hazardous Substances Data Bank. MENOTROPINS .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17578372.001).
  • [ISSN] 1341-8076
  • [Journal-full-title] The journal of obstetrics and gynaecology research
  • [ISO-abbreviation] J. Obstet. Gynaecol. Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 4TI98Z838E / Estradiol; 9002-68-0 / Follicle Stimulating Hormone
  •  go-up   go-down


73. Maeda D, Ota S, Takazawa Y, Aburatani H, Nakagawa S, Yano T, Taketani Y, Kodama T, Fukayama M: Glypican-3 expression in clear cell adenocarcinoma of the ovary. Mod Pathol; 2009 Jun;22(6):824-32
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Glypican-3 expression in clear cell adenocarcinoma of the ovary.
  • Glypican-3 is a heparan sulfate proteoglycan that is overexpressed in various neoplasms such as hepatocellular carcinoma, malignant melanoma, and testicular yolk sac tumor.
  • To clarify the significance of glypican-3 expression in ovarian clear cell adenocarcinoma, we evaluated glypican-3 expression by immunohistochemistry in nonneoplastic and neoplastic ovaries, and other Müllerian duct derivatives including endometrium in different menstrual phases.
  • A total of 213 cases of ovarian adenocarcinoma, including 94 clear cell adenocarcinomas, were studied.
  • Glypican-3 expression was observed in 44% of clear cell adenocarcinomas, whereas it was rarely observed in other histological subtypes: mucinous (4%), endometrioid (5%), and serous (11%; P<0.0001).
  • All six ovarian yolk sac tumors showed diffuse immunoreactivity for glypican-3.
  • In cases of clear cell adenocarcinoma, no correlations were found between glypican-3 expression and clinicopathological factors, such as tumor stage, lymph node metastasis, peritoneal dissemination, and death rate.
  • However, glypican-3 expression was significantly associated with poor overall survival in stage III/IV clear cell adenocarcinoma cases.
  • Our results suggest that overexpression of glypican-3 may be related to the development and aggressive behavior of ovarian clear cell adenocarcinoma.
  • [MeSH-major] Adenocarcinoma, Clear Cell / metabolism. Biomarkers, Tumor / analysis. Glypicans / biosynthesis. Ovarian Neoplasms / metabolism

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19329941.001).
  • [ISSN] 1530-0285
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Glypicans
  •  go-up   go-down


74. Fujibayashi M, Aiba M, Iizuka E, Igarashi A, Muraoka M, Takagi K: Granulosa cell tumor-like variant of endometrioid carcinoma of the ovary exhibiting nuclear clearing with biotin activity: a subtype showing close macroscopic, cytologic, and histologic similarity to adult granulosa cell tumor. Arch Pathol Lab Med; 2005 Oct;129(10):1288-94
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Granulosa cell tumor-like variant of endometrioid carcinoma of the ovary exhibiting nuclear clearing with biotin activity: a subtype showing close macroscopic, cytologic, and histologic similarity to adult granulosa cell tumor.
  • CONTEXT: The sex cord-like variant of endometrioid carcinoma of the ovary shows many similarities to Sertoli-Leydig cell tumor and granulosa cell tumor.
  • However, few cases of the granulosa cell tumor-like variant have been reported, suggesting this tumor might often be hidden under the diagnosis of granulosa cell tumor.
  • OBJECTIVE: To investigate the similarities and differences between the granulosa cell tumor-like variant of endometrioid carcinoma and granulosa cell tumor of the ovary and to evaluate a newly observed feature, namely, nuclear clearing (or optically clear nuclei), in this variant tumor.
  • DESIGN: A comparative macroscopic, cytologic, histopathologic, and immunohistochemical study in specimens obtained from the following patients: 1 patient with granulosa cell tumor-like variant of endometrioid carcinoma diagnosed by frozen section examination, 3 patients with granulosa cell tumor, and 6 patients with classic endometrioid carcinoma.
  • CONCLUSION: Because the granulosa cell tumor-like variant is pathologically similar to granulosa cell tumor, showing only some dissimilarities to the latter, it can easily be misdiagnosed if the possibility of this variant is not kept in mind.
  • Identification of the typical endometrioid histologic features or related lesions or immunohistochemistry may lead to a proper diagnosis.
  • The observation of nuclear clearing with biotin activity in nonmorular nests suggests that this tumor has endometrioid epithelial characteristics.
  • [MeSH-major] Carcinoma, Endometrioid / pathology. Cell Nucleus / pathology. Granulosa Cell Tumor / pathology. Ovarian Neoplasms / pathology
  • [MeSH-minor] Adult. Biomarkers, Tumor / analysis. Biotin / analysis. Carcinoma in Situ / chemistry. Carcinoma in Situ / pathology. Cytodiagnosis. Female. Humans. Immunoenzyme Techniques. Middle Aged

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. BIOTIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Arch Pathol Lab Med. 2008 Aug;132(8):1222. Okamura, Mitsue [corrected to Muraoka, Mitsue]
  • (PMID = 16196518.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 6SO6U10H04 / Biotin
  •  go-up   go-down


75. Kobayashi H: Ovarian cancer in endometriosis: epidemiology, natural history, and clinical diagnosis. Int J Clin Oncol; 2009 Oct;14(5):378-82
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ovarian cancer in endometriosis: epidemiology, natural history, and clinical diagnosis.
  • We review whether endometriosis-associated ovarian cancer is a specific entity compared with ovarian cancer not associated with endometriosis, with respect to epidemiology, natural history, and clinical diagnosis; we present a review of the English-language literature for ovarian cancer in endometriosis with respect to these three features.
  • A recent prospective study in Japan directly showed that, during a follow-up of up to 17 years of an ovarian endometrioma cohort (n = 6398), 46 incident ovarian cancers were identified, showing that the ovarian cancer risk was significantly elevated in patients with ovarian endometrioma (standardized incidence ratio [SIR], 8.95; 95% confidence interval [CI], 4.12 to 15.3).
  • Advancing age (>40 years) and the size of the endometriomas (>9 cm) were independent predictors of the development of ovarian cancer among the women with ovarian endometrioma.
  • Although some endometriosis lesions may predispose to clear cell carcinoma (CCC) and endometrioid adenocarcinoma (EAC) of the ovary, both of these cancers differ from the other histological types with respect to their clinical characteristics and carcinogenesis.
  • In patients with endometriosis-associated ovarian cancer, benign-appearing ovarian masses are typically present several years before the diagnosis of the cancer.
  • A slightly elevated carbohydrate antigen [CA] 125 level is also typically present many years before the diagnosis in these patients.
  • However, serous-type ovarian cancer may exhibit a rapid progression possibly through de-novo carcinogenesis.
  • Ovarian endometrioma could be viewed as a neoplastic process, particularly in perimenopausal women.
  • Understanding the mechanisms of the development of endometriosis and elucidating its pathogenesis and pathophysiology are intrinsic to the prevention of endometriosis-associated ovarian cancer and the search for effective therapies.
  • [MeSH-major] Cell Transformation, Neoplastic. Endometriosis / diagnosis. Endometriosis / epidemiology. Ovarian Neoplasms / diagnosis. Ovarian Neoplasms / epidemiology. Precancerous Conditions / diagnosis. Precancerous Conditions / epidemiology

  • Genetic Alliance. consumer health - Endometriosis.
  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Endometriosis.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Gynecol Cancer. 2005 Jan-Feb;15(1):37-44 [15670295.001]
  • [Cites] Gynecol Oncol. 2003 Mar;88(3):309-17 [12648580.001]
  • [Cites] Lancet Oncol. 2009 Apr;10 (4):327-40 [19282241.001]
  • [Cites] J Obstet Gynaecol Res. 2008 Oct;34(5):872-7 [18834345.001]
  • [Cites] Int J Gynecol Cancer. 2007 Jan-Feb;17(1):37-43 [17291229.001]
  • [Cites] Gynecol Oncol. 2000 Dec;79(3):466-70 [11104621.001]
  • [Cites] Int J Gynecol Pathol. 2008 Apr;27(2):151-60 [18317228.001]
  • [Cites] BMJ. 1993 Apr 17;306(6884):1030-4 [8490497.001]
  • [Cites] Clin Cancer Res. 2008 Jan 1;14(1):32-40 [18172249.001]
  • [Cites] Gynecol Oncol. 1999 Mar;72(3):342-6 [10053105.001]
  • [Cites] Int J Gynecol Cancer. 2003 Jul-Aug;13(4):466-71 [12911723.001]
  • [Cites] BMJ. 1996 Nov 30;313(7069):1355-8 [8956699.001]
  • [Cites] Cancer. 1995 Nov 15;76(10 Suppl):2086-91 [8635005.001]
  • [Cites] Gynecol Obstet Invest. 2000;50 Suppl 1:11-7 [11093056.001]
  • [Cites] Med J Aust. 2003 Jun 16;178(12 ):655-6 [12797860.001]
  • [Cites] Ann Acad Med Singapore. 1998 Sep;27(5):676-82 [9919339.001]
  • [Cites] Curr Opin Obstet Gynecol. 2000 Feb;12 (1):39-42 [10752515.001]
  • [Cites] Br J Cancer. 1999 Oct;81(3):559-63 [10507786.001]
  • [Cites] Int J Gynaecol Obstet. 2001 Jul;74(1):45-50 [11430940.001]
  • [Cites] Gynecol Oncol. 2003 Oct;91(1):15-31 [14529658.001]
  • [Cites] Int J Gynecol Cancer. 2008 May-Jun;18(3):414-20 [17645503.001]
  • [Cites] Semin Reprod Med. 2003 May;21(2):209-22 [12917790.001]
  • [Cites] Fertil Steril. 2004 Aug;82(2):405-14 [15302291.001]
  • [Cites] Lancet. 1999 Apr 10;353(9160):1207-10 [10217079.001]
  • [Cites] Lancet. 1988 Feb 6;1(8580):268-71 [2893084.001]
  • [Cites] Am J Obstet Gynecol. 1997 Mar;176(3):572-9 [9077609.001]
  • [Cites] Br J Cancer. 1999 Jul;80(10 ):1644-7 [10408412.001]
  • [Cites] Acta Obstet Gynecol Scand. 2004 Apr;83(4):395-400 [15005789.001]
  • [Cites] Cancer. 2002 Mar 1;94(5):1612-8 [11920519.001]
  • [Cites] Gynecol Obstet Invest. 2000;50 Suppl 1:18-25 [11093057.001]
  • [Cites] Semin Oncol. 1998 Jun;25(3):255-64 [9633839.001]
  • [Cites] Int J Gynaecol Obstet. 2007 Nov;99(2):95-9 [17643440.001]
  • [Cites] Oncol Rep. 2009 Aug;22(2):233-40 [19578761.001]
  • [Cites] Int J Gynaecol Obstet. 1997 Dec;59(3):245-50 [9486515.001]
  • [Cites] Eur J Obstet Gynecol Reprod Biol. 1996 Apr;65(2):221-5 [8730628.001]
  • [Cites] Obstet Gynecol Clin North Am. 2001 Dec;28(4):637-51, vii [11766142.001]
  • [Cites] Am J Obstet Gynecol. 2003 Jul;189(1):280-94 [12861175.001]
  • [Cites] Semin Oncol. 1998 Jun;25(3):315-25 [9633843.001]
  • [Cites] Clin J Oncol Nurs. 2003 Jan-Feb;7(1):41-7 [12629933.001]
  • [Cites] Eur J Obstet Gynecol Reprod Biol. 2008 Jun;138(2):187-93 [18162283.001]
  • [Cites] Am J Epidemiol. 2002 Feb 1;155(3):217-24 [11821246.001]
  • (PMID = 19856043.001).
  • [ISSN] 1437-7772
  • [Journal-full-title] International journal of clinical oncology
  • [ISO-abbreviation] Int. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Japan
  • [Number-of-references] 41
  •  go-up   go-down


76. Hong DG, Chong GO, Seong WJ, Lee YS, Cho YL, Park JY, Chae JM, Park IS: A case of ovarian endometrioid adenocarcinoma with yolk sac tumor in a 35-year-old woman. Eur J Gynaecol Oncol; 2010;31(4):471-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of ovarian endometrioid adenocarcinoma with yolk sac tumor in a 35-year-old woman.
  • Ovarian yolk sac tumor (YST) is a malignant ovarian neoplasm differentiated from primordial germ cells that occur in young age, while endometrioid carcinoma (ECA) is a müllerian epithelial tumor that usually occurs in older patients.
  • The coexistence of an ovarian ECA and YST component is very rare.
  • The parts of both ovaries that showed an endometrioid-like glandular pattern were positive for cytokeratin 7 and negative for AFP, but the YST component was negative for cytokeratin 7 and positive for AFP.
  • [MeSH-major] Carcinoma, Endometrioid / pathology. Endodermal Sinus Tumor / pathology. Ovarian Neoplasms / pathology

  • Genetic Alliance. consumer health - Yolk sac tumor.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20882900.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Italy
  •  go-up   go-down


77. Ardavanis A, Karamouzis MV, Alexopoulos A, Rigatos G: Simultaneous endometrioid ovarian and uterine carcinoma diagnosed after an in vitro fertilization procedure--case report and review of the literature. Eur J Gynaecol Oncol; 2005;26(6):654-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Simultaneous endometrioid ovarian and uterine carcinoma diagnosed after an in vitro fertilization procedure--case report and review of the literature.
  • BACKGROUND: The presence of simultaneous carcinomas involving both the ovary and uterus is relatively uncommon, while the possible link between fertility drugs and carcinogenesis still remains controversial.
  • CASE: The case of a 40-year-old patient with simultaneous aggressive endometrioid carcinoma of the ovary and uterus a few months after the sixth attempt of in vitro fertilization is presented.
  • The patient had de novo lung disease at surgery and diffuse metastatic spread to adjacent bone, subcutaneous tissue and the central nervous system (CNS) soon after a spectacular response to the primary paclitaxel/carboplatinum chemotherapy and while on maintenance and second-line chemotherapy, respectively.
  • [MeSH-major] Carcinoma, Endometrioid / pathology. Fertilization in Vitro / adverse effects. Lung Neoplasms / secondary. Neoplasms, Multiple Primary / pathology. Ovarian Neoplasms / pathology. Uterine Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16398231.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Italy
  • [Number-of-references] 16
  •  go-up   go-down


78. Torng PL, Lin CW, Chan MW, Yang HW, Huang SC, Lin CT: Promoter methylation of IGFBP-3 and p53 expression in ovarian endometrioid carcinoma. Mol Cancer; 2009;8:120
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Promoter methylation of IGFBP-3 and p53 expression in ovarian endometrioid carcinoma.
  • Promoter methylation has been linked to gene silencing and cancer progression.
  • We studied the correlation between IGFBP-3 and p53 expression as well as IGFBP-3 promoter methylation in ovarian endometrioid carcinoma (OEC) by immunohistochemical staining and quantitative methylation-specific PCR (qMSP).
  • CONCLUSION: Our data suggests that IGFBP-3 silencing through IGFBP-3 promoter methylation in the absence of p53 overexpression is associated with cancer progression.
  • [MeSH-major] Carcinoma, Endometrioid / genetics. DNA Methylation. Insulin-Like Growth Factor Binding Protein 3 / genetics. Ovarian Neoplasms / genetics. Promoter Regions, Genetic. Tumor Suppressor Protein p53 / genetics

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Cancer. 2007 Feb 1;120(3):566-73 [17096329.001]
  • [Cites] J Clin Pathol. 2009 Sep;62(9):777-85 [18977806.001]
  • [Cites] Int J Gynecol Pathol. 2008 Apr;27(2):151-60 [18317228.001]
  • [Cites] Oncogene. 2008 Apr 3;27(15):2137-47 [17952116.001]
  • [Cites] APMIS. 2008 May;116(5):400-9 [18452430.001]
  • [Cites] Crit Rev Oncol Hematol. 2008 Oct;68(1):1-11 [18430583.001]
  • [Cites] Nat Genet. 2000 Feb;24(2):132-8 [10655057.001]
  • [Cites] Mol Genet Metab. 2000 Jun;70(2):85-98 [10873390.001]
  • [Cites] Int J Cancer. 2000 Nov 1;88(3):448-53 [11054675.001]
  • [Cites] J Biol Chem. 2000 Dec 15;275(50):39174-81 [10998426.001]
  • [Cites] Cancer. 2001 Dec 25;93(6):376-80 [11748577.001]
  • [Cites] Cancer Lett. 2002 Feb 25;176(2):149-58 [11804742.001]
  • [Cites] Endocr Rev. 2002 Dec;23(6):824-54 [12466191.001]
  • [Cites] Clin Cancer Res. 2002 Dec;8(12):3669-75 [12473575.001]
  • [Cites] Gynecol Oncol. 2004 Feb;92(2):559-67 [14766248.001]
  • [Cites] Oncogene. 2004 Aug 26;23(39):6569-80 [15247904.001]
  • [Cites] Nat Genet. 1992 Apr;1(1):45-9 [1301998.001]
  • [Cites] Nature. 1995 Oct 19;377(6550):646-9 [7566179.001]
  • [Cites] Semin Oncol. 1996 Oct;23(5 Suppl 12):40-7 [8941409.001]
  • [Cites] Oncogene. 1997 Jan 9;14(1):85-94 [9010235.001]
  • [Cites] Cancer. 1997 Sep 1;80(5):892-8 [9307189.001]
  • [Cites] BMC Cancer. 2005 Jan 20;5:9 [15661074.001]
  • [Cites] Mod Pathol. 2005 Feb;18 Suppl 2:S19-32 [15761464.001]
  • [Cites] J Clin Endocrinol Metab. 2005 Jun;90(6):3568-74 [15769996.001]
  • [Cites] Clin Cancer Res. 2005 Oct 15;11(20):7376-83 [16243810.001]
  • [Cites] Int J Gynecol Cancer. 2006 Jan-Feb;16(1):210-8 [16445635.001]
  • [Cites] Cancer. 2006 Jul 15;107(2):299-308 [16773633.001]
  • [Cites] J Biol Chem. 2006 Aug 25;281(34):24588-601 [16793770.001]
  • [Cites] Gynecol Oncol. 2008 Dec;111(3):487-95 [18834621.001]
  • [Cites] Neoplasia. 2007 Dec;9(12):1091-8 [18084616.001]
  • (PMID = 20003326.001).
  • [ISSN] 1476-4598
  • [Journal-full-title] Molecular cancer
  • [ISO-abbreviation] Mol. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Insulin-Like Growth Factor Binding Protein 3; 0 / Tumor Suppressor Protein p53
  • [Other-IDs] NLM/ PMC2799391
  •  go-up   go-down


79. Olawaiye AB, Boruta DM 2nd: Management of women with clear cell endometrial cancer: a Society of Gynecologic Oncology (SGO) review. Gynecol Oncol; 2009 May;113(2):277-83
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Management of women with clear cell endometrial cancer: a Society of Gynecologic Oncology (SGO) review.
  • OBJECTIVE: Clear cell endometrial cancer (CCE) is an uncommon but important disease because of its aggressive behavior.
  • This review explores the differences between clear cell and endometrioid endometrial cancer.
  • Diagnosis can be made using the same tests that are used in the diagnosis of other types of endometrial cancer.
  • Clear cell histology is morphologically and genetically different from the more prevalent endometrioid endometrial cancer histology.
  • It shares many similarities with clear cell neoplasms of the ovary and kidney.
  • Adjuvant pelvic and/or whole abdominal radiotherapy have not been shown to be clearly beneficial in women diagnosed with clear cell endometrial cancer.
  • Careful long term surveillance following treatment is indicated given the higher rate of recurrence compared to endometrioid endometrial cancer.
  • [MeSH-major] Adenocarcinoma, Clear Cell / diagnosis. Adenocarcinoma, Clear Cell / therapy. Endometrial Neoplasms / diagnosis. Endometrial Neoplasms / therapy

  • Genetic Alliance. consumer health - Endometrial cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19251307.001).
  • [ISSN] 1095-6859
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 59
  •  go-up   go-down


80. Rossing MA, Cushing-Haugen KL, Wicklund KG, Doherty JA, Weiss NS: Risk of epithelial ovarian cancer in relation to benign ovarian conditions and ovarian surgery. Cancer Causes Control; 2008 Dec;19(10):1357-64
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Risk of epithelial ovarian cancer in relation to benign ovarian conditions and ovarian surgery.
  • OBJECTIVE: Some forms of ovarian neoplasms may be preventable through the removal of precursor lesions.
  • We assessed the risk associated with a prior diagnosis of, and ovarian surgery following, ovarian cysts and endometriosis, with a focus on characterizing risk among tumor subgroups.
  • METHODS: Information was collected during in-person interviews with 812 women with ovarian cancer diagnosed in western Washington State from 2002 to 2005 and 1,313 population-based controls.
  • RESULTS: The risk of a borderline mucinous ovarian tumor associated with a history of an ovarian cyst was increased (OR=1.7, 95% CI: 1.0-2.8), but did not vary notably according to receipt of subsequent ovarian surgery.
  • While risk of invasive epithelial ovarian cancer was slightly increased among women with a cyst who had no subsequent ovarian surgery, it was reduced when a cyst diagnosis was followed by surgery (OR = 0.6, 95% CI: 0.4-0.9).
  • Women with a history of endometriosis had a threefold increased risk of endometrioid and clear cell invasive tumors, with a lesser risk increase among women who underwent subsequent ovarian surgery.
  • CONCLUSIONS: Our results suggest differences in the relation of ovarian cysts and endometriosis with risk of specific subtypes of ovarian cancer as well as the possibility that ovarian surgery in women with these conditions may lower the risk of invasive disease.

  • Genetic Alliance. consumer health - Ovarian cancer.
  • Genetic Alliance. consumer health - Ovarian epithelial cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Epidemiol. 2000 Jan;10(1):14-23 [10658685.001]
  • [Cites] Cancer Causes Control. 2008 May;19(4):413-20 [18080774.001]
  • [Cites] Lancet. 2000 Mar 25;355(9209):1060-3 [10744092.001]
  • [Cites] Eur J Cancer Prev. 2001 Apr;10(2):197-9 [11330466.001]
  • [Cites] Gynecol Oncol. 2001 Oct;83(1):100-8 [11585420.001]
  • [Cites] Am J Epidemiol. 2002 Feb 1;155(3):217-24 [11821246.001]
  • [Cites] Am J Obstet Gynecol. 2003 Jul;189(1):280-94 [12861175.001]
  • [Cites] Acta Obstet Gynecol Scand. 2004 Apr;83(4):395-400 [15005789.001]
  • [Cites] Am J Pathol. 2004 May;164(5):1511-8 [15111296.001]
  • [Cites] Int J Gynecol Pathol. 2004 Jul;23(3):200-5 [15213595.001]
  • [Cites] Epidemiology. 1996 May;7(3):319-22 [8728451.001]
  • [Cites] Int J Epidemiol. 1997 Aug;26(4):710-5 [9279601.001]
  • [Cites] Eur J Cancer. 1997 Sep;33(10):1634-7 [9389926.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Feb;14(2):299-305 [15734950.001]
  • [Cites] Mod Pathol. 2005 Feb;18 Suppl 2:S19-32 [15761464.001]
  • [Cites] Gynecol Oncol. 2005 May;97(2):318-22 [15863124.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Dec;14(12):2929-35 [16365012.001]
  • [Cites] Hum Reprod. 2006 May;21(5):1237-42 [16431901.001]
  • [Cites] Cancer Causes Control. 2006 Jun;17(5):623-32 [16633908.001]
  • [Cites] J Pathol. 2007 Jan;211(1):26-35 [17117391.001]
  • [Cites] Curr Opin Obstet Gynecol. 2007 Feb;19(1):3-9 [17218844.001]
  • [Cites] Int J Gynecol Cancer. 2007 Jan-Feb;17(1):37-43 [17291229.001]
  • [Cites] Clin Med Res. 2007 Mar;5(1):35-44 [17456833.001]
  • [Cites] Gynecol Oncol. 2007 Nov;107(2):223-30 [17662378.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2007 Dec;16(12):2548-56 [18086757.001]
  • [Cites] Lancet. 2000 Mar 25;355(9209):1028-9 [10744081.001]
  • (PMID = 18704718.001).
  • [ISSN] 1573-7225
  • [Journal-full-title] Cancer causes & control : CCC
  • [ISO-abbreviation] Cancer Causes Control
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA087538-01A2; United States / NCI NIH HHS / CA / R01 CA087538-05; United States / NCI NIH HHS / CA / R01 CA087538; United States / NCI NIH HHS / CA / R01 CA87538; United States / NCI NIH HHS / CA / R01 CA087538-02; United States / NCI NIH HHS / CA / CA087538-05; United States / NCI NIH HHS / CA / R01 CA087538-03; United States / NCI NIH HHS / CA / R01 CA087538-04; United States / NCI NIH HHS / CA / CA087538-01A2
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] Netherlands
  • [Other-IDs] NLM/ NIHMS146032; NLM/ PMC2751585
  •  go-up   go-down


81. Abbott KL, Nairn AV, Hall EM, Horton MB, McDonald JF, Moremen KW, Dinulescu DM, Pierce M: Focused glycomic analysis of the N-linked glycan biosynthetic pathway in ovarian cancer. Proteomics; 2008 Aug;8(16):3210-20
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Focused glycomic analysis of the N-linked glycan biosynthetic pathway in ovarian cancer.
  • Epithelial ovarian cancer is the deadliest female reproductive tract malignancy in Western countries.
  • Less than 25% of cases are diagnosed when the cancer is confined, however, pointing to the critical need for early diagnostics for ovarian cancer.
  • Identifying the changes that occur in the glycome of ovarian cancer cells may provide an avenue to develop a new generation of potential biomarkers for early detection of this disease.
  • We performed a glycotranscriptomic analysis of endometrioid ovarian carcinoma using human tissue, as well as a newly developed mouse model that mimics this disease.
  • Our results show that the N-linked glycans expressed in both nondiseased mouse and human ovarian tissues are similar; moreover, malignant changes in the expression of N-linked glycans in both mouse and human endometrioid ovarian carcinoma are qualitatively similar.
  • This study provides evidence that glycotranscriptome analysis can be an important tool in identifying potential cancer biomarkers.

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Biol Chem. 1982 Oct 10;257(19):11235-40 [7118881.001]
  • [Cites] J Biol Chem. 1982 Oct 10;257(19):11230-4 [7118880.001]
  • [Cites] J Biol Chem. 1987 Feb 5;262(4):1602-7 [3805046.001]
  • [Cites] Clin Chim Acta. 1989 Dec 15;185(3):325-32 [2482796.001]
  • [Cites] Cancer Res. 1991 Jan 15;51(2):718-23 [1985789.001]
  • [Cites] Biochim Biophys Acta. 1991 Jan 29;1076(2):187-90 [1998719.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Sep 12;92(19):8754-8 [7568011.001]
  • [Cites] Glycobiology. 1996 Oct;6(7):691-4 [8953279.001]
  • [Cites] J Biol Chem. 1997 Aug 1;272(31):19575-81 [9235963.001]
  • [Cites] Cancer Res. 1998 Jul 1;58(13):2881-7 [9661906.001]
  • [Cites] Glycoconj J. 1998 Oct;15(10):1033-7 [10211708.001]
  • [Cites] Nat Med. 2005 Jan;11(1):63-70 [15619626.001]
  • [Cites] Hum Pathol. 2005 Jun;36(6):605-19 [16021566.001]
  • [Cites] Immunol Cell Biol. 2005 Aug;83(4):429-39 [16033539.001]
  • [Cites] Gynecol Oncol. 2005 Dec;99(3):631-9 [16112178.001]
  • [Cites] J Proteome Res. 2006 Jul;5(7):1626-35 [16823970.001]
  • [Cites] Exp Cell Res. 2006 Sep 10;312(15):2837-50 [16857188.001]
  • [Cites] Gynecol Oncol. 2006 Nov;103(2):692-7 [16793127.001]
  • [Cites] J Pathol. 2007 Jan;211(1):26-35 [17117391.001]
  • [Cites] Oncologist. 2007 Jan;12(1):20-37 [17227898.001]
  • [Cites] J Biol Chem. 2007 Jul 27;282(30):22150-62 [17537730.001]
  • [Cites] J Proteome Res. 2007 Nov;6(11):4374-87 [17915907.001]
  • [Cites] Glycobiology. 2007 Dec;17(12):1344-56 [17884841.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2008 Feb;17(2):397-404 [18268124.001]
  • [Cites] J Biol Chem. 2008 Jun 20;283(25):17298-313 [18411279.001]
  • [Cites] Biochim Biophys Acta. 1999 Dec 6;1473(1):247-66 [10580143.001]
  • [Cites] Int J Oncol. 2000 Mar;16(3):567-76 [10675491.001]
  • [Cites] Biochim Biophys Acta. 2000 Feb 28;1495(3):297-307 [10699467.001]
  • [Cites] Endocr Rev. 2001 Apr;22(2):255-88 [11294827.001]
  • [Cites] Cancer Cell. 2002 Feb;1(1):53-62 [12086888.001]
  • [Cites] Biochim Biophys Acta. 2002 Dec 19;1573(3):363-8 [12417419.001]
  • [Cites] Cancer Res. 2002 Dec 1;62(23):6837-45 [12460896.001]
  • [Cites] J Biol Chem. 2003 Jul 18;278(29):27059-67 [12732625.001]
  • [Cites] J Biol Chem. 2003 Aug 1;278(31):28619-34 [12734200.001]
  • [Cites] J Biol Chem. 2003 Dec 26;278(52):52412-24 [14561752.001]
  • [Cites] Cancer Cell. 2004 Jan;5(1):19-24 [14749123.001]
  • [Cites] Biochemistry. 1969 Jun;8(6):2518-24 [4307997.001]
  • [Cites] J Biol Chem. 1986 Aug 15;261(23):10772-7 [3015940.001]
  • (PMID = 18690643.001).
  • [ISSN] 1615-9861
  • [Journal-full-title] Proteomics
  • [ISO-abbreviation] Proteomics
  • [Language] ENG
  • [Grant] United States / NCRR NIH HHS / RR / P41RR018502; United States / NCI NIH HHS / CA / R01 CA064462; United States / NCRR NIH HHS / RR / P41 RR018502; United States / NCI NIH HHS / CA / UO/CA128454; United States / NCI NIH HHS / CA / U01 CA128454; United States / NCI NIH HHS / CA / R01CA064462
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Lectins; 0 / Polysaccharides; EC 2.3.- / Acyltransferases; EC 2.3.1.22 / 2-acylglycerol O-acyltransferase; EC 2.4.1.- / Fucosyltransferases; EC 2.4.1.- / N-Acetylglucosaminyltransferases; EC 2.4.1.155 / alpha-1,6-mannosylglycoprotein beta 1,6-N-acetylglucosaminyltransferase; EC 2.4.1.68 / Glycoprotein 6-alpha-L-fucosyltransferase
  • [Other-IDs] NLM/ NIHMS559841; NLM/ PMC3970323
  •  go-up   go-down


82. Zhang GY, Ahmed N, Riley C, Oliva K, Barker G, Quinn MA, Rice GE: Enhanced expression of peroxisome proliferator-activated receptor gamma in epithelial ovarian carcinoma. Br J Cancer; 2005 Jan 17;92(1):113-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Enhanced expression of peroxisome proliferator-activated receptor gamma in epithelial ovarian carcinoma.
  • This study demonstrates the relative expression of PPARgamma in normal ovaries and different pathological grades of ovarian tumours of serous, mucinous, endometrioid, clear cell and mixed subtypes.
  • A total of 56 ovarian specimens including 10 normal, eight benign, 10 borderline, seven grade 1, nine grade 2 and 12 grade 3 were analysed using immunohistochemistry.
  • Immunoreactive PPARgamma was not expressed in normal ovaries.
  • An altered staining pattern of PPARgamma was observed in high-grade ovarian tumours with PPARgamma being mostly localized in the nuclei with little cytoplasmic immunoreactivity.
  • Significantly increased PPARgamma immunoreactivity was observed in malignant ovarian tumours (grade 1, 2 and 3) compared to benign and borderline tumours (chi2 = 48.80, P < 0.001).
  • Western blot analyses showed significant elevation in the expression of immunoreactive PPARgamma in grade 3 ovarian tumours compared with that of normal ovaries and benign ovarian tumours (P < 0.01).
  • These findings suggest an involvement of PPARgamma in the onset and development of ovarian carcinoma and provide an insight into the regulation of this molecule in the progression of the disease.
  • [MeSH-major] Ovarian Neoplasms / metabolism. PPAR gamma / metabolism
  • [MeSH-minor] Adenocarcinoma, Clear Cell / metabolism. Blotting, Western. Carcinoma, Endometrioid / metabolism. Cystadenocarcinoma, Mucinous / metabolism. Cystadenocarcinoma, Serous / metabolism. Female. Humans. Immunohistochemistry. Ovary / metabolism

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Cancer. 2003 Sep 20;106(5):752-7 [12866036.001]
  • [Cites] Oncogene. 2003 Jun 19;22(25):3888-900 [12813462.001]
  • [Cites] Mol Cell Biol. 2003 Sep;23(17):6159-73 [12917338.001]
  • [Cites] Oncogene. 2003 Aug 21;22(35):5446-50 [12934104.001]
  • [Cites] Arch Pathol Lab Med. 2003 Sep;127(9):1121-3 [12946234.001]
  • [Cites] J Clin Endocrinol Metab. 2003 Sep;88(9):4440-5 [12970322.001]
  • [Cites] Clin Cancer Res. 2003 Oct 1;9(12):4627-35 [14555539.001]
  • [Cites] Minerva Ginecol. 2003 Aug;55(4):297-314 [14581855.001]
  • [Cites] Nat Immunol. 2004 Jan;5(1):104-12 [14691478.001]
  • [Cites] Am J Physiol Endocrinol Metab. 2004 Feb;286(2):E201-7 [14701665.001]
  • [Cites] Biochem Biophys Res Commun. 2004 Mar 5;315(2):497-501 [14766236.001]
  • [Cites] Cancer Res. 2004 Feb 1;64(3):1181-9 [14871855.001]
  • [Cites] Gut. 2004 Mar;53(3):331-8 [14960510.001]
  • [Cites] Mol Cell Proteomics. 2004 Apr;3(4):355-66 [14764655.001]
  • [Cites] Mol Cell Biol. 2004 Apr;24(8):3430-44 [15060163.001]
  • [Cites] Clin Cancer Res. 2004 Apr 1;10(7):2415-20 [15073119.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 Jul 19;91(15):7355-9 [8041794.001]
  • [Cites] Eur J Biochem. 1996 Jul 1;239(1):1-7 [8706692.001]
  • [Cites] Curr Opin Cell Biol. 1998 Jun;10(3):384-91 [9640540.001]
  • [Cites] Nat Med. 1998 Sep;4(9):1053-7 [9734399.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Mar 30;96(7):3951-6 [10097144.001]
  • [Cites] Cancer Res. 1999 Apr 15;59(8):2011-7 [10213514.001]
  • [Cites] Int J Gynecol Pathol. 2000 Jan;19(1):7-15 [10638449.001]
  • [Cites] Cell. 2000 Jan 7;100(1):57-70 [10647931.001]
  • [Cites] Mutat Res. 2000 Mar 17;448(2):139-51 [10725468.001]
  • [Cites] Nature. 2000 May 25;405(6785):421-4 [10839530.001]
  • [Cites] Clin Cancer Res. 2000 Aug;6(8):3241-8 [10955810.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Sep 26;97(20):10990-5 [10984506.001]
  • [Cites] Cancer Res. 2000 Oct 1;60(19):5494-8 [11034093.001]
  • [Cites] Br J Cancer. 2000 Nov;83(10):1394-400 [11044367.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Nov 21;97(24):13275-80 [11087869.001]
  • [Cites] Toxicol Lett. 2000 Dec 20;118(1-2):79-86 [11137312.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Feb 27;98(5):2598-603 [11226285.001]
  • [Cites] Neoplasia. 2000 Nov-Dec;2(6):483-90 [11228540.001]
  • [Cites] Cancer Res. 2001 Jul 1;61(13):5307-10 [11431375.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2001 Oct;127(10):1253-9 [11587608.001]
  • [Cites] Annu Rev Med. 2002;53:409-35 [11818483.001]
  • [Cites] J Biol Chem. 2002 May 17;277(20):17830-5 [11884400.001]
  • [Cites] Lung Cancer. 2002 Jun;36(3):249-55 [12009233.001]
  • [Cites] Mol Hum Reprod. 2002 Jun;8(6):574-9 [12029076.001]
  • [Cites] Invest New Drugs. 2002 May;20(2):195-200 [12099579.001]
  • [Cites] Jpn J Clin Oncol. 2002 Jul;32(7):238-43 [12324573.001]
  • [Cites] Int J Cancer. 2003 May 1;104(5):597-602 [12594814.001]
  • [Cites] J Biol Chem. 2003 Apr 4;278(14):11945-53 [12551936.001]
  • [Cites] Clin Cancer Res. 2003 Aug 1;9(8):3198-203 [12912973.001]
  • (PMID = 15583697.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / PPAR gamma
  • [Other-IDs] NLM/ PMC2361744
  •  go-up   go-down


83. Kato N, Sasou S, Motoyama T: Expression of hepatocyte nuclear factor-1beta (HNF-1beta) in clear cell tumors and endometriosis of the ovary. Mod Pathol; 2006 Jan;19(1):83-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of hepatocyte nuclear factor-1beta (HNF-1beta) in clear cell tumors and endometriosis of the ovary.
  • Clear cell tumors of the ovary are frequently associated with ovarian endometriosis.
  • Microarray analysis revealed recently that hepatocyte nuclear factor-1beta (HNF-1beta) was significantly upregulated in clear cell carcinoma of the ovary.
  • In the present study, we examined 30 clear cell tumors (26 malignant, three borderline, and one benign) and 40 endometriotic cysts to clarify if differentiation into the clear cell lineage already begins in ovarian endometriosis.
  • All of the 30 clear cell tumors, including borderline and benign ones, showed immunohistochemical expression of HNF-1beta in the nucleus, while other types of ovarian epithelial tumors (endometrioid, serous, mucinous, and Brenner tumors) rarely expressed it.
  • Our results indicate that HNF-1beta is an excellent molecular marker for ovarian clear cell tumors, including benign, borderline and malignant lesions.
  • Early differentiation into the clear cell lineage takes place in ovarian endometriosis, not only in atypical endometriosis, but also in endometriosis with degenerative and regenerative changes, and this is probably responsible for the frequent occurrence of clear cell carcinoma in ovarian endometriosis.
  • [MeSH-major] Adenocarcinoma, Clear Cell / pathology. Endometriosis / pathology. Hepatocyte Nuclear Factor 1-beta / biosynthesis. Ovarian Diseases / pathology. Ovarian Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Epithelial Cells / chemistry. Epithelial Cells / pathology. Female. Humans. Immunohistochemistry. Middle Aged. Ovarian Cysts / metabolism. Ovarian Cysts / pathology

  • Genetic Alliance. consumer health - Endometriosis.
  • MedlinePlus Health Information. consumer health - Endometriosis.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16258507.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 138674-15-4 / Hepatocyte Nuclear Factor 1-beta
  •  go-up   go-down


84. Fambrini M, Bargelli G, Peruzzi E, Buccoliero AM, Pieralli A, Andersson KL, Scarselli G, Gallorini M, Zolfanelli F, Marchionni M: Levonorgestrel-releasing intrauterine system alone as primary treatment in young women with early endometrial cancer: case report. J Minim Invasive Gynecol; 2009 Sep-Oct;16(5):630-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Levonorgestrel-releasing intrauterine system alone as primary treatment in young women with early endometrial cancer: case report.
  • Young women with polycystic ovary syndrome (PCOS) are at increased risk of endometrial adenocarcinoma (EAC) through chronic unopposed estrogen production.
  • We describe the first case, to our knowledge, of grade 1 endometrioid EAC arising in the context of complex atypical endometrial hyperplasia in a 26-year-old woman with thrombophilia and PCOS who wished to retain fertility potential and was treated using a levonorgestrel-releasing intrauterine system alone.
  • This successful outcome suggests that insertion of a levonorgestrel-releasing intrauterine system is a treatment option in selected young women with early-stage EAC who are not candidates for systemic therapy and who wish to maintain fertility potential.
  • Close histologic follow-up is required, and immediate surgery is mandatory if endometrial cancer persists.
  • [MeSH-major] Adenocarcinoma / drug therapy. Contraceptive Agents, Female / administration & dosage. Endometrial Neoplasms / drug therapy. Intrauterine Devices. Levonorgestrel / administration & dosage
  • [MeSH-minor] Adult. Comorbidity. Female. Humans. Polycystic Ovary Syndrome / epidemiology

  • Genetic Alliance. consumer health - Endometrial cancer.
  • Hazardous Substances Data Bank. LEVONORGESTREL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19835809.001).
  • [ISSN] 1553-4650
  • [Journal-full-title] Journal of minimally invasive gynecology
  • [ISO-abbreviation] J Minim Invasive Gynecol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Contraceptive Agents, Female; 5W7SIA7YZW / Levonorgestrel
  •  go-up   go-down


85. Maruthini D, Amin A, Buxton J: Endometrioid adenocarcinoma of the ovary arising from endometriosis and presenting as an acute abdomen. J Obstet Gynaecol; 2007 Jul;27(5):540-1
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endometrioid adenocarcinoma of the ovary arising from endometriosis and presenting as an acute abdomen.
  • [MeSH-major] Abdomen, Acute / etiology. Carcinoma, Endometrioid / etiology. Endometriosis / complications. Ovarian Neoplasms / etiology

  • Genetic Alliance. consumer health - Endometriosis.
  • MedlinePlus Health Information. consumer health - Endometriosis.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17701820.001).
  • [ISSN] 0144-3615
  • [Journal-full-title] Journal of obstetrics and gynaecology : the journal of the Institute of Obstetrics and Gynaecology
  • [ISO-abbreviation] J Obstet Gynaecol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


86. Hart WR: Diagnostic challenge of secondary (metastatic) ovarian tumors simulating primary endometrioid and mucinous neoplasms. Pathol Int; 2005 May;55(5):231-43
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnostic challenge of secondary (metastatic) ovarian tumors simulating primary endometrioid and mucinous neoplasms.
  • Secondary (metastatic) neoplasms to the ovary often cause diagnostic problems, especially those tumors that produce large, symptomatic ovarian tumors that masquerade clinically and pathologically as primary ovarian tumors of surface epithelial type.
  • Except for typical Krukenberg tumors, which usually originate in the stomach and generally are easily recognized, the most diagnostically problematic secondary ovarian tumors are those that originate in the large intestine, appendix, and pancreas.
  • Metastases from these sites typically produce histologic patterns resembling primary ovarian endometrioid carcinoma or mucinous epithelial neoplasms of borderline and malignant types.
  • This review focuses on the diagnostic challenge of distinguishing these secondary ovarian tumors from primary ovarian neoplasms.
  • [MeSH-major] Carcinoma, Endometrioid / pathology. Cystadenoma, Mucinous / pathology. Ovarian Neoplasms / secondary
  • [MeSH-minor] Appendiceal Neoplasms / pathology. Diagnosis, Differential. Female. Humans. Intestinal Neoplasms / pathology. Intestine, Large / pathology. Ovary / pathology. Pancreatic Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15871720.001).
  • [ISSN] 1320-5463
  • [Journal-full-title] Pathology international
  • [ISO-abbreviation] Pathol. Int.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Australia
  • [Number-of-references] 243
  •  go-up   go-down


87. Kato N, Takeda J, Fukase M, Motoyama T: Alternate mucoid and hyalinized stroma in clear cell carcinoma of the ovary: manifestation of serial stromal remodeling. Mod Pathol; 2010 Jun;23(6):881-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Alternate mucoid and hyalinized stroma in clear cell carcinoma of the ovary: manifestation of serial stromal remodeling.
  • The stroma in ovarian clear cell carcinoma often shows alternate mucoid and hyalinized change.
  • We examined 60 ovarian clear cell carcinomas for the distribution and nature of the mucoid stroma.
  • For comparison, 125 other surface epithelial ovarian tumors were examined.
  • It also exhibited a cribriform pattern, resembling that of adenoid cystic carcinoma.
  • In vitro, a clear cell carcinoma cell line, HAC-2, formed a spherule-like structure containing hyaluronan in the center, and a significant amount of hyaluronan was detected by latex agglutination immunoturbidimetry, indicating that HAC-2 itself has the potential to produce hyaluronan.
  • All of these facts indicate that the spherule-like mucoid stroma and hyalinized stroma represent different phases of the stromal remodeling process, which is promoted by the deposition of different extracellular matrices produced by clear cell carcinoma cells.
  • The spherule-like mucoid stroma and hyalinized stroma are considered complementary diagnostic signatures of ovarian clear cell carcinoma.
  • [MeSH-major] Carcinoma / metabolism. Extracellular Matrix / metabolism. Hyaluronic Acid / metabolism. Mucins / metabolism. Ovarian Neoplasms / metabolism. Stromal Cells / metabolism
  • [MeSH-minor] Adenocarcinoma, Mucinous / metabolism. Adenocarcinoma, Mucinous / pathology. Adult. Aged. Animals. Carcinoma, Endometrioid / metabolism. Carcinoma, Endometrioid / pathology. Cell Line, Tumor. Female. Humans. Immunohistochemistry. Mice. Mice, Inbred BALB C. Mice, Nude. Middle Aged. Neoplasm Staging

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. HYALURONIC ACID .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20305617.001).
  • [ISSN] 1530-0285
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Mucins; 9004-61-9 / Hyaluronic Acid
  •  go-up   go-down


88. Natee J, Kietpeerakool C, Srisomboon J, Khunamornpong S, Suprasert P, Phongnarisorn C, Cheewakriangkrai C, Charoenkwan K, Siriaree S, Pantusart A: Clinicopathologic analysis of women with synchronous primary carcinomas of the endometrium and ovary: 10- year experience from Chiang Mai University Hospital. Asian Pac J Cancer Prev; 2006 Apr-Jun;7(2):234-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinicopathologic analysis of women with synchronous primary carcinomas of the endometrium and ovary: 10- year experience from Chiang Mai University Hospital.
  • The aim of this study was to analyze the clinicopathologic features and survival outcomes of women with synchronous primary carcinomas of the endometrium and ovary that were treated at Chiang Mai University Hospital between January 1995 and December 2004.
  • Median age at diagnosis was 49 years (range: 34-60 years).
  • Twenty-seven (62.8%, 95%CI= 46.7-77.0%) women had concordant endometrioid carcinomas of the endometrium and ovary.
  • There was no significant difference in survival outcomes among the women who had endometrioid/endometrioid histology and those who had other histological subtypes (P=0.674).
  • In conclusion, synchronous primary carcinomas of the endometrium and ovary, although uncommon, should be considered in differential diagnosis in premenopausal women presenting with abnormal uterine bleeding and ovarian tumors.
  • [MeSH-major] Adenocarcinoma / pathology. Endometrial Neoplasms / pathology. Neoplasms, Multiple Primary / pathology. Ovarian Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16839215.001).
  • [ISSN] 1513-7368
  • [Journal-full-title] Asian Pacific journal of cancer prevention : APJCP
  • [ISO-abbreviation] Asian Pac. J. Cancer Prev.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Thailand
  •  go-up   go-down


89. Dhakal HP, Pradhan M: Histological pattern of gynecological cancers. JNMA J Nepal Med Assoc; 2009 Oct-Dec;48(176):301-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • INTRODUCTION: The information on cancer incidence is an important basis to prioritize the preventive policy of a country.
  • METHODS: A retrospective analysis was performed in histopathologically proven gynecological malignancies by retrieving data from the archives of the Department of Pathology, BP Koirala Memorial Cancer Hospital between July 1999 and April 2004.
  • RESULTS: Out of total 1517 cases of gynecological cancers diagnosed, 1293 cases (85.23%) were cervical, 97 (6.39%) ovarian, 48 (3.16%) vulval, 41 (2.7%) vaginal, 32 (2.11%) endometrial cancers as well as 5 (0.33%) choriocarcinoma and 1 (0.07%) fallopian tube cancer.
  • Squamous cell carcinoma was the commonest histologic type in cervical, vaginal and vulval cancers whereas serous adenocarcinoma and endometrioid adenocarcinoma were commonest histological types in the ovary and endometrium respectively.
  • CONCLUSIONS: Cervical cancer is the most frequent gynecological malignancy in Nepal.
  • Since it is a preventable disease, national screening and awareness programs are necessary to reduce the burden of the cancer and to improve the health of women in Nepal.
  • [MeSH-major] Carcinoma / pathology. Genital Neoplasms, Female / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21105554.001).
  • [ISSN] 0028-2715
  • [Journal-full-title] JNMA; journal of the Nepal Medical Association
  • [ISO-abbreviation] JNMA J Nepal Med Assoc
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Nepal
  •  go-up   go-down


90. Rees M: Gynaecological oncology perspective on management of the menopause. Eur J Surg Oncol; 2006 Oct;32(8):892-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Treatment for gynaecological cancer may ablate ovarian function through surgery (oophorectomy), radiotherapy or chemotherapy.
  • This article will describe the use of oestrogen and non-oestrogen-based treatments as well as alternative and complementary therapies in gynaecological cancer survivors.
  • AIMS: To review the use of oestrogen and non-oestrogen-based treatments as well as alternative and complementary therapies in gynaecological cancer survivors in whom ovarian function has been ablated through surgery (oophorectomy), radiotherapy or chemotherapy.
  • RESULTS: Ovarian, cervical, vaginal and vulval cancers are not oestrogen dependent conditions and oestrogen replacement is not contraindicated.
  • However, there is some doubt with regard to endometrioid ovarian cancer and endometrial carcinoma is often listed in data sheets as an absolute contra-indication to hormone replacement therapy.
  • There is little scientific evidence that complementary and alternative therapies can help menopausal symptoms or conserve bone mass and there are no safety data in women with gynaecological cancer.

  • MedlinePlus Health Information. consumer health - Menopause.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16698224.001).
  • [ISSN] 0748-7983
  • [Journal-full-title] European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  • [ISO-abbreviation] Eur J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 47
  •  go-up   go-down


91. Cai KQ, Caslini C, Capo-chichi CD, Slater C, Smith ER, Wu H, Klein-Szanto AJ, Godwin AK, Xu XX: Loss of GATA4 and GATA6 expression specifies ovarian cancer histological subtypes and precedes neoplastic transformation of ovarian surface epithelia. PLoS One; 2009 Jul 31;4(7):e6454
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Loss of GATA4 and GATA6 expression specifies ovarian cancer histological subtypes and precedes neoplastic transformation of ovarian surface epithelia.
  • GATA4 and GATA6 were found to be frequently lost in ovarian cancer, and the loss is proposed to account for dedifferentiation of the cancer cells.
  • METHODOLOGY/PRINCIPAL FINDINGS: We further investigated the expression of GATA4 and GATA6 in ovarian surface epithelial lesions and histological subtypes of ovarian carcinomas by immunostaining.
  • GATA4 and GATA6 were found to be absent in high percentages (80 to 90%) of serous, clear cell, and endometrioid ovarian cancer examined.
  • In contrast, both were found positive in 11 out of 12 cases of mucinous carcinomas, suggesting the expression of the GATA factors can distinguish mucinous cancer from other histological subtypes.
  • GATA4 was frequently lost in preneoplastic lesions such as morphologically normal inclusion cysts and epithelial hyperplasia adjacent to malignant cells.
  • The loss of GATA6 correlates closely with neoplastic morphological transformation of ovarian surface epithelia.
  • In culture, GATA4 expression was progressively reduced upon passaging primary ovarian surface epithelial cells, which correlated with changes in histone modification of the GATA4 locus.
  • A reduced GATA6 gene dosage as in GATA6 (+/-) mice led to an increased pre-neoplastic changes and inclusion cysts in the ovaries, suggesting the loss of GATA6 contributes to ovarian cancer development.
  • CONCLUSIONS/SIGNIFICANCE: This study suggests that the expression status of GATA4 and GATA6 may dictate distinct pathologic pathways leading to serous or mucinous ovarian carcinomas.

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mod Pathol. 2005 Feb;18 Suppl 2:S19-32 [15761464.001]
  • [Cites] Dev Biol. 1996 Jul 10;177(1):309-22 [8660897.001]
  • [Cites] Am J Pathol. 2006 Jul;169(1):258-67 [16816378.001]
  • [Cites] Cancer Lett. 2006 Sep 28;241(2):281-8 [16337738.001]
  • [Cites] Oncogene. 2006 Aug 31;25(39):5446-61 [16607277.001]
  • [Cites] Gynecol Oncol. 2006 Nov;103(2):719-28 [16698071.001]
  • [Cites] J Pathol. 2007 Jan;211(1):26-35 [17117391.001]
  • [Cites] J Biol Chem. 2007 Apr 27;282(17):13114-22 [17339320.001]
  • [Cites] Gynecol Oncol. 2008 May;109(2):161-3 [18455635.001]
  • [Cites] Dev Dyn. 2008 Oct;237(10):2820-9 [18816845.001]
  • [Cites] J Cell Biochem Suppl. 1995;23:208-18 [8747398.001]
  • [Cites] Cell. 2000 Jan 7;100(1):57-70 [10647931.001]
  • [Cites] J Reprod Med. 2000 Feb;45(2):159-61 [10710752.001]
  • [Cites] J Biol Chem. 2000 Jun 30;275(26):19949-54 [10779506.001]
  • [Cites] Oncogene. 2000 Oct 5;19(42):4847-54 [11039902.001]
  • [Cites] J Biol Chem. 2000 Dec 15;275(50):38949-52 [11042222.001]
  • [Cites] Nature. 2001 Mar 1;410(6824):116-20 [11242053.001]
  • [Cites] Histopathology. 2001 Feb;38(2):87-95 [11207821.001]
  • [Cites] Science. 2001 Aug 10;293(5532):1074-80 [11498575.001]
  • [Cites] EMBO J. 2002 Apr 2;21(7):1555-64 [11927540.001]
  • [Cites] Cancer. 2002 May 1;94(9):2380-92 [12015763.001]
  • [Cites] EMBO J. 2002 Sep 16;21(18):4915-26 [12234931.001]
  • [Cites] Nature. 2002 Sep 26;419(6905):407-11 [12353038.001]
  • [Cites] Dev Biol. 2002 Nov 1;251(1):27-44 [12413896.001]
  • [Cites] Cancer Res. 2003 Aug 15;63(16):4967-77 [12941822.001]
  • [Cites] Nat Cell Biol. 2004 Jan;6(1):73-7 [14661024.001]
  • [Cites] EMBO J. 2004 Jan 14;23(1):138-49 [14685282.001]
  • [Cites] Cancer Cell. 2004 Jan;5(1):19-24 [14749123.001]
  • [Cites] Cell. 1980 Nov;22(2 Pt 2):629-32 [6160916.001]
  • [Cites] N Engl J Med. 1985 Feb 21;312(8):474-83 [3881673.001]
  • [Cites] J Natl Cancer Inst. 1996 Dec 18;88(24):1810-20 [8961970.001]
  • [Cites] Genes Dev. 1997 Apr 15;11(8):1048-60 [9136932.001]
  • [Cites] Genes Dev. 1998 Nov 15;12(22):3579-90 [9832509.001]
  • [Cites] Development. 1999 Feb;126(4):723-32 [9895320.001]
  • [Cites] Gynecol Oncol. 1999 Mar;72(3):437-42 [10053122.001]
  • [Cites] Oncogene. 1999 May 20;18(20):3104-13 [10340382.001]
  • [Cites] Gynecol Oncol. 1992 Oct;47(1):53-7 [1427402.001]
  • [Cites] Am J Obstet Gynecol. 1994 Jan;170(1 Pt 1):246-52 [8296829.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Jan 31;92(3):647-8 [7846030.001]
  • [Cites] Recent Results Cancer Res. 1995;139:1-19 [7541145.001]
  • [Cites] Dev Biol. 2005 Oct 15;286(2):574-86 [16162334.001]
  • (PMID = 19649254.001).
  • [ISSN] 1932-6203
  • [Journal-full-title] PloS one
  • [ISO-abbreviation] PLoS ONE
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA79716; United States / NCI NIH HHS / CA / R01 CA079716; United States / NCI NIH HHS / CA / R01 CA079716-10; United States / NCI NIH HHS / CA / #CA006927; United States / NCI NIH HHS / CA / R01 CA095071; United States / NCI NIH HHS / CA / CA75389; United States / NCI NIH HHS / CA / P50 CA083638; United States / NCI NIH HHS / CA / CA079716-10; United States / NCI NIH HHS / CA / CA095071-06; United States / NCI NIH HHS / CA / P30 CA006927; United States / NCI NIH HHS / CA / P50CA83638; United States / NCI NIH HHS / CA / R01 CA095071-06
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Chromatin; 0 / GATA4 Transcription Factor; 0 / GATA4 protein, human; 0 / GATA6 Transcription Factor; 0 / GATA6 protein, human
  • [Other-IDs] NLM/ PMC2715102
  •  go-up   go-down


92. Pothacharoen P, Siriaunkgul S, Ong-Chai S, Supabandhu J, Kumja P, Wanaphirak C, Sugahara K, Hardingham T, Kongtawelert P: Raised serum chondroitin sulfate epitope level in ovarian epithelial cancer. J Biochem; 2006 Oct;140(4):517-24
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Raised serum chondroitin sulfate epitope level in ovarian epithelial cancer.
  • OBJECTIVE: To determine the value of serum chondroitin sulfate epitope WF6 and hyaluronan (HA) levels as a biomarker for early detection of ovarian epithelial cancer and other gynecological disorders.
  • METHOD: Serum WF6 CS epitope and HA were measured in 91 patients with ovarian epithelial cancer, 39 patients with non-cancer gynecological disorders and 30 healthy women.
  • RESULTS: The serum concentration of CS (WF6) epitope was highly increased in epithelial types of ovarian cancer and at all stages of development (p < 0.005).
  • Serum HA in ovarian cancer patients was significantly higher than normal controls (p < 0.05).
  • CONCLUSION: These results reflect changes in ECM metabolism in progressive ovarian cancer, which cause an increase in serum CS epitopes and HA.
  • Therefore, serum CS epitopes may provide useful biomarkers for cancers and other disorders of the ovary.
  • Measurement of serum HA provided complementary information, which may be useful as a discriminator between benign ovarian disorders and malignant ovarian diseases.
  • [MeSH-major] Chondroitin Sulfates / blood. Hyaluronic Acid / blood. Ovarian Neoplasms / diagnosis
  • [MeSH-minor] Adenocarcinoma, Clear Cell / diagnosis. Adenocarcinoma, Clear Cell / immunology. Adenocarcinoma, Clear Cell / pathology. Adenocarcinoma, Mucinous / diagnosis. Adenocarcinoma, Mucinous / immunology. Adenocarcinoma, Mucinous / pathology. Adenocarcinoma, Papillary / diagnosis. Adenocarcinoma, Papillary / immunology. Adenocarcinoma, Papillary / pathology. Adult. Aged. Antibodies, Monoclonal. Biomarkers, Tumor / blood. Carcinoma, Endometrioid / diagnosis. Carcinoma, Endometrioid / immunology. Carcinoma, Endometrioid / pathology. Cells, Cultured. Cross-Sectional Studies. Epitopes. Female. Humans. Hybridomas. Middle Aged

  • Genetic Alliance. consumer health - Ovarian cancer.
  • Genetic Alliance. consumer health - Ovarian epithelial cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. HYALURONIC ACID .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16936295.001).
  • [ISSN] 0021-924X
  • [Journal-full-title] Journal of biochemistry
  • [ISO-abbreviation] J. Biochem.
  • [Language] eng
  • [Grant] United Kingdom / Wellcome Trust / /
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Biomarkers, Tumor; 0 / Epitopes; 9004-61-9 / Hyaluronic Acid; 9007-28-7 / Chondroitin Sulfates
  •  go-up   go-down


93. Tothill RW, Tinker AV, George J, Brown R, Fox SB, Lade S, Johnson DS, Trivett MK, Etemadmoghadam D, Locandro B, Traficante N, Fereday S, Hung JA, Chiew YE, Haviv I, Australian Ovarian Cancer Study Group, Gertig D, DeFazio A, Bowtell DD: Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome. Clin Cancer Res; 2008 Aug 15;14(16):5198-208
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome.
  • PURPOSE: The study aim to identify novel molecular subtypes of ovarian cancer by gene expression profiling with linkage to clinical and pathologic features.
  • EXPERIMENTAL DESIGN: Microarray gene expression profiling was done on 285 serous and endometrioid tumors of the ovary, peritoneum, and fallopian tube.
  • Two subtypes represented predominantly serous low malignant potential and low-grade endometrioid subtypes, respectively.
  • The remaining four subtypes represented higher grade and advanced stage cancers of serous and endometrioid morphology.
  • Class prediction identified similar subtypes in an independent ovarian dataset with similar prognostic trends.
  • CONCLUSION: Gene expression profiling identified molecular subtypes of ovarian cancer of biological and clinical importance.
  • [MeSH-major] Biomarkers, Tumor / analysis. Gene Expression Profiling. Ovarian Neoplasms / genetics. Ovarian Neoplasms / pathology


94. Silva EG, Young RH: Endometrioid neoplasms with clear cells: a report of 21 cases in which the alteration is not of typical secretory type. Am J Surg Pathol; 2007 Aug;31(8):1203-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endometrioid neoplasms with clear cells: a report of 21 cases in which the alteration is not of typical secretory type.
  • The presence of clear cells in genital tract neoplasms often reflexly prompts the diagnosis of a clear cell tumor but clear cells may be seen in many other neoplasms.
  • In one such, those of endometrioid type, they are well known and generally readily characterized when they have the secretory pattern that recapitulates the well-known morphology of early secretory endometrium.
  • In this report, we describe various clear cell morphologies, some possibly related to the secretory variant, but others not, and all potentially the source of significant diagnostic difficulty.
  • We reviewed 21 endometrioid tumors that occurred in patients from 27 to 88 (median 64) years.
  • One tumor formed a cystic mass in the pelvis, 1 tumor involved the right fallopian tube, 1 the endometrium, and 18 the ovary.
  • All the neoplasms had the typical architecture of endometrioid tumors but differed markedly in their cytoplasmic features.
  • Tubulocystic, solid, and papillary patterns of clear cell carcinoma were absent.
  • Although a few cases had a focal slight resemblance to secretory endometrioid carcinoma most did not and the orderly morphology of classic secretory carcinoma was noteworthy for its absence.
  • The distinction from clear cell carcinoma depends on awareness of this unusual variant of endometrioid neoplasia and a lack of the distinctive patterns of clear cell carcinoma; at this time, special studies, including immunohistochemistry, do not aid significantly although certainly negative reactions, such as for thyroglobulin protein (arguing against clear cell struma ovarii) may play a role in some differential diagnostic considerations.
  • There are prognostic and therapeutic implications in the distinction with clear cell carcinoma.
  • [MeSH-major] Adenocarcinoma, Clear Cell / pathology. Carcinoma, Endometrioid / pathology. Ovarian Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Am J Surg Pathol. 2007 Oct;31(10):1628
  • (PMID = 17667544.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


95. Tang L, Zheng M, Xiong Y, Ding H, Liu FY: [Clinical characteristics and prognosis of epithelial ovarian cancer in young women]. Ai Zheng; 2008 Sep;27(9):951-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical characteristics and prognosis of epithelial ovarian cancer in young women].
  • BACKGROUND & OBJECTIVE: Epithelial ovarian cancer mostly appears in aged women, but rarely in young women.
  • Little is known about the clinical characteristics and prognosis of epithelial ovarian cancer in women aged below 35 years.
  • This study was to evaluate the clinical characteristics, treatment, survival and prognosis of young patients with epithelial ovarian cancer.
  • METHODS: A total of 71 patients with confirmed epithelial ovarian cancer under the age of 35 years between Jun.1980 and Dec.
  • The tumor was located at one side of the ovary in 52 cases (73.2%).
  • Serous adenocarcinoma (40 cases, 56.3%) and mucinous adenocarcinoma (22 cases, 30.9%) were the most common pathologic types.
  • Pathological grade and residual tumor size were independent prognostic factors affecting ovarian cancer.
  • CONCLUSIONS: Young women with epithelial ovarian cancer under the age of 35 years mostly have serous adenocarcinoma; tumors are normally unilateral; and the prognosis is good.
  • The ovarian function can be preserved in part of stage Ia and Grade I patients.
  • Pathological grade and residual tumor size are independent prognostic factors of epithelial ovarian cancer.
  • [MeSH-major] Cystadenocarcinoma, Mucinous / surgery. Cystadenocarcinoma, Serous / surgery. Ovarian Neoplasms / surgery
  • [MeSH-minor] Adolescent. Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Endometrioid / drug therapy. Carcinoma, Endometrioid / pathology. Carcinoma, Endometrioid / surgery. Cisplatin / therapeutic use. Combined Modality Therapy. Cyclophosphamide / therapeutic use. Female. Follow-Up Studies. Humans. Hysterectomy. Lymph Node Excision. Neoplasm Staging. Neoplasm, Residual / pathology. Ovariectomy. Prognosis. Proportional Hazards Models. Retrospective Studies. Survival Rate. Taxoids / therapeutic use. Tumor Burden. Young Adult


96. Chen S, Leitao MM, Tornos C, Soslow RA: Invasion patterns in stage I endometrioid and mucinous ovarian carcinomas: a clinicopathologic analysis emphasizing favorable outcomes in carcinomas without destructive stromal invasion and the occasional malignant course of carcinomas with limited destructive stromal invasion. Mod Pathol; 2005 Jul;18(7):903-11
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Invasion patterns in stage I endometrioid and mucinous ovarian carcinomas: a clinicopathologic analysis emphasizing favorable outcomes in carcinomas without destructive stromal invasion and the occasional malignant course of carcinomas with limited destructive stromal invasion.
  • Stage I, low-grade endometrioid and mucinous ovarian carcinomas have an excellent prognosis.
  • We investigated this by studying all FIGO stage I, grades 1 and 2 (of 3) endometrioid and mucinous ovarian carcinomas that were surgically staged at the Memorial Sloan-Kettering Cancer Center from 1980 to 2000.
  • Cases studied included 13 endometrioid ovarian carcinomas (stage IA, eight; stage IC, five) and six intestinal mucinous ovarian carcinomas (stage IA, three; stage IC, three).
  • Six tumors contained at least one focus of destructive stromal invasion (two endometrioid and four mucinous ovarian carcinomas).
  • Four additional cases showed a focus suspicious for but not diagnostic of destructive invasion ('indeterminate for destructive invasion') (two endometrioid and two mucinous ovarian carcinomas).
  • The size, number, and nuclear grade of destructive stromal invasion foci did not appear to have an impact on survival in this relatively limited number of patients.
  • Outcome data in patients with stage I, low-grade endometrioid and mucinous ovarian carcinomas without destructive stromal invasion indicate that these tumors have a very limited malignant potential.
  • The literature has not documented recurrences in this setting when the staging has been complete, the sampling adequate, and the cytologic features no more than grade 2, and metastasis to the ovary has been excluded.
  • In contrast, carcinomas harboring even limited foci of destructive stromal invasion, although frequently cured surgically, can pursue a malignant clinical course.
  • [MeSH-major] Adenocarcinoma, Mucinous / pathology. Carcinoma, Endometrioid / pathology. Ovarian Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15696121.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


97. Yan X, Gao YN, Jiang GQ, Gao M, An N: [Impact of surgical resection extent on the prognosis of clinical stage I endometrial carcinoma]. Zhonghua Zhong Liu Za Zhi; 2009 Mar;31(3):208-12
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Impact of surgical resection extent on the prognosis of clinical stage I endometrial carcinoma].
  • OBJECTIVE: To investigate the impact of surgical resection extent and other clinicopathological characteristics on the prognosis in patients with clinical stage I endometrial carcinoma.
  • METHODS: The data of 135 surgically treated patients with clinical stage I endometrial carcinoma were retrospectively analyzed.
  • The impact of surgery extent and other clinicopathological characteristics on the prognosis in patients with clinical stage I endometrial carcinoma were retrospectively analyzed.
  • RESULTS: There were no significant differences between two groups in the pathological stage, pathologic type, tumor grade, depth of myometrial invasion, vascular tumor emboli, ovary invasion, lymph node metastasis, positive peritoneal cytology and adjuvant therapy (P > 0.05).
  • Multivariate analysis demonstrated that the important risk factors for clinical stage I endometrial carcinoma were deep myometrium invasion, high pathological grade, positive peritoneal cytology and ovarian metastasis, rather than surgical resection extent.
  • CONCLUSION: Surgery extent is not an important factor affecting the prognosis in patients with clinical stage I endometrial carcinoma, and extended surgery does not improve their survival.
  • [MeSH-major] Carcinoma, Endometrioid / surgery. Endometrial Neoplasms / surgery. Hysterectomy / methods
  • [MeSH-minor] Adenocarcinoma, Clear Cell / pathology. Adenocarcinoma, Clear Cell / surgery. Adenocarcinoma, Clear Cell / therapy. Adult. Aged. Aged, 80 and over. Blood Loss, Surgical. Carcinoma, Adenosquamous / pathology. Carcinoma, Adenosquamous / surgery. Carcinoma, Adenosquamous / therapy. Chemotherapy, Adjuvant. Female. Humans. Length of Stay. Lymph Node Excision. Middle Aged. Neoplasm Invasiveness. Neoplasm Recurrence, Local. Radiotherapy, Adjuvant. Retrospective Studies. Survival Rate

  • MedlinePlus Health Information. consumer health - Hysterectomy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19615262.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


98. Ehara R, Koga T, You S, Natori H, Kamimura T, Nishimura M, Matsuo K: Pseudo-Meigs'syndrome as a cause of exertional dyspnea: a case report. Kurume Med J; 2009;56(3-4):85-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A 61-year-old otherwise healthy woman presented with gradually worsening exertional dyspnea.
  • Systemic examinations showed ascites and a pelvic tumor, which turned out to be right ovarian endometrioid adenocarcinoma.
  • Surgical removal and chemotherapy against the ovarian cancer resulted in disappearance of the ascites and pleural effusion, establishing a diagnosis of pseudo-Meigs'syndrome.
  • It is common for reported cases of pseudo-Meigs' syndrome to initially present with dyspnea, therefore it is important to consider this disorder when attempting a differential diagnosis in female patients presenting with dyspnea without other noticeable conditions.

  • Genetic Alliance. consumer health - Dyspnea.
  • MedlinePlus Health Information. consumer health - Breathing Problems.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20505286.001).
  • [ISSN] 1881-2090
  • [Journal-full-title] The Kurume medical journal
  • [ISO-abbreviation] Kurume Med J
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / CA-125 Antigen; 0 / MUC16 protein, human; 0 / Membrane Proteins
  •  go-up   go-down


99.